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ABSTRACT 
Nuclear pre-mRNA splicing occurs within the spliceosome. The spliceosome is a dynamic 
structure in which multiple interactions among splicing factors catalyze the removal of introns 
from pre-mRNA molecules. The PRP8 gene of Saccharomyces cereviiae encodes a 280 kD protein 
that is essential for splicing (Jackson et aL, 1988). Previously, antibodies were raised against PRP8 
protein, and an immunological approach was used to identify PRP8 protein as a stable component 
of both the US snRNP and the U4/U5/U6 multi-snRNP complex (Lossky et aL, 1987). In this 
thesis, these immunological studies are extended, and the possible role of PRP8 protein as a 
spliceosomal pre-mRNA splicing factor is investigated. 
The association of PRP8 protein with yeast splicing complexes was demonstrated by the 
ability of PRP8-specific antibodies to precipitate precursor RNA, splicing reaction intermediates 
and lariat intron product from in vitro splicing reactions. PRP8 protein maintains its association 
with spliceosomal complexes throughout both steps of the splicing reaction and remains associated 
with the excised intron in a post-splicing complex that does not contain the spliced exons. The 
association of PRP8 protein with pre-mRNA molecules is splicing-dependent, for PRP8-specific 
antibodies did not precipitate mutant precursor RNAs. nor did they precipitate wild-type pre-
mRNA in the absence of ATP. 
A novel method for the immuno-affinity purification of yeast spliceosomes was developed. 
In vitro splicing reactions were assembled with polyadenylated pre-mRNA substrates. Poly(A)-
binding protein (PAB), endogenous to yeast splicing extracts, associated with the poly(A) tail of 
the pre-mRNA, and spliceosomes were precipitated with antibodies raised against yeast PAB. 
Analysis of the affinity-selected spliceosomal proteins revealed the presence of PRP8 protein; thus 
it was established that PRP8 protein is a component of yeast spliceosomes. 
The possible function of PRP8 protein within spliceosomal complexes was explored by 
a combination of immunological and UV-crosslinking techniques. Short-wave UV light forms 
covalent crosslinks between adjacent protein and RNA molecules. PRP8-specific antibodies 
precipitated PRP8 protein—pre-mRNA adducts from UV-irradiated in vitro splicing reactions. This 
demonstrated that the two molecules were in direct contact at the time of exposure to UV light. 
The interaction between PRP8 protein and substrate RNA is a splicing-specific event. The 
protein—RNA interaction is dependent on the presence of ATP, and there was no crosslinking 
observed between PRP8 protein and RNA substrates that were not spliced, even if PRP8 protein 
assembled into complexes with these substrates. It was established that PRP8 protein would only 
interact with pre-mRNA molecules capable of participating in at least the first step of the splicing 
reaction, thereby implicating additional cis- or trans-acting factors in the PRP8 protein—pre-
mRNA contact event. 
ii 
Finally, Ribonuclease Ti protection mapping studies were conducted to locate PRP8 
protein's binding site(s) on pre-mRNA and pre-mRNA-derived moleules. Preliminary results are 
presented which suggest that PRP8 protein may interact with both the 5' splice site region of pre-
mRNA molecules and the branch structure of the lariat intermediate and/or lariat intron. The 
implications of these results are explored. 
lii 
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1.1 PRE-mRNA SPLICING 
The discovery of introns and RNA splicing in 1977 prompted a dramatic revision of our 
picture of the organization of eukaryotic genes. The coding regions of DNA (exons) are not 
continuous, but interrupted by intervening sequences (introns) that are removed post-
transcriptionally, prior to translation of the mRNA. The gene is now viewed as a mosaic of exons 
and introns (Gilbert, 1978), its expression in some cases regulated by the same mechanism that 
removes the introns, RNA splicing. 
1.2 THE ORIGIN OF INTRONS 
There exist two theories concerning the origin of introns. One view is that genes have 
always contained introns, and that they evolved as discontinuous structures (Darnell and Doolittle, 
1986; Gilbert et aL, 1986). Alternatively, introns could have arisen by insertion of transposable 
elements into pre-existing, continuous genes (Cavalier-Smith, 1985). Analysis of intron distribution 
in the actin and tubulin gene families lends weight to the latter theory. Actin and tubulin proteins 
are highly conserved among fungi, plants and vertebrates, so it is believed that the genes for these 
proteins arose by the duplication of a common ancestral gene. The distribution of introns within 
these genes, however, varies considerably, so it is likely that the introns were not present in a 
common ancestral gene, but were gained later, during eukaryotic evolution. Dibb and Newman 
(1989) propose that the consensus sequences that flank most introns may represent "proto-splice 
sites", possible integration sites for self-splicing introns inserted during evolution. 
Group II introns (or their ancestors) are plausible candidates for the "transposable' 
elements" which contributed to the origin of introns in nuclear genes. Group II introns are found 
in organellar genes of lower eukaryotes and plants; they are classed together on the basis of 
conserved sequence elements and secondary structure which differs from nuclear pre-mRNA 
introns and other intron types (Cech and Bass, 1986). The yeast mitochondrial mRNA intron bli 
undergoes self-splicing in vitro (Peebles et aL, 1986; van der Veen et aL, 1986). A remarkable 
feature of this group II intron is that it can also reintegrate itself into an RNA molecule 
1 
The differential RNA processing mechanisms involved in the progression from membrane-bound 
to secreted Ig.t are actually more complex. The alteration in RNA processing of the Igu transcript 
during B-cell maturation is most likely regulated by differential usage of polyadenylation signals, 
I 	 which results in the observed altered splicing pattern at the 3 end of the transcript. 
composed of the ligated exons by a reversal of the self-splicing process (Augustin et at, 1990; MOrl 
and Schmelzer, 1990). Furthermore, MOrl and Schmelzer (1990) demonstrate that the intron can 
even integrate into a foreign RNA species, presumably by recognition of a sequence that can base 
pair with the exon binding site of the intron. The sequence element required for intron integration 
may correspond to the proto-splice site described by Dibb and Newman (1989). The recombined 
RNA molecule resulting from reverse splicing could then be reverse-transcribed into eDNA (some 
group II introns contain open reading frames which could encode reverse transcriptases; Augustin 
et at, 1990), and integrated into the genomic DNA by homologous recombination (Mörl and 
Schmelzer, 1990). Rogers (1989) observes that once a group II intron has been integrated into the 
genome, only a single base change in one of the splicing consensus sequence elements would be 
required to convert it into a classical nuclear pre-mRNA intron, capable of being excised by the 
nuclear splicing machinery. 
The nuclear pre-mRNA splicing process itself may have evolved from the RNA-catalyzed 
self-splicing reaction of group II introns. Dissection of the autocatalytic reaction revealed that it 
occurs by the same mechanism as nuclear pre-mRNA splicing (Cech, 1986), although in contrast 
to group II introns, catalysis is mediated by trans-acting factors in nuclear RNA splicing (see 
below, section 1.7). 
There are selective advantages for higher organisms in both the retention of introns and 
the loss of autonomy in splicing. Both confer flexibility to biological systems. Introns provide 
genes with the capacity to express different products, solely by alternating their splicing patterns. 
The transfer of the catalytic role in splicing from the intron itself to nuclear trans-acting factors 
allows the cellular environment to dictate alternative splicing patterns. 
1.3 ALTERNATIVE SPLICING 
Alternative pre-mRNA splicing is an important biological regulatory mechanism for the 
control of gene expression in higher eukaryotes (for a review, see Smith et at, 1989a, from which 
much of this discussion is derived). Alternative processing produces different mRNAs from 
identical pre-mRNA transcripts in a cell- or developmental stage-specific manner. 
Most often, alternative splicing is used to subtly modify protein function, whereby various 
protein products can be generated from a single gene. For example, regulated alternative 
processing can control the targeting of a protein to different cellular locations. The 
immunoglobulin A (Ig&) heavy chain molecule exists in early B lymphocytes as a membrane-bound 
protein. Launching of the immune response is accompanied by B-cell maturation; in this altered 
cellular environment, the splicing pattern of the Igu transcript changes. An alternative 3 exon 
is used, which substitutes a hydrophilic domain for the membrane-binding segment of the protein. 
As a result, Iga is secreted in mature B lymphocytes (Smith et at, 1989a). 
2 
Protein domain variation arising from alternative splicing patterns also affects protein 
activity. Troponin-T (TnT) contractile protein interacts directly with tropomyosin in the concerted 
control of muscle contraction. The TnT transcript is spliced in a tissue-specific manner, generating 
three major TnT isoforms that differ in the domain which interacts with tropomyosin. Each 
different TnT protein isoform varies in the way it interacts with tropomyosin; since the activation 
of a muscle filament is a cooperative process involving the interaction of many factors, the actual 
mechanical parameters required for muscle contraction depend on which TnT isoform is expressed 
in the tissue (Smith et aL, 1989a). Alternative processing of some transcription factors regulates 
their ligand and DNA-binding activities. The factors that bind to the immunoglobulin K light 
chain enhancer element vary within their DNA-binding domains and thus display different binding 
affinities for their target site (Smith et aL, 1989a). The rat a thyroid hormone receptor gene 
produces two products that differ solely in their hormone binding domains, yet display distinct 
DNA-binding activities as well. In this instance, more than one of the protein's activities has been 
altered by a single domain substitution (Smith et aL, 1989a). Domain substitutions may also result 
in the expression of two entirely different products from a single gene, as is the case for the 
calcitonin/CGRP gene. The alternatively spliced region of the calcitonin/CGRP transcript encodes 
the active domains of the two protein products, calcitonin (CT) and calcitonin gene-related 
peptide (CGRP). As a consequence of this alternative splicing pattern, the peptide hormones CT 
and CGRP possess totally different functions (Smith et aL, 1989a). 
Alternative splicing also functions as an on/off regulator of gene expression. In this 
instance, alternative processing generates either functional or non-functional gene products. The 
P transposable element of Drosophila melanogaster displays cell-specific activity. Transposition 
occurs in the germ line but never in somatic cells. Molecular analysis of the P element 
demonstrated that P transposition requires four separate peptide-coding segments, produced from 
a spliced P transcript (Bingham et aL, 1988). Laski et aL (1986) found that P transcripts in somatic 
cells produce non-functional proteins due to retention of the third intron which contains a 
translational stop codon. In the germ line, however, all three introns of the P pre-mRNA are 
removed, generating a functional gene product (Laski et aL, 1986). Cell-specific transposition of 
the P element is due to a cell-specific splicing event. 
On/off regulation by alternative splicing is most often used to control entire 
developmental pathways, by switching on or off the activity of a gene product required early in 
the regulatory cascade. In Drosophila, alternative splicing plays a critical role in sexual 
differentiation, by producing active or inactive gene products whose presence is essential for 
determining whether male or female differentiation genes are activated. Sex-lethal (Sxl) is a central 
element among the many genes known to be involved in sexual development. The Sxl transcript 
is spliced to produce an active product in females, but the male-specific splicing pattern produces 
a truncated, non-functional protein, due to incorporation of an exon containing a translational 
3 
stop codon (Bell et al., 1988). Expression of the Sxl gene is required for sex-specific regulation of 
the transformer (Ira) gene. The product of the tra gene acts in concert with the transformer-2 (ira-
2) gene product to establish the male or female mode of somatic differentiation, via the sex-
specific expression of the doublesa (dsx) gene (Smith et aL, 1989a). 
The female Sxl protein has been identified as the trans-acting factor which mediates sex-
specific alternative splicing of the tra transcript (Inoue et aL, 1990). Production of the functional 
Ira gene product is turned on or off by alternating the 3' splice site used in removing the first 
intron from the primary transcript (Bingham et aL, 1988). SW protein possesses a characteristic 
RNA-binding motif (Bell et aL, 1988), and Inoue et aL (1990) demonstrated that it interacts 
directly with the ira pre-mRNA in the region of the non-sex-specific 3' splice site, thereby 
blocking its usage (Inoue et aL, 1990). In this way, the SW gene product imposes female-specific 
RNA splicing of the ira gene. 
The female ira protein is thought to interact with the tra-2 gene product to direct the sex-
specific splicing of the dsx transcript (A.mrein et aL, 1988). The tra-2 protein shares sequence 
homology with RNA-binding proteins, so it may act as the alternative splicing trans-acting factor 
for regulation of dsx splicing (Amrein et aL, 1988). Dsx is the only gene in the sexual development 
pathway whose functional expression is required for both males and females (Smith et aL, 1989a). 
In males, dsx acts to repress the genes required for female differentiation, and in females it acts 
to repress the genes required for male differentiation (Smith et aL, 1989a). The mode of dsx gene 
expression is controlled by alternative splicing of its 3' end exons (Burtis and Baker, 1989). The 
default splicing pattern utilizes the male splice site, most likely because it is more similar to the 
Drosophila consensus splice acceptor sequence than is the female splice site (Burtis and Baker, 
1989). Cis-acting mutations in the dx gene which result in the default pattern of splicing 
(regardless of the sex of the fly) are all located 3 to the female splice acceptor site (Nagoshi and 
Baker, 1990). Nagoshi and Baker (1990) propose that the female-specific splicing pattern is 
mediated by trans-acting factor(s), such as tra-2 protein, that bind to the weak female splice 
acceptor site of drr to promote its usage. Therefore, in Drosophila, trans-acting regulators of 
splicing can act as either positive or negative regulators of sexual differentiation. A trans-acting 
factor(s) positively regulates the expression of drx by directing the splicing machinery to an 
alternate splice site on the dsx transcript (Nagoshi and Baker, 1990), and the Sxl gene product 
negatively regulates the expression of ira by blocking the usage of the natural splice site in Ira pre-
mRNA (Inoue et aL, 1990). 
The preceding examples demonstrate the flexibility provided by alternative splicing as a 
mechanism to regulate gene expression involved in cellular differentiation, development, and 
modulation of gene product function. The existence of tissue-specific trans-acting splicing factors 
and the ability of alternative splice sites to compete for the splicing machinery allow complex 
multicellular organisms to tailor gene expression to a particular cellular environment. 
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1.4 PRE-mRNA SPLICING IN YEAST AND IN MAMMALS 
The flexibility of the RNA splicing mechanism in higher eukaryotes, as demonstrated by 
alternative splicing, is not a characteristic of the splicing process for the yeasts Saccharomyces 
cerevisiae and Schizosaccharomyces pombe. The stringency of the S. cerevisiae RNA splicing 
machinery is reflected by the fact that mammalian introns are not spliced in S. cerevisiae (Beggs 
et at, 1980), although S. cerevisiae primary transcripts are spliced in mammalian in vitro splicing 
systems (Ruskin et at, 1986). S. pomt'e genes, however, possess splicing consensus sequences 
which are more similar to those in higher organisms than to the stringently conserved sequence 
elements required for the splicing of S. cerevisiae transcripts. The mammalian SV40 T antigen 
intron is correctly excised in S. pombe ( Kaufer a at, 1985), yet only one of the two modes of 
splicing of this gene operates. Several other mammalian transcripts have been tested, and they are 
not spliced in S. pombe ( D.Frendewey, pers. comm.); splicing of the SV40 T antigen gene in S. 
pombe may be the exception. Plant genes also possess cis-acting sequences which are similar to 
the vertebrate consensus elements required for pre-mRNA splicing. Although two different plant 
introns, one frOm a monocotyledonous and the other from a dicotyledonous plant, are spliced in 
HeLa cell nuclear extracts (Brown et at, 1986), plants are unable to remove the introns of the 
human growth hormone pre-mRNA in vivo (Barta et at, 1986). It appears that the specificity of 
the cis-acting elements required for splicing varies from organism to organism, and these cis-acting 
determinants are overridden in the more flexible mammalian splicing system. 
The differences among the splicing systems of S. cerevisiae, S. pombe, plants and 
metazoans are largely superficial, however, for these organisms remove introns from pre-mRNA 
by the same biochemical mechanism, with the aid of similar cellular trans-acting factors. In fact, 
much of the progress made in determining the roles of particular trans-acting factors in the 
splicing pathway and the mechanism of splicing in general has been derived from study of the S. 
cerevisiae splicing system. This is due to the amenability of S. cerevisiae (hereafter referred to 
simply as "yeast") to both genetic and biochemical manipulation, a powerful combination of 
analytical tools. 
1.5 THE MECHANISM OF NUCLEAR PRE-mRNA SPLICING 
The development of efficient in vitro splicing systems quickly led to the elucidation of 
the splicing pathway. The structural characterization of splicing, reaction intermediates and 
products initially established the kinetics of the reaction, that 5 splice site cleavage preceeds 3 
splice site cleavage (Kramer, et at, 1984). The exciting discovery of lariat structures- (Padgett et 
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aL, 1984; Ruskin, et aL, 1984; Domdey et al., 1984) established splicing as a two-step process 
(Figure 1.1). 
It is generally accepted that the splicing reaction proceeds by two transesterification 
reactions (Green, 1986). In the first reaction, the pre-mRNA is cleaved at a Y -5' phosphodiester 
bond at the Y splice site, and, simultaneously, a 2' -5' phosphodiester bond is formed between 
the 5' phosphorylated terminus of the intron and the 2 hydroxyl group of an adenosine residue 
in the internal branch region of the intron. The second transesterification reaction consists of 
cleavage of the 3' -5' phosphodiester bond at the Y splice site concomitant with formation of a 
3' -5' phosphodiester bond upon exon ligation, which results in the excision of the intron in lariat 
form and production of mature messenger RNA. The efficiency of pre-mRNA splicing is 
determined by several cis-acting factors: pre-mRNA nucleotide sequence at the 5' splice site, 3' 
splice site and branchpoint regions; and the distances between these cis-acting elements. 
1.6 CIS-ACTING DETERMINANTS OF SPLICING 
1.6.1 5' Splice Site 
In higher eukaryotes, almost all introns have the dinucleotide GU at their 5 ends, which 
comprises part of the 5' splice site consensus sequence: (C/A)AG IGURAGU (Mount, 1982). All 
mutations at the almost invariant GU and some mutations within the splice site sequence 
inactivate the 5' splice site, and frequently activate "cryptic" (alternative) splice sites (Green, 
1986). 
The yeast 5' splice junction is more highly conserved than in higher eukaryotes. The 
consensus sequence is IGUAYGU (Teem et aL, 1984), and mutations in this region do not 
activate cryptic splice sites, but inhibit splicing altogether, or, in some cases, lead to the 
accumulation of nonproductive intermediates resulting from aberrant 5' splice site cleavages 
(Green, 1986). 
1.6.2 Branchpoint 
Splicing of introns in yeast pre-mRNAs also requires the highly conserved internal intron 
sequence UACUAAC, located 20-40 nucleotides from the 3' intron boundary (Padgett et aL, 
1986). The third adenosine residue of the UACUAAC box is the site of branch formation. The 
UACUAAC element defines a rigid sequence requirement for lariat formation since mutations 
and deletions in this region completely abolish splicing (Green, 1986). 
FIGURE 1.1 THE MECHANISM OF NUCLEAR PRE-mRNA SPLICING 
The two steps of the splicing reaction are illustrated. Exons are represented by boxes, and the 
intron by a horizontal line. The phosphate and hydroxyl groups involved in the two 
transesterification reactions of the splicing pathway are denoted by P and OH, respectively. The 
mammalian conserved sequence elements are indicated; the conserved sequence elements of S. 
cerevisiae are in italics. 
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The mammalian branchpoint sequence is less stringently defined, and cryptic branchpoints 
are utilized when the authentic branchpoints are altered by mutation or deletion (Green, 1986). 
Parker et aL (1987) derived a consensus sequence from a comparison of mapped branchpoints 
compiled by Green (1986): YNCURAC. This consensus sequence closely resembles the yeast 
element in both nucleotide composition and location of branch formation. 
Reed and Maniatis (1988) studied the effects of deletions and single base changes in the 
mammalian branchpoint sequence. They eliminated cryptic branchpoints in their analyses, and 
showed that alterations of the branchpoint sequence element dramatically decreased the efficiency 
of splicing in vitro and altered 3' splice site selection in vivo; these effects on splicing efficiency 
parallel the effects of analogous mutations in yeast. Thus, although less stringently defined in 
mammals than in yeast, the branchpoint may play a similar role in the two splicing systems. 
1.6.3 3 Splice Site, Polypyrimidine Tract and Lariat Formation 
In both yeast and higher eukaryotes, the 3' splice occurs at an invariant AG dinucleotide. 
For higher eukalyotes, the consensus sequence at the 3' splice site is. YAG IG (Mount, 1982). 
It is generally assumed that the 3 splice site consensus sequence includes a pyrimidine-rich region 
of variable length (the polypyrimidine tract) directly upstream of the 3' splice site, which is 
thought to specify 3' splice site selection. Recently, however, studies of the functional 
organization of sequences at. the 3' end of mammalian introns and their influence on 3' splice 
site selection suggest that the polypyrimidine tract actually may be considered one of the 
sequence elements that defines the mammalian branchpoint. Reed (1989) showed that maximum 
efficiency of lariat formation was achieved only when a pyrimidine stretch was located immediately 
downstream of the branchpoint sequence. Smith et aL (1989b) reported similar results from their 
multiple deletion studies of a-tropomyosin pre-mRNA, and they also showed that a functional 
polypyrimidine tract (one which allows efficient lariat formation) was not due to sequence 
specificity but due to its proximity to the branchpoint only. Reed (1989) analysed the utilization 
of cryptic branchpoints and demonstrated that the pyrimidine content of sequences immediately 
adjacent to the branchpoint is a critical determinant of branchsite selection. For example, when 
the yeast actin intron was spliced in a HeLa cell nuclear extract, a cryptic branchpoint was used 
rather than the normal yeast UACUAAC branchpoint (Ruskin et aL, 1986). The branchpoint 
selected In HeLa cells is adjacent to pyrimidine-rich sequences whereas the yeast branchpoint is 
followed by more purine-rich sequences. In addition, Smith et aL (1989b) showed that adenosine 
residues which had suitable pyrimidine-rich regions downstream, yet were not used as 
branchpoints, were activated when their sequence environment was converted to the strong (yeast) 
branchpoint consensus UACUAAC. Thus, one may conclude from the above studies that the lariat 
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branchpoint in mammalian introns is defined both by the sequence context of the branchpoint and 
by an adjacent downstream polypyrimidine tract. 
There remains the possibility, however, that a polypyrimidine tract specifies 3' splice site 
recognition as well as lariat formation, for all the authentic and cryptic 3' splice site AG dinucleo-
tides utilized in the studies by Smith et aL (1989b) possessed pyrimidine-rich regions upstream. 
Smith et aL (1989b) tested this possibility by changing the 30 nucleotides upstream from 70% 
pyrimidine to 70% purine; they observed no effect on either step of splicing. In her studies with 
fl-globin pre-mRNAs, Reed (1989) also found that as long as there existed a polypyrimidine tract 
immediately adjacent to the branchpoint, efficient exon ligation was observed even when the 3' 
AG was preceeded by a purine stretch. Fu et aL (1988) reported similar results for the SV40 early 
pre-mRNA 
These observations provide convincing evidence that the polypyrimidine tract is not 
obligatorily associated with the 3' splice site, and that it may indeed have no role in 3' splice site 
selection. The polypyrimidine tract may actually impart a specificity to mammalian branchpoint 
selection which had been considered lacking when compared to the stringently defined yeast 
branchpoint element. In fact, the pyrimidine tract appears to be a significant determinant for the 
selection of alternative splicing patterns. For example, in the alternatively spliced SV40 early pre-
mRNA, the primary role of the pyrimidine-rich sequence element is to influence 5' splice site 
choice (Fu et aL, 1988). In splicing of the rat a-tropomyosin pre-mRNA, Mullen et aL (pers. 
comm., Cold Spring Harbor RNA Processing Meeting, 1990; referred to hereafter as "CSH90") 
have shown that the relative quality of the pyrimidine tracts is the primary determinant of default 
exon selection. It seems that the utilization of two sequence elements for branchpoint selection 
may provide the flexibility required for higher eukaryotic systems to accommodate alternative 
splicing pathways. 
Both Reed (1989) and Smith et aL (1989b) and earlier work by Ruskin and Green (1985a) 
demonstrate that lariat formation can occur independently of the 3' splice site AG. This may be 
a general principle of splicing, for in yeast, neither the 3' AG nor a polypyrimidine tract is 
necessary for cleavage of the 5' splice site and lariat formation (Rymond and Rosbash, 1985). It 
seems that there is merely a sequence-independent length requirement downstream of the 
branchpoint for the first step of splicing to proceed. Rymond et aL (1987) defined this distance 
as at least 29 nucleotides for ribosomal protein rp5 1A pre-mRNA (similar results were achieved 
for other pre-mRNAs) by generating transcripts cleaved 10-15 nucleotides downstream of the 
UACUAAC box that were inactive splicing substrates, and relieving the lariat formation block by 
addition of ribohomopolymer tails to the shortened 3' end of the transcripts. 
The observed passive role of the AG dinucleotide with respect to step 1 of the splicing 
reaction prompted Smith et aL (1989b) to propose a model for 3' splice site selection in 
mammalian introns which involves scanning from the independently specified branchpoint. They 
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provide as evidence for their model that naturally occuring 3' splice sites are always within 18-40 
nucleotides downstream of the branchpoint. In addition, when alternative 3' splice site AG 
dinucleotides are activated, they are always the first AG located 3' of the polypyrimidine tract. 
More evidence for the scanning model of Smith et aL (1989b) is that secondary structure 
introduced in the region of the intron between the polypyrimidine stretch and the 3' splice site 
AG abrogates the second step of splicing. In yeast, however, a scanning process to locate the 3' 
splice site does not appear to be involved in 3' splice site selection. 
Apart from the nucleotide sequence elements at the boundaries of and internal to the 
intron, an additional cis-acting determinant for the efficient splicing of pre-mRNA is the length 
of the intron itself. The minimum length for a mammalian intron is approximately 60 nucleotides 
(Steitz et aL, 1988). This most likely represents the requirement for multiple splicing factors to 
interact with the specific intron regions, in order to assemble the pre-mRNA into the appropriate 
architecture for catalysis of the splicing reaction. 
1.7 THE ROLE OF SMALL NUCLEAR RIBONUCLEOPROTEIN PARTICLES IN SPLICING 
1.7.1 Introduction 
Small nuclear ribonucleoprotein particles (snRNPs) are present in the nuclei of all higher 
eukaryotes and yeast. Each major nucleoplasmic snRNP is composed of a characteristic set of 
proteins, seven of which are common to all snRNPs (Bnngmann and LUhrmann, 1986), and it is 
associated with a small nuclear RNA (snRNA) molecule; the name of the snRNP is derived from 
the particular snRNA species it contains. Ui, U2 and U5 snRNPs contain a single snRNA 
molecule and several characteristic proteins in addition to the seven core snRNP polypeptides 
(Luhrmann, 1988). The U4/U6 snRNP contains both U4 and U6 snRNAs, associated by direct 
RNA—RNA base-pairing (Bringmann et aL, 1984; Hashimoto and Steitz, 1984). Several of the 
snRNP proteins bear "Sm" epitopes, antigenic determinants which react with antibodies developed 
by patients with the autoimmune disease systemic lupus erythematosus (SLE; Lerner and Steitz, 
1979). 
In higher eukaryotes, snRNAs are present in an abundance of 10 5-106 copies per cell 
(LUhrmann, 1988). Except for U6 snRNA, the snRNA molecules are characterized by a unique 
2,2,7-trimethylguanosine (m 3G) cap structure at their 5' ends, and the Sm binding site AU 4 G 
embedded in a single-stranded region of the snRNA (Branlant et aL, 1982; Mattaj and De 
Robertis, 1985). 
Yeast snRNAs escaped detection for many years due to their low abundance (10-500 
copies per cell; Wise et aL, 1983). Yeast snRNAs are similar to mammalian snRNAs in that they 
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are stable nucleoplasmic species, have an m 3G cap at their 5' ends, and are Sm-associated. 
Although the yeast snRNAs differ markedly in size from their mammalian counterparts (Table 
1.1), they contain regions of sequence and/or structural homology that allowed their unambiguous 
identification as analogues of Ui, U2, U4, U5 and U6 snRNAs (Guthrie and Patterson, 1988). 
The function of the extra yeast snRNA sequences is not known, but in the case of U2 snRNA, 
most of the additional sequence is not essential for splicing (Igel and Ares, 1988; Shuster and 
Guthrie, 1988). Indeed, Shuster and Guthrie (1990) showed that human U2 snRNA can 
complement a lethal deletion of the yeast U2 snRNA gene; since human U2 snRNA functions in 
yeast, it is presumably assembled with yeast U2 snRNP proteins into a chimeric U2 snRNP. In 
contrast to the other snRNAs, yeast U4 and U6 are similar in size to their mammalian 
counterparts. The primary sequences of yeast and human U4 are quite different, but yeast U6 
snRNA is 75% homologous to human U6 over more than half its length (Brow and Guthrie, 
1988). (i is - generãlii ptecltht differences between yeast and human snRNPs are only 
superficial. 
Table 1.1 Comparison-of nucleotide sizes of mammalian and yeast snRNAs 	 - 
snRNA 	Mammals 	Yeast 
Ui 	 164 	568 
U2 187 1175 
U4 	 145 	 160 
U5 116 214 (L) 
179(S) 
U6 	 106 	112 
1.7.2 SnRNPs are Required for Splicing 
When it was discovered that the 5' end of Ui snRNA is exactly complementary to the 
mammalian 5' splice site consensus sequence, a direct Watson-Crick base pairing interaction was 
proposed, and snRNPs were immediately implicated as the trans-acting factors involved in splicing 
(Lerner et al, 1980; Rogers and Wall, 1980). The first experimental evidence for the active role 
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of snRNPs in splicing was obtained with antibody inhibition studies. Padgett et aL (1983) 
demonstrated that anti-Sm human autoimmune sera inhibited splicing in vitro, and later, Kramer 
et at (1984) reported similar results with antibodies directed against the trimethylated cap 
structure of the U snRNAs. Kramer et at (1984) also provided evidence for the specific 
involvement of Ui snRNP in splicing by demonstrating an inhibition of splicing upon removal of 
the 5 terminus of Ui snRNA by selective degradation with a complementary 
oligodeoxynucleotide and RNase H. Kretzner et at (1987) established that the yeast analogue of 
the mammalian Ui snRNA plays a vital role in the yeast splicing pathway. Splicing was abolished 
in vitro when yeast splicing extracts (which contain endogenous RNase H activity; Rymond and 
Rosbash, 1986) were treated with an oligodeoxynucleotide complementary to the 5' end of 
metazoan Ui snRNA. Similar targeted nuclease digestion experiments were conducted to 
demonstrate a requirement for U2 and U4/U6 snRNPs in yeast and mammalian splicing systems 
(Maniatis and Reed, 1987). The RNA component of US snRNP is not accessible to cleavage by 
RNase H (Black and Pinto, 1989), so its involvement in splicing could not be assessed in these 
studies. 
1.7.3 Ui snRNP 
The interaction of Ui snRNP with the 5' splice site was biochemically verified with 
RNase Ti protection experiments conducted by Mount et at (1983), in which they demonstrated 
selected protection of the 5' splice site by U! snRNPs. This interaction was protease-sensitive, 
so the protein components of Ui snRNP were also implicated in 5' splice site recognition. 
Direct evidence for the Ui snRNA-5 splice site interaction was provided by the elegant 
genetic studies of Zhuang and Weiner (1986). They co-transfected HeLa cells with mutant 
adenovirus E1A and human Ui snRNA genes, and showed that the splicing defect caused by a 
single point mutation in the Y splice site consensus sequence could be suppressed by a 
compensatory base change in the 5' end of the Ui snRNA which restored the postulated 
snRNA—pre-mRNA base pairing. Not all mutations engineered into the E1A 5' splice site were 
efficiently suppressed by compensatory mutations in Ui snRNA, however. These variable effects 
suggest that base pairing between the 5' splice site and Ui snRNA is essential but not sufficient 
for 5' splice site selection; other snRNA or protein molecules may be involved in subsequent 
interactions with the 5' splice site during the splicing reaction. indeed, Nelson and Green (1988) 
inserted synthetic 5' splice sites at different positions within fi-globin genes, and they found that 
even if the 5 splice Site was not utilized, it was still bound by Ul snRNP, indicating that 
complementarity with Ul snRNA is not the sole determinant in 5' splice site selection. 
Studies in yeast have also emphasized the multiplicity of interactions at the 5' splice site. 
From in vivo experiments using a pre-mRNA substrate with a point mutation in the 5' splice site, 
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Seraphin et al. (1988) and Siliciano and Guthrie (1988) showed that despite restoring the pairing 
between Ui snRNA and the 5 splice site by compensatory mutation in Ui snRNA, aberrant Y 
cleavage events still occurred outside the pairing region. These results suggest that the Ul 
snRNA—pre-mRNA base pairing defines a recognition "window" in which the actual cleavage site 
is selected by other factors. 
1.7.4 U2 snRNP 
Keller and Noon (1984) proposed a base-pairing interaction between U2 snRNA and the 
branch site of pre.mRNA from their analyses of conserved sequence elements in the region of 
metazoan branch formation. Indeed, RNase protection studies conducted by Black et al. (1985) 
demonstrated that the U2 snRNP is associated with the intron fragment containing the 
branchpoint sequence. 
Lamond et aL (1989) provided additional indirect evidence for an interaction between U2 
snRNP and pre-mRNA through their utilization of a novel approach for detecting individual 
snRNPs. Sproat et äL (1989) reported the synthesis of oligonucleotides made of 2'-0- 
methylribonucleic acid (2' -OMe RNA). These 2' -OMe oligoribonucleotides can be used as 
antisense probes for particular snRNPs when made complementary to regions of the snRNA 
available for RNA—RNA duplex formation. A distinct advantage of this method over targeted 
RNase H digestion of individual snRNPs is that the 2' -OMe RNA-targeted snRNP is not 
destroyed. As a consequence, it is possible to "tag" a particular snRNP by 5' end-labelling the 
complementary 2' -OMe oligoribonucleotide with 32P (Lamond et aL, 1989) or, using an antisense 
oligonucleotide coupled to biotin, the snRNP's interactions with other molecules can be analysed 
by affinity selection with streptavidin-agarose beads (Barabino a aL, 1989). 
Lamond et aL (1989) synthesized 2' -OMe oligoribonucleotides complementary to specific 
regions of U2 snRNA, and conducted "antisense inhibition" studies. The 2-OMe probe 
complementary to the proposed region of base pairing with the branchpoint inhibited splicing, 
whereas the antisense probe to the 5' terminus of U2 snRNA did not. Barabino et aL (1989) 
detected a stable interaction between U2 snRNP and pre-mRNA by biotin-streptavidin affinity 
selection with a biotinylated antisense probe to the 5' end of U2 snRNA, but could detect no 
interaction when U2 snRNP was affinity selected with a 2'-OMe probe to the region of 
branchpoint complementarity. Although these results do not provide direct evidence for Watson-
Crick base pairing between the branchpoint and U2 snRNA, they demonstrate that the region of 
U2 snRNA complementary to the branchpoint sequence must be available for binding to or 
interaction with other factor(s) in order for splicing to occur. 
It was in the yeast system, however, that it was demonstrated directly that recognition of 
the branch site by U2 snRNPs is mediated, at least in part, by Watson-Crick complementarity. 
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Parker et aL (1987) used a genetic approach (similar to that used by Zhuang and Weiner, 1986, 
to define the interaction between Ui snRNA and the 5 splice site) to show that a splicing defect 
caused by the introduction of a single base change in the invariant yeast branch site UACUAAC 
could be suppressed by a compensatory mutation in U2 snRNA which was expected to restore 
base pairing. Some of the yeast strains carrying the constructed suppressor mutations exhibited 
growth defects, however; this submaximal suppression indicates that other factors besides Watson-
Crick complementarity may be necessary for efficient branchpoint recognition and/or formation. 
Parker et aL (1987) derived a consensus sequence for the metazoan branchpoint which 
demonstrated significant homology to the yeast UACUAAC box, and they also noted that the 
sequence in the yeast U2 snRNA that base pairs with the UACUAAC element is conserved in 
mammalian U2 snRNA (Ares, 1986). In addition, Reed and Maniatis (1988) showed that. 
mutations in mammalian and yeast branchpoint sequences exhibited similar relative effects on the 
efficiency of splicing (see section 1.6.2). These observations prompted both groups of investigators 
to suggest that despite apparent sequence stringency differences, the yeast and mammalian 
branchpoints may be functionally similar and that the mammalian branchpoint also may 
participate in a direct base pairing interaction with U2 snRNA. Indeed, both Zhuang and Weiner 
(1989) and Wu and Manley (1989) verified the base pairing model for mammalian cells, again by 
providing direct genetic evidence from in vivo suppression experiments. 
Ruskin et aL (1988) demonstrated, however, that partially purified U2 snRNP is unable 
to interact with its target pre-mRNA sequence. They identified a U2 snRNP auxiliary factor 
(U2AF) required for the specific interaction of U2 snRNP with the mammalian pre-mRNA 
branchpoint region. Substrate exclusion assays demonstrated that U2AF associates with pre-
mRNA prior to binding of U2 snRNP, and that U2AF has binding specificity for the 
polypyrimidine tract (Ruskin et al., 1988). Zamore and Green (1989) purified U2AF to 
homogeneity, and showed that it comprises two associated polypeptides of 65 and 35 kD. The 65 
kD polypeptide possesses the specific binding activity for the polypyrimidine tract, and as yet, the 
function of the 35 kD polypeptide is unknown. It may mediate the interaction between U2AF and 
U2 snRNP or another splicing factor (Zamore and Green, 1989). The studies of U2AF and U2 
snRNP provide additional evidence for the involvement of two sequence elements in mammalian 
branchpoint recognition (refer to section 1.6.3), for branch formation is regulated by two 
sequence-specific interactions: U2AF with the polypyrimidine tract and U2 snRNA with the 
branch site. 
1.7.5 US snRNP 
Studies by Chabot et aL (1985) initially suggested that US snRNP is involved in 
recognition of the 3 end of the intron. RNase protection experiments identified the association 
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of a factor with the polypyrimidine tract and the 3 splice site AG which was immunoprecipitable 
with anti-Sm and anti-m 3G antibodies but was not Ui or U2 snRNP. Chabot et aL (1985) found 
that this intron binding component is highly resistant to micrococcal nuclease; US snRNP is 
unique among the abundant snRNPs in displaying a comparable resistance to nuclease, and on 
this basis, they concluded that the Sm snRNP involved in binding the 3' end of the intron is U5 
snRNP. Tazi et aL (1986) and Gerke and Steitz (1986) identified a snRNP-associated protein with 
intrinsic binding specificity for the polypyrimidine tract and the 3' splice site AG of mammalian 
pre-mRNAs, the same intron region protected in the studies by Chabot et aL (1985). Ruskin et 
al. (1988) demonstrated that this intron binding protein (IBP) is unrelated to U2AF, the U2 
snRNP-associated polypyrimidine tract binding factor described above. IBP co-fractionates with 
US snRNP during chromatography and centrifugation (Tazi et aL, 1986), so it is likely that US 
snRNP is involved in recognition of the 3' end of introns, the interaction mediated, at least in 
part, by a polypeptide component of the snRNP. 
Direct proof that U5 snRNP contributes to the splicing reaction was provided by 
Patterson and Guthrie (1987) who demonstrated that the yeast U5 snRNA is essential for splicing 
in vivo. Cells which were substantially depleted of U5 snRNA showed a marked accumulation of 
unspliced precursor RNA. For some of the mRNAs analysed, significant amounts of lariat 
intermediate accumulated as well, which led Patterson and Guthrie to propose that U5 snRNA 
participates in both step 1 and step 2 of the splicing pathway. 
More information on the role of U5 snRNP in splicing was obtained by Winkelmann et 
al. (1989) who conducted complementation assays in vitro with purified individual snRNP 
fractions, prepared by extensive chromatography of HeLa cell nuclear extracts. Fractions highly 
enriched in Ui and U2 snRNPs and U4/U6 snRNP were sufficient for the production of a low 
level (5% of activity in unfractionated extracts) of splicing intermediates, but no 3' splice site 
cleavage or exon ligation was observed. Only upon complementation of the two fractions with the 
U5 snRNP fraction did both steps of splicing proceed efficiently. (That step 1 occurred at all in 
the absence of the U5 snRNP fraction may be due to a small amount of contaminating U5 
snRNPs present in the Ui and U2 snRNP fraction). From their results, Winkelmann etal. (1989) 
concluded that U5 snRNP is both necessary for the efficient initiation of the splicing event and 
absolutely required for the second step of splicing. 
The exact role that US snRNP plays in splicing remained enigmatic until genetic studies 
performed by A.Newman and C.Norman (pers. comm., CSH90) fortuitously shed light on the 
subject. Newman and Norman transformed yeast with a gene containing a Gi to A mutation in 
the 5' splice site consensus sequence. The mutation does not inhibit the first step of splicing in 
vivo, but causes the accumulation of lariat intermediate containing an aberrant A-A 2' -5' branch 
structure, which precludes the second step of splicing (Newman et aL, 1985). Newman isolated 
mutants which suppressed the 5' splice site mutation through activation of a cryptic 5' splice site 
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12 nucleotides upstream of the authentic site. Surprisingly, all of the mutations mapped to the U5 
snRNA gene, specifically to atU to C substitution at position 7 in the conserved stem loop 
structure of the snRNA (Figure 1.2a). In addition, Newman randomly mutagenized a 9 nucleotide 
conserved sequence in the loop, and all of the suppressors of the original splice site mutation 
contained substitutions in the U at position 7 or in the C at position 10. The substitution at 
position 10 of the U5 snRNA leads to the use of the aberrant (A-A) lariat intermediate in 
processing to wild-type mRNA. 
The fact that single nucleotide changes in U5 snRNA can influence both 5' splice site 
selection and catalysis of 3' splice site cleavage and exon ligation suggests that specific 
interactions between U5 snRNA and other splicing factors dictate events in both steps of the 
splicing reaction. Indeed, Black and Pinto (1989) have shown that nucleotides 36 and 38-44 in 
stem loop I of mammalian U5 snRNA are accessible in the snRNP to chemical modification 
reagents (Figure 1.2b), which indicates that this region maybe available for interactions with other 
factors during the splicing reaction. The third U and/or the surrounding nucleotides in stem loop 
I of US snRNA may participate in RNA—RNA interactions at the 5' splice site consensus 
sequence or with another snRNA molecule, or the loop may represent a binding site for a protein 
co-factor. involved in 5' splice site selection and/or 3' splice site cleavage. Perhaps it is U5 snRNP 
which contains the auxiliary factors (protein and/or RNA molecules) that select the 5' cleavage 
site in the intron, following recognition of the 5' splice site by U! snRNP (see section 1.7.3). 
1.7.6 U4/U6 snRNP 
Although targeted RNase H digestion studies demonstrated that U4/U6 snRNP is 
essential for splicing (Berget and Robberson, 1986; Black and Steitz, 1986), no intron binding site 
has been identified for U4/U6 snRNP (Bindereif and Green, 1987). It is likely that the function 
of U4/1J6 snRNP is mediated via interactions with other snRNPs during the splicing reaction. 
Investigators have concentrated on a functional analysis of the RNA moieties of U4/U6 snRNP 
in order to elucidate its role in splicing. 
The U4/U6 snRNP is unique among the abundant snRNPs in that it contains two snRNA 
molecules joined by intermolecular base pairing. Using photochemical crosslinking, Rinke et aL 
(1985) mapped the exact region of interaction of the two snRNA molecules within U4/U6 snRNP, 
and phylogenetic comparison of sequence elements of U6 snRNA led Brow and Guthrie (1988) 
to propose a conserved secondary structure for the U4—U6 interaction domain (Figure 1.3). 
U6 snRNA is the most highly conserved of the snRNAs known to be involved in splicing 
(Brow and Guthrie, 1988). The apparent constraints on the size, sequence and structure of U6 
snRNA imply that this molecule may play a fundamental role in the splicing process (Brow and 
Guthrie, 1988). In fact, the discovery of an intron in the U6 snRNA gene of S. pombe (Tani and 
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FIGURE 1.2 SEQUENCE AND SECONDARY STRUCTURE OF US snRNA 
U5 snRNA of S. cerevisiae. The nucleotides in the loop of stem I are numbered to indicate the 
location of nucleotide substitutions. This figure was modified from Patterson and Guthrie (1987). 
Mammalian US snRNA. The nucleotides of US snRNA accessible to chemical modification 
reagents within the U5 snRNP are indicated by dark circles. This figure was adapted from Black 
and Pinto (1989). 
FIGURE 1.3 PROPOSED SECONDARY STRUCTURE OF THE U4—U6 snRNA 
INTERACTION 
The mammalian sequence of the highly conserved region of U6 snRNA, and the region of U4 
snRNA with which it pairs, are shown. The nucleotides are numbered according to the S. 
cerevisiae sequence. The highly conserved regions of U6 snRNA which are essential for splicing 
are boxed. The arrow indicates the site of insertion of the S. pombe U6 intron. This figure was 
modified from Brow and Guthrie (1989). 
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Ohshima, 1989) prompted Brow and Guthrie (1989) to speculate that the pre-mRNA-like intron 
could have originated from insertion into the U6 snRNA during an aberrant splicing event, and 
that the site of intron insertion could represent a catalytic active site either proximal to or within 
U6 snRNA. 
H.Madhani and C.Guthrie conducted in vivo mutational analyses of yeast U6 snRNA 
(pers. comm., CSH90), and they found that the majority of lethal single nucleotide substitutions 
clustered in the conserved ACAGAGA region and in the invariant nucleotides YAGC 
immediately downstream of the insertion site of the S. pombe intron in stem I of the U4—U6 
interaction domain (Figure 1.3). Compensatory mutation of sequences in U4 snRNA opposite the 
U6 mutations did not supress the U6 mutations, so it seems these residues in the interaction 
domain of U6 snRNA have a function independent of base pairing with U4 snRNA (KShannon 
and C.Guthne, pers. comm., CSH90). Indeed, Brow and Guthrie (1989) propose that U4 snRNA 
acts as an antisense RNA that negatively regulates U6 catalytic activity. 
Significant progress has been made in the delineation of the functional domains of U4 
and U6 snRNAs with the development of in vitro reconstitution systems for both mammalian and 
yeast U4/U6 snRNPs. Pikielny et at (1989) prepared HeLa cell extracts enriched in snRNP 
structural polypeptides, and they were able to reconstitute functional U4/U6 snRNPs upon the 
addition of U4 and U6 snRNAs, either synthesized in vitro or purified individually from nuclear 
RNA. Fabrizio et at (1989) reconstituted yeast U4/U6 snRNPs by treating splicing extracts with 
an oligodeoxynucleotide complementary to U6 snRNA, which led to RNase H cleavage of 
endogenous U6 snRNA and loss of splicing activity. In vitro synthesized yeast U6 snRNA was 
added to the oligonucleotide-treated extracts, and reconstitution of U4ILJ6 snRNP was achieved 
as evidenced by restoration of efficient splicing activity. U4/U6 snRNP reconstitution provided 
these investigators with a system in which to conduct an in vitro study of the structural basis for 
function of U6 snRNA. 
Bindereif et at (1990) performed deletion mutagenesis and chemical 
modification/interference assays on the U6 snRNA component of reconstituted HeLa U4/U6 
snRNPs, and identified the domain required for U4/U6 snRNP assembly as being located in the 
region of interaction of the two snRNAs postulated by Brow and Guthrie (1988). This was the 
first experimental evidence to support the existence of a U4/U6 interaction domain; the hypothesis 
had been based solely on phylogenetic evidence. Additional mutational analysis of HeLa in vitro 
reconstituted U4/1J6 snRNPs demonstrated that deletion of the ACAGAGA region of U6 snRNA 
as well as several single point mutations in the conserved sequence abolish splicing (M.Cross, 
K.Groning, A.GUnzl, ZPalfi, C.Wersig, T.Wolff, and A.Bindereif, pers. comm., CSH90). 
Consistent with these results and in correlation with yeast in vivo studies (H.Madhani and 
C.Guthrie, see above), P.Fabnzio and J.Abelson (pers. comm., CSH90) localized all the mutations 
in yeast U6 snRNA which affected splicing to the conserved ACAGA region and to the U4—U6 
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interaction domain downstream of the site of S. pombe intron insertion (Figure 1.3). Most exciting 
is that through detailed mutational analysis of these regions, Fabrizio and Abelson were able to 
identify single nucleotides which are indespensible for specific steps of the splicing pathway. 
Substitution of C48 with any other nucleotide completely abolishes splicing, as does substitution 
of 060 with C. More interesting is that changing A59 to G or U, substituting C58 with A or 0, 
or all changes at position 51 of U6 snRNA do not affect the first step of splicing, but completely 
inhibit 3 splice site cleavage and exon ligation. Fabrizio and Abelson have identified possible 
catalytic centres in U6 snRNA with the mutations which block the second step of splicing. 
1.8 SPLICING COMPLEXES AND SPLICEOSOME ASSEMBLY 
In the preceeding section, abundant evidence was presented for the fundamental and, in 
some cases, catalytic roles played by particular snRNA molecules in the splicing reaction. The 
observation that some group II introns are self-splicing sets a precedent for nuclear pre-mRNA 
splicing being primarily an RNA-catalyzed process (see section 1.2). Cech (1986) proposed that 
the protein components of snRNPs may serve primarily as structural elements for organizing the 
intron into the proper configuration for RNA-mediated catalysis. The two-step mechanism of 
splicing also necessitates the existence of a specific structure to ensure that splicing intermediates 
do not diffuse away from each other after the first cleavage-ligation step. 
Multicomponent RNA—protein complexes containing primarily the splicing intermediates 
were first identified by glycero}nd sucrose gradient sedimentation (Brody and Abelson, 1985; 
Grabowski et aL, 1985; Frendewey and Keller,1985). These 40S (in yeast) or 60S (in mammals) 
complexes were designated the "spliceosome (Brody and Abelson, 1985). SnRNPs were identified 
as the major constituents of spliceosomes by immunoprecipitation of splicing complexes with 
anti-Sm and anti-(U1)RNP antibodies (Bindereif and Green, 1986). In addition, affinity 
purification of splicing complexes by oligo(dT)-cellulose chromatography (Pikielny and Rosbash, 
1986) or biotin-streptavidin affinity chromatography (Grabowski and Sharp, 1986) demonstrated 
the presence of snRNA molecules corresponding to U2, U5 and U4/U6 snRNPs. 
A variety of methods were developed which facilitated the analysis of spliceosome 
assembly, and contributed to an understanding of the initiation of splicing as a dynamic process 
involving the formation and destabilization of multiple snRNP—snRNP interactions. 
Native gel electrophoresis of in vitro splicing reactions revealed the existence of multiple 
forms of the spliceosome; this observation corresponded to an ordered pathway of spliceosome 
assembly. Konarska and Sharp (1986) fractionated HeLa cell in vitro splicing reactions through 
native low percentage polyacrylamide gels, and identified three complexes, A, B and I, whose 
formation was both splicing- and ATP-dependent. Complex A contains precursor RNA and U2 
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snRNP, and with time it is converted to a larger, slower migrating complex B, which contains the 
splicing reaction intermediates and U5 and U4/U6 snRNPs in addition to U2 snRNP (Konarska 
and Sharp, 1987). After prolonged incubation, a faster migrating "post-splicing complex", I, ap-
pears, which contains the excised lariat intron bound to U5, U6 and U2 snRNPs (Konarska and 
Sharp, 1987). Similar native gel analyses were performed on yeast spliceosomes (Pikielny et at, 
1986; Cheng and Abelson, 1987), and comparable to the mammalian system, an early complex was 
identified which contains pre-mRNA substrate and U2 snRNP (complex "III", Pikielny et at, 1986; 
complex "B", Cheng and Abelson, 1987). A greater number of more slowly migrating complexes 
were resolved, however, which most likely correspond to comigrating complexes within the 
mammalian complex B (Cheng and Abelson, 1987). Pikielny et at (1986) showed that complex III 
leads to subsequent formation of complex I, which has a much slower electrophoretic mobility 
and contains U5 and U4IU6 snRNPs in addition to the components present in complex III. This 
is followed by formation of the faster migrating splicing complex II, which contains the 
intermediates of the splicing reaction and U2, US and U6, but not U4 snRNAs. Cheng and 
Abelson (1987) identified complexes similar to complexes I and II in their gel system (designated 
A2-1 and A2-2, respectively); in addition, they were able to resolve another complex, Al, an 
intermediate between A2-1 and A2-2 complex formation, which contains the same components 
as Al-i (or I), but migrates more slowly on native gels than Al-i and A2-2. A pathway of snRNP 
binding to pre-mRNA was proposed on the basis of these kinetic studies of complex formation. 
In this pathway, U2 snRNP binds first, in an ATP-dependent manner. Next, U5 and U4/U6 
snRNPs join the complex. Then the active spliceosome is formed upon dissociation of U4 snRNP. 
In these initial studies of spliceosome assembly, Ui snRNP was not detected as a 
component of splicing complexes. Bindereif and Green (1987), however, demonstrated that 
association of Ui snRNP with pre-mRNA is extremely sensitive to salt concentration. They 
analysed splicing complexes using biotin-streptavidin affinity chromatography under low stringency 
conditions, and detected Ui snRNP as well as U2, U5 and U4/1J6 snRNPs both associated with 
pre-mRNA and present in the functional splicing complex. Zillman et at (1988) altered the native 
gel electrophoresis conditions utilized by Konarska and Sharp (1987), and demonstrated that Ui 
snRNP is a stable component of spliceosomes under their modified fractionation conditions. 
The observed lability of the association of Ui snRNP with the spliceosome may be due 
to a weakened interaction with the spliceosome, caused perhaps by a conformational change 
involving the interaction of U5 sñRNP or other factors at the 5' splice site which could disrupt 
the basepairing between Ui snRNA and pre-mRNA; alternatively, the 5' cleavage event itself 
could destabilize Ul snRNP's interaction with the spliceosome, for Ui snRNA's target pre-mRNA 
sequence is destroyed upon 5' splice site cleavage. 
In experiments to investigate the early requirements for yeast spliceosome assembly, 
Legrain et at (1988) demonstrated that stable complexes containing pre-mRNA were formed in 
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vitro, as assayed by native gel electrophoresis, in the absence of functional U2 snRNP. These 
complexes were referred to as "commitment complexes" because the introduction of pre-mRNA 
into these complexes could not be reversed, even upon the addition of a high concentration of 
competitor pre-mRNA. In addition, Legrain et aL (1988) showed that the commitment complexes 
could be chased into active spliceosomes upon complementation with fully active extract. The 
commitment step is AT?-independent, and requires both the 5' splice site and UACUAAC 
sequence elements (Legrain et al., 1988). Interestingly, both mammalian and yeast Ui snRNPs 
were shown to interact with pre-mRNA in a rapid and ATP-independent manner (Black et aL, 
1985; Bindereif and Green, 1987; Ruby and Abelson, 1988). In addition, yeast Ui snRNP binding 
requires an active 5' splice site as well as a UACUAAC sequence (Ruby and Abelson, 1988), and 
it has been suggested that U 1 snRNP proteins in mammalian in vitro systems bind to branchpoint 
sequences (Zillman et aL, 1987). These observations suggest that Ui snRNP is involved in 
interactions with the branchpoint as well as the 5' splice site, supporting an early role of Ui 
snRNP in spliceosome formation. 
Elegant experiments by Seraphin and Rosbash (1989) unambiguously identify Ul snRNP 
as the commitment factor involved in the early stages of intron recognition and spliceosome 
assembly. They constructed yeast strains which conditionally express either Ui or U2 snRNA. 
Seraphin and Rosbash (1989) prepared splicing extracts from the snRNA-depleted strains, and 
performed a two-step assay for commitment to spliceosome assembly. The first step involved a 
commitment reaction in which one of the snRNA-depleted extracts was incubated with 
radiolabeled substrate RNA; this was followed by a chase reaction in which an excess of unlabelled 
pre-mRNA was added, prior to the addition of the other depleted extract. If stable commitment 
complexes had been formed in the first step, they could be chased into mature spliceosomes in 
the second step, and visualized by native gel electrophoresis. Seraphin and Rosbash (1989) found 
that commitment complexes were formed upon incubation with U2 5nRNP-depleted extracts, and 
these could be chased into functional spliceosomes upon addition of Ui snRNP-depleted extracts 
(which contain active U2 snRNPs); however, U2 snRNP was unable to form commitment 
complexes in the absence of Ui snRNP. Seraphin and Rosbash (1989) concluded that Ui snRNP 
and not U2 snRNP is required for commitment complex formation. 
Seraphin and Rosbash (1989) developed new gel electrophoresis conditions which allowed for 
the visualization of two commitment complexes, of faster mobility than the previously 
characterized complexes I, II and III of Pikielny etal. (1986); both commitment complexes contain 
Ui snRNP only. From a thorough analysis of mutant RNA splicing substrates, it was determined 
that the 5' splice site alone is the requirement for the irreversible and rate-limitting step of 
commitment complex formation, while the presence of a branch sequence is only a requirement 
for assembly of the second commitment complex (B.Seraphin, X.Liao, B.Rymond, Y.Wang, 
N.Abovich, V.Goguel, M.Rosbash, pers. comm., CSH90). 
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It seems that interactions of Ui and U2 snRNPs constitute an ordered process in early 
spliceosome assembly. After formation of the Ui snRNP—pre-mRNA complex, another factor(s) 
must mediate initial branchpoint recognition prior to binding of U2 snRNP. This interaction may 
be mediated by Ui snRNP itself; alternatively, Ui snRNP may interact with proteins that indepen-
dently recognize the 3 region of the intron, such as U2AF (Ruskin et al., 1988; see section 1.7.4) 
or IBP (Tazi et aL, 1986; Gerke and Steitz, 1986; see section 1.7.5). In fact, Zamore and Green 
(1989) report that U2AF binds to the polypyrimidine tract of pre-mRNA rapidly and in the 
absence of ATP; they conclude that early events in the assembly of functional mammalian 
spliceosomes may be similar to the pathway described for yeast, in that conserved sequence 
elements which define the 5 splice site and branchpoint region are recognized prior to the ATP-
dependent step of U2 snRNP assembly on splicing complexes. 
Subsequent to the formation of a complex containing Ui and U2 snRNPs, U5 and U4/U6 
snRNPs are assembled into the splicing complex. In experiments following the time course of 
spliceosome assembly, it appears that U5 and U41U6 snRNPs bind simultaneously to the 
spliceosome (Bindereif and Green, 1987; Cheng and Abelson, 1987; Konarska and Sharp, 1987; 
Lamond et at, 1988). In fact, U5 and U4/U6 snRNPs exist in a single complex, independent of 
the spliceosome, in both yeast and HeLa cell extracts, as observed by native gel electrophoresis 
(Cheng and Abelson, 1987; Konarska and Sharp, 1987, 1988). Lossky et at (1987) have shown that 
yeast US snRNP assembles into a U4/US/U6 snRNP complex only upon incubation of extracts 
with ATP. Black and Pinto (1989) demonstrated a similar ATP-dependence for formation of the 
human U4/U5/U6 snRNP particle. 
Native gel electrophoresis of splicing complexes indicated that assembly of the complex 
containing U!, U2, US and U4/U6 snRNPs is followed by formation of an active splicing complex 
which does not contain U4 snRNA (Pikielny et at, 1986; Cheng and Abelson, 1987; Lamond et 
at, 1988). These results led the investigators to conclude that U4 snRNP, but not U6 snRNA, 
dissociates from the splicing complex prior to the first covalent modification of the pre-mRNA. 
Functional spliceosomes purified by gel filtration chromatography (Reed et at, 1988) or by 
immuno-affinity purification (Whittaker et at, 1990), however, are enriched for Ui, U2, US, U6 
as well as U4 snRNAs. Results presented by Blencowe et at (1989) also controvert the proposal 
that U4 snRNP is released during spliceosome assembly. They prepared biotinylated 2 -OMe 
RNA oligonucleotides complementary to regions of U4 snRNA which served as highly specific 
affinity probes for U4 snRNP (Sproat et at, 1989; Lamond et at, 1989; see also section 1.7.4). 
Blencowe et at (1989) demonstrated that U4 snRNP is stably associated with the fully excised 
intron product, which indicates that U4 snRNP is associated with the spliceosome throughout the 
assembly pathway. Perhaps, as was the case for Ui snRNP (see above), the experimental 
conditions for native gel analysis are too stringent to maintain the association of U4 snRNP with 
the spliceosome. Rather than U4 snRNP being released from the spliceosome, it may be that the 
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stability of the U4—U6 interaction is modulated during the splicing process. The conformational 
change that results in the "release" of U4 snRNP under native gel electrophoresis conditions is 
concomitant with the appearance of splicing intermediates; this suggests a role for the U4—U6 
snRNA interaction in the catalytic activation of the spliceosome. The model for U6 snRNA as 
catalyst and U4 snRNA as its negative anti-sense regulator (Brow and Guthrie, 1989) is supported 
by the results from mutational analysis of U6 snRNA in reconstituted U4/U6 snRNPs (P.Fabrizio 
and J.Abelson, pers. comm., CSH90; see section 1.7.6). 
Following intron excision and exon ligation, the intron product is maintained in a "post-
splicing complex", observed by Konarska and Sharp (1987) and Cheng and Abelson (1987) to 
migrate with greater mobility on native gels than the active spliceosome. The post-splicing 
complex may possess either a different snRNP conformation or fewer splicing factors than does 
the active splicing complex. Anti-U4 2' -OMe probes (Blencowe et aL, 1989) and anti-U2 2' -OMe 
probes (Barabino et aL, 1989) cannot bind their target snRNAs in active HeLa spliceosomes, but 
both U4 and U2 snRNPs are accessible to affinity selection in the post-splicing complex. In 
addition, studies of the yeast spliceosomal protein PRP8 suggest a greater availability of PRP8 
epitopes to antibodies in the post-splicing complex than in the active spliceosome (Whittaker et 
aL, 1990). 
1.8.1 A Model 
On the basis of the preceeding data both for snRNP function and spliceosome formation, 
a model can be proposed for the stepwise assembly of spliceosomes from snRNPs and other 
factors (Figure 1.4). First, Ui snRNP binds the 5' splice site by base pairing, then interacts with 
the branchpoint recognition factor(s), one of which is, in mammalian systems, most likely U2AF 
bound to the pyrimidine-rich sequence of the branchpoint recognition element. The branchpoint 
recognition factor(s) recruit U2 snRNP to the complex, and its interaction is stabilized by base 
pairing between U2 snRNA and the branchpoint sequence of the pre-mRNA. Next, the U4/U5/U6 
snRNP complex is assembled onto the pre-splicing complex, in mammalian systems, this 
interaction may be mediated by recognition of the polypyrimidine tract by the US snRNP-
associated IBP, which could require the prior dissociation of U2AF. US snRNA may interact 
directly or indirectly with the 5' splice site, in some way promoting catalysis of the splicing 
reaction by U6 snRNA, as the U4—U6 snRNA base pairing interaction is destabilized, presumably 
by some other factor(s). Following intron excision and exon ligation, the mRNA molecule is 
released from the spliceosome; as a consequence, some factors may dissociate, resulting in confor-
mational changes within the snRNPs. The intron remains in a post-splicing complex until it is 
debranched, and the remaining snRNPs and factors are recycled. 
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FIGURE 1.4 SnRNPS AND SPLICEOSOME ASSEMBLY 
A model postulated from a combination of published data and results presented at the Cold 
Spring Harbor RNA Processing Meeting, 1990. The nomenclature of Pikielny et aL (1986) is used 
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1.9 PRP GENE PRODUCTS 
1.9.1 Introduction 
Investigation of snRNPs and their assembly into splicing complexes has revealed that the 
spliceosome is a dynamic structure in which multiple factors participate in a variety of interactions 
which catalyze the removal of introns from pre-mRNA molecules. Yeast genetics in combination 
with biochemical analysis represents a powerful means for dissecting the components of the 
splicing apparatus. Genes whose products are involved in splicing can be cloned, and the functions 
of their products investigated in vitro. The PRP (Pre-messenger RNA Processing) genes of yeast 
encode proteins involved in splicing, and comprise over 20 complementation groups. The number 
of PRP genes continues to grow as investigators develop novel or more thorough schemes for the 
isolation of pre-mRNA splicing mutants in yeast. 
1.9.2 Isolation of pT Mutants 
The first set of yeast splicing mutants was isolated in a genetic screen which identified 
genes involved in ribosome biogenesis (Hartwell, 1967). Temperature-sensitive mutants rna2 to 
mall (renamed pip2-11) specifically block the synthesis of ribosomes at the non-permissive 
temperature (Hartwell et aL, 1970), due to a depletion of ribosomal protein mRNA (Warner and 
Gorenstein, 1977). Ribosomal protein genes are some of the few genes in yeast that contain 
introns; prp2 mutants accumulate ribosomal protein pre-mRNA at the restrictive temperature 
(Rosbash et aL, 1981). Lustig et aL (1986) showed that the pip mutant phenotype is in fact caused 
by a defect in nuclear pre-mRNA splicing. They prepared extracts from prp mutants and assayed 
their splicing activity in vitro. Extracts isolated from prp2, prp3, prp4, prp5, prp8 and pipll mutants 
demonstrated heat sensitivity in this assay. Inactivated extract from one mutant was able to 
complement heat-inactivated extract prepared from a different mutant (with the exception of pip4 
and pip8 mutant extracts), which indicates that heat lability is due to the specific loss of an 
exchangeable splicing component; the product of the particular PRP gene (Lustig et aL, 1986). 
Vijayraghavan a aL (1989) identified more genes whose products are involved directly or indirectly 
in pre-mRNA splicing. They generated a bank of 750 temperative-sensitive yeast strains, and 
screened them by Northern blot analysis with an intron-containing probe. Eleven new 
complementation groups were isolated (prpl 7-27) that affect various stages of the splicing pathway 
(Vijayraghavan et aL, 1989; Table 1.2). 
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Table 1.2 Pre-mRNA splicing mutants 
Complementation 	Observed Splicing Defect 














prp20 pre-mRNA and larger transcript 
pip21 pre-mRNA 






Another approach is to isolate suppressors of existing temperature-sensitive mutations, 
thereby identifying more gene products that interact with components of the splicing machinery. 
DJamieson has used this procedure to isolate cold-sensitive suppressors of the pip8.1 mutation 
(pers.comm.). In a similar approach, Couto et aL (1987) isolated pip16 by virtue of its ability to 
suppress a pre-mRNA branch site mutation. J.Morran and JBeggs (pers. comm.) developed a 
novel screening method for the isolation of new yeast splicing mutants. A yeast intron-containing 
gene was fused to the lacZ gene of E. coli so that only the pre-mRNA could be translated to 
produce fl-galactosidase activity. An accumulation of pre-mRNA results in an increase in fi-
galactosidase activity, so a simple colourimetric assay was developed to screen a pool of 
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temperature-sensitive mutants for defects in pre-mRNA splicing. At least three newp,p mutants 
have been isolated by this approach. 
1.9.3 PRP Gene Products and Spliceosome Assembly 
Many of the PRP gene products are involved in spliceosome formation. Heat-inactivated 
extracts from prp3, prp4, prp5, prp7, prp8, prpll and prpl9 mutants do not form spliceosomes (Lin 
et aL, 1987; pipl9: W.-Y.Tarn, H.-Y.Kao and S.-CCheng, pers. comm., CSH90). Heat-inactivated 
pip2 extracts, although heat-sensitive for splicing (Lustig et aL, 1986), form complexes which 
contain uncleaved pre-mRNA (Lin et aL, 1987). These complexes can be chased into active 
spliceosomes upon addition of complementing extracts, which suggests that PRP2 protein does 
not participate in spliceosome assembly, but mediates its function immediately prior to 5' splice 
site cleavage and branch formation (Lin et al., 1987). 
1.9.4 Immunological Analysis of PRP Gene Products 
All of the PRP genes investigated to date encode proteins. Cloning the genes provides the 
basis for preparing immunological reagents with which to probe the interactions between these 
proteins and the splicing machinery. Antibodies raised against PRP8 protein precipitate U5 
snRNA and, in the presence of ATP, U4 and U6 snRNAs also, from yeast splicing extracts 
(Lossky et aL, 1987). These studies identified the 280 kD PRP8 protein (Jackson et aL, 1988) as 
a stable component of both the U5 snRNP and the U4/U5/U6 multi-snRNP complex (Lossky et 
aL, 1987). 
Immunoprecipitation studies performed with anti-PRP4 antibodies demonstrated that 
PRP4 protein is a component of yeast U4I1J6 snRNP (Petersen-BjOrn et aL, 1989; Banroques and 
Abelson, 1989). Micrococcal nuclease protection experiments (Xu et aL, 1990) revealed an 
association of PRP4 protein primarily with the 5' portion, of U4 snRNA in U41U6 snRNP. 
Banroques and Abelson (1989) were able to detect PRP4 protein in U4/U5/U6 snRNP as well. 
in vivo analyses of the functional domains of yeast U4 snRNA (R.Bordonne and C.Guthrie, pers. 
comm., CSH90) demonstrated that a 5' hairpin deletion mutant asssociates efficiently with U6 
snRNA, but does not bind PRP4 protein and does not assemble into a U4/U5/U6 particle, which 
suggests that PRP4 plays an essential role in the interaction between U4/U6 snRNP and US 
snRNP. In fact, there is the possibility that PRP4 and PRP8 proteins interact, perhaps at the stage 
of U4/U5/U6 snRNP complex formation, for pip4 and pip8 heat-inactivated extracts are unable 
to complement one another (Lustig et al., 1986). 
Immunological procedures are also useful for characterizing the interactions of non-
snRNP PRP proteins. Anti-PRP19 antibodies do not precipitate any snRNAs, but spliceosomes 
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are immunoprecipitated to a similar degree as with anti-m 3G antibodies (W.-Y.Tarn, H.-Y.Kao 
and S.-C.Cheng, pers. comm., CSH90). PRP19 may interact with PRP11 protein, another PRP 
gene product integral to the spliceosome (Chang etal., 1988), for prpl9 and pipll heat-inactivated 
extracts are unable to complement each other (W.-Y.Tarn, H.-Y.Kao and S.-C.Cheng, pers. comm., 
CSH90). PRP2 protein, although thought to be a factor extrinsic to the spliceosome (Lin et al, 
1987; see above, section 1.9.3), appears to become transiently associated with the spliceosome late 
in the assembly pathway, upon catalysis of the first cleavage-ligation reaction, for anti-PRP2 
antibodies precipitate splicing precursor and intermediates only, from in vitro splicing reactions 
(D.King and J.Beggs, in preparation). 
PRP 18 protein is another splicing factor not required for spliceosome assembly. In vivo, 
pip18 mutants accumulate lariat intermediate (Vijayraghavan et aL, 1989). Extracts from this 
mutant strain are heat labile for the second step of splicing in vitro (Vijayraghavan and Abelson, 
1990), and antibodies raised against PRP18 do not affect step 1 of splicing, yet inhibit step 2 of 
splicing in wild-type extracts (D.Horowitz, U.Vijayraghavan, and J.Abelson, pers. comm., CSH90). 
The class of prp mutants that have been shown to inhibit specifically the second step of splicing 
in vivo (prpló, prpl 7, pip18; Couto et al., 1987; Vijayraghavan et aL, 1989) will prove very useful 
in identifying the factors which participate in intron excision and exon ligation. In addition, the 
ability to reproduce the inhibition of step 2 in vitro creates an exciting experimental system in - 
which the two steps of the splicing reaction are uncoupled, thereby providing ample opportunity 
for the biochemical characterization of the factors involved in catalysis of either the first or the 
second cleavage-ligation events in splicing. 
1.9.5 DNA Sequence Analysis of PRP Genes 
Detailed DNA sequence analysis of the PRP genes has revealed a variety of protein motifs 
shared by the PRP gene products. The various protein motifs help to shed light on the possible 
roles played by certain PRP proteins during the splicing process. The largest motif group 
comprises the "zinc finger" proteins. A zinc finger consists of an amino acid sequence unit, which 
when folded about a zinc (or another divalent metal) atom, forms a structural domain that binds 
DNA or RNA (Kiug and Rhodes, 1987). The zinc finger motif was first identified in the Xenopus 
transcription factor lilA (TFIIIA Miller et aL, 1985), and it is now recognized as a common 
structural feature of nucleic acid binding proteins (Berg, 1986). 
PRP2, PRP6, PRP9, and PRP1 1 proteins all contain a putative nucleic acid binding zinc 
finger motif(s) (PRP9 contains two). Although these motifs are only loosely related to the TFIIIA 
type of zinc finger, with respect to sequence similarities, the PRP zinc fingers are all very similar 
to each other, and to the putative zinc finger in the human WC protein, a peptide specifically 
associated with Ui snRNP (Legrain and Choulika, 1990). Legrain and Choulika (1990) propose 
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that the PRP and U1C protein zinc finger domains define a new family of structurally related 
proteins which are involved in RNA processing. In pp6 and pp9 mutants, cessation of splicing 
at the nonpermissive temperature is accompanied by a large increase in transport of unspliced pre-
mRNA from the nucleus to the cytoplasm (Legrain and Rosbash, 1989). The splicing deficiency 
exhibited byprpó and pi'p9 mutants appears to be an intron recognition defect, which allows pre-
mRNA to escape the splicing pathway; this suggests that PRP6 and PRP9 proteins are required 
at an early stage of spliceosome assembly for commitment of pre-mRNA to the splicing pathway 
(Legrain and Rosbash, 1989). PRP6 and PRP9 proteins may interact in the same commitment 
complex, for each protein contains a "leucine repeat" motif, a protein domain implicated in homo-
and hetero-dimerization processes (Legrain and Choulika, 1990). 
Legrain and Rosbash (1989) propose that PRP6 and PRP9 may represent the yeast 
analogues of human pre-mRNA commitment factors such as a Ui snRNP protein, the pyrimidine 
tract binding protein U2AF (Ruskin et al., 1988; see above), or heterogeneous nuclear RNP 
protein C, which also participates early in spliceosome assembly (Choi et aL, 1986). PRP11 and 
human U1C proteins display significant sequence similarities in addition to those in the zinc finger 
region, which suggests that these two proteins may be functionally homologous (Legrain and 
Choulika, 1990). Interestingly, human WC protein is required for efficient U1 snRNP-5' splice 
site complex formation (Heinrichs et aL, 1990). Perhaps PRP6, PRP9, and PRP1 1 proteins are all 
involved in commitment complex formation, and their putative RNA binding activities (conferred 
by their zinc finger domains) are involved in recognition at the 5' splice site and/or branchpoint 
of pre-mRNA PRP2 protein, involved much later in spliceosome assembly, could use its putative 
RNA binding domain to guide the 5' end of the intron to the branch site during the first 
cleavage-ligation step of the splicing pathway.' 
PRP2 is part of another PRP sequence motif family which includes PRP16 and PRP22. 
Each of these three proteins shares a large internal region of sequence homology that contains 
a conserved ATP binding motif (PRP2: J.Beggs, unpublished data;  PRP16: Burgess et al., 1990; 
PRP22: J.Abelson, pers. comm., Second European Meeting on Structure and Function of 
Eukaryotic RNP, Delphi, 1990, hereafter referred to as "RNP90"). The prpl6 mutant was isolated 
as a suppressor of the branchpoint mutation UACUACC; the A to C substitution at the site of 
branch formation results in inefficient splicing of the transcript; and the trans-acting suppressor 
prp16 increases splicing of the transcript four-fold (Couto et aL, 1987). The prpló suppressor 
mutation was localized to the putative Al? binding domain of the protein. This prompted Burgess - 
et aL (1990) to propose an elegant "proof-reading" model for branchpoint recognition: suppression 
by prp16 may result from an increase in Al? hydrolysis. Mutations in the translational apparatus 
which are postulated to increase the rate of hydrolysis of Gil' result in an increase in wrongly 
incorporated amino acids during translation. The pip16 mutation may therefore confer a relaxed 
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fidelity to a branchpoint recognition mechanism, which allows greater utilization of the mutant 
branch site UACUACC. 
In vivo and in vitro studies indicate that PRP16 protein is required for the second step 
of splicing. Prp16 mutants accumulate both wild-type pre-mRNA and lariat intermediate (Couto 
et at, 1987). Antibodies raised against PRP 16 inhibit step 2 of splicing, and immunodepleted 
extracts are also blocked at the second step of splicing (B.Schwer and C.Guthrie, pers. comm., 
CSH90). Perhaps the proposed proofreading mechanism of PRP16 is not required for branchpoint 
formation, but rather for intron excision and exon ligation, which may involve another ATP-
dependent recognition event. That PRP2 protein contains a possible ATP-binding domain is 
significant in that its function is required during the ATP-dependent 5' cleavage and lariat 
formation event. It may be that PRP2 protein functions in the proofreading mechanism for branch 
formation. PRP22, the third member of this family of very similar putative ATP binding proteins, 
has an in vivo mutant phenotype of accumulating both pre-mRNA and intron product 
(Vijayraghavan et at, 1989). Vijayraghavan et at (1989) postulate that this phenotype results from 
mutation of a factor involved early in spliceosome assembly; the accumulation of intron may be 
due to the continued association of this factor, thereby affecting the recycling of splicing factors 
after intron release. It is possible then that PRP22 protein is involved in the first ATP-requiring 
step of spliceosome assembly, binding of U2 snRNP to pre-mRNA. PRP22 may bind or hydrolyze 
ATP as part of a branch site recognition mechanism for the snRNA component of U2 snRNP. 
The gene products of PRP4 and PRP17 show striking similarity to fi subunits of 0 
proteins (Dalyrymple et at, 1989; J.Abelson, pers. comm., RNP90). G protein subunits are 
involved in association/dissociation cycles catalyzed by hydrolysis of GTP. A cyclical aspect of the 
pre-mRNA splicing pathway is the postulated stabilization/destabilization cycle of the U4—U6 
snRNA interaction (Dalrymple et at, 1989); U4 snRNA is thought to be a negative regulator of 
U6 snRNA, and upon dissociation of U4, U6 snRNA is free to catalyze the splicing reaction 
(Brow and Guthrie, 1989; also see section 1.7.6). PRP4 and PRP17 proteins, which may share 
structural similarities with 0 protein subunits, may be involved in this catalytic cycle. Another 
possibility is that this motif simply has a general role in protein—protein recognition (Dalrymple 
et at. 1989). In the case of PRP4 protein, these domains could be involved in mediating the 
postulated interactions between U4/U6 snRNP and U5 snRNP in the formation of the U4/U5/U6 
particle (see section 1.9.4). PRP17 is a protein whose in vivo mutant phenotype of lariat 
intermediate accumulation suggests that it is required for step 2 of the splicing reaction 
(Vijayraghavan et at, 1989); it may participate in snRNP—snRNP interactions during the second 
cleavage-ligation reaction. 
PRP5, PRP28, and SPP81 (formerly called DEDJ, a suppressor of the pip8.1 mutation; 
D.Jamieson, pers. comm.) belong to the RNA helicase gene family, which encodes a group of 
homologous proteins, some of which have been shown to possess an intrinsic RNA-dependent 
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ATPase activity capable of unwinding double-stranded RNA in an ATP-dependent manner (Linder 
et aL, 1989). All of the proteins in the RNA helicase family share three highly conserved amino 
acid sequence elements: (I) DX 4AX4GKT is a specialized AT? binding motif; (ii) 
(VII)LDEADX2L, the "DEAD box", represents a modified AT? binding motif, unique to these 
proteins; and (iii) HRIGR is the sequence element thought to participate in polynucleotide 
binding and/or the unwinding activity (Linder et aL, 1989). 
It is interesting to speculate about the roles of helicase proteins in pre-mRNA splicing, 
for there are several aspects of the splicing process which could necessitate the unwinding of 
double-stranded RNA. Functional PRP5 protein is required for the first ATP-dependent step in 
splicing, binding of U2 snRNP to pre-mRNA, but not for Ui snRNP binding (Dalbadie-
McFarland and Abelson, 1990). PRP5 may mediate its heli case activity on a component of the Ui 
5nRNP—pre.mRNA commitment complex, or on U2 snRNP itself, to adopt conformations which 
allow U2 snRNP binding; alternatively, PRP5 may simply need to be assembled early into the 
spliceosome, and use its helicase activity later in the splicing pathway (Dalbadie-McFarland and 
Abelson, 1990), perhaps for dissociation of U2 snRNA from the branch site of pre-mRNA. 
A.Newman and C.Norman demonstrated an involvement of U5 snRNA in mediating 5' cleavage 
(pers. comm., CSH90; see section 1.7.5), so one can imagine that the US snRNP may utilize the 
helicase activity of SPP81, a protein which interacts with the U5 snRNP protein PRP8, to unpair 
Ui snRNA from the 5' splice site region of the pre-mRNA and allow catalysis of the 5' cleavage 
event. 
By far the most obvious aspect of splicing which would require helicase activity is the 
unwinding of U4 from U6 snRNA. Indeed, Brow and Guthrie (1988) predicted that due to both 
the extensive region of base pairing between U4 and U6 snRNAs and the high melting 
temperature (53 0C) of the RNA—RNA complex, an energy-dependent "active mechanism" would 
be required to achieve the destabilization of the U4—U6 snRNA interaction. It is likely that 
PRP28 protein caries out this function. Genetic studies conducted by E.Strauss and C.Guthrie 
(pers. comm., CSH90) indicate that PRP28 and PRP24 proteins interact closely in the splicing 
machinery, for prp281prp24 double mutants are inviable. PRP24 protein contains three regions 
homologous to the approximately 90 amino acid "RNA binding domain" conserved among many 
RNA binding proteins from yeast to man (Bandziulis a aL, 1989). Prp24 was isolated as a 
suppressor of a mutation in U4 snRNA which destabilizes the U4—U6 snRNA complex 
(K.W.Shannon and C.Guthrie, pers. comm., CSH90). The mutation inprp24 is a single nucleotide 
substitution in the carboxy-terminal RNA binding domain. Anti-PRP24 antibodies precipitate U6 
snRNA in both the presence and absence of AT?, yet the precipitation of U4 snRNA is enriched 
to a level comparable to precipitated U6 snRNA only in the presence of AT?. Shannon and 
Guthrie conclude that PRP24 may act to sequester U6 in a form which is unable to interact with 
U4 and may act to stabilize U6 in a low-stability U4—U6 complex. Strauss and Guthrie propose 
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that PRP28 is the helicase that may catalyze the destabilization of U4—U6, and that PRP24 and 
PRP28 cooperate in a helix stabilization/destabilization cycle during the splicing process. 
PRP8 protein does not share sequence similarities with any other known protein. It does, 
however, contain an interesting region at its amino-terminus in which the motif (P 6 acidic) is 
repeated four times (J.Beggs, pers. comm.). In fact, there is not a single basic residue for 83 amino 
acids in the amino-terminal region of PRP8 protein. This proline-rich acidic domain is likely to 
be unstructured, perhaps forming a flexible tail which protrudes from the rest of the protein. 
Although the function of the amino-terminal region of PRP8 protein is not known, one can 
speculate that it may be involved in protein—protein interactions. Indeed, several transcriptional-
regulatory proteins possess highly acidic carboxy- or amino-termini which are thought to stimulate 
the assembly and/or activation of transcriptional pre-initiation complexes (Sigler, 1988). 
1.9.6 A Model 
Data from in vivo and. in vitro studies, in combination with ample speculation provided 
by DNA sequence analysis, has elucidated the possible roles played by many of the PRP gene 
products in pre-mRNA splicing. Figure 1.5 summarizes the preceeding discussion of PRP gene 
products and depicts their postulated roles in spliceosome assembly and in the splicing process. 
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FIGURE 1.5 PR!' GENE PRODUCTS AND SPLICEOSOME ASSEMBLY 
A model proposed on the basis of published data and results presented at the Cold Spring Harbor 
RNA Processing Meeting, 1990. Splicing complexes are depicted according to the model and 
nomenclature of Cheng and Abelson (1987). Splicing complexes corresponding to those identified 
by Pikielny et aL (1986) are labelled with the appropriate nomenclature, in parentheses. 
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1.10 THE AIM OF THIS THESIS 
Immunological procedures were employed to probe the interactions between PRP8 
protein and other factors in the splicing apparatus, in order to gain insight to the role of PRP8 
protein in the splicing process. The results of these investigations and their implications for 
understanding PRP8 function are discussed. In this thesis, I present: 
Immunoprecipitation of RNA precursors, splicing intermediates and products 
from in vitro splicing reactions; 
Affinity purification of yeast spliceosomes and identification of PRP8 protein as 
a component of functional spliceosomes; 
UV-Crosslinking of PRP8 protein to pre-mRNA and demonstration that the 
PRP8 protein—pre-mRNA interaction occurs immediately prior to or 
concomitant with step 1 of the splicing reaction; 
Preliminary nbonuclease protection mapping of the region(s) of pre-mRNA with 
which PRP8 protein interacts. 
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CHAPTER TWO 
GENERAL METHODS AND MATERIALS 
2.1 SUPPLIERS OF LABORATORY REAGENTS 
RNA and DNA modifying enzymes: 
Ainersham International, Bethesda Research Laboratories (BRL), Boehringer Mannheim, New 
England Biolabs, Pharmacia, and Sigma. 
Ribonucleotides and deoxyribonucleotides: 
Pharmacia and Sigma. 
Radiochemicals: 
Amersham International and Du Pont (NEN Research Products). 
Acrylamide and bis-acrylamide: 
BDH Chemicals, "Electran" grade. 
SDS, recrystalized: 
Serva, Research grade. 
Standard laboratory reagents (analytical grade or better): 
BDH Chemicals, Bio-Rad, Fisons, Koch-Light and Sigma. 
2.2 GENERAL MlcnIODS 
2.2.1 General Guidelines 
Unless otherwise stated all small-scale procedures were performed in sterile 1.5 ml 
polypropylene microfuge tubes (handled only with gloved hands, to avoid nbonuclease 
contamination), while large-scale procedures were performed in 15 ml or 30 ml sterile Corex tubes 
or in 10 ml Sterilin tubes or 50 ml Falcon tubes (sterile when purchased). Liquids were dispensed 
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using Gilson Pipetman P-20, P-200 and P-1000 automatic pipettors with sterile tips or sterile glass 
pipettes. All procedures were performed at room temperature unless otherwise stated. 
Centrifugation of volumes less than 1.5 ml was performed in an Eppendorf 
microcentrifuge at 13,000 rpm, and centrifugation of volumes up to 50 ml was performed in an 
IEC Centra-4X bench-top centrifuge with a 215A swing-out rotor. High speed centrifugation of 
volumes greater than 1.5 ml was performed in a Sorvall RC-5B Superspeed centrifuge with the 
appropriate Sorvall rotor. 
2.2.2 Sterilization Procedures 
Polypropylene microfuge tubes, Gilson Pipetman tips and most solutions were sterilized 
by autoclaving at 1200C, 15 pounds/inch2 for 15 minutes. 
Corex tubes, glass pipettes and other glassware were dry-sterilized by baking in an oven 
at 2500C for 16 hours, a procedure which eliminates ribonuclease. 
Small volumes of solutions were sterilized by filtration through Acrodisc filter-sterilisation 
units (0.45 micron pore size; Gelman Sciences). 
2.2.3 Preparation of Solutions 
All solutions were prepared in sterile glassware, using distilled or double-distilled water 
and (for stock solutions) were filtered through two sheets of Whatman No. 1 filter paper. 
Solutions were sterilised either by autoclaving or by filtration (2.2.2). Solutions were stored at 
room temperature unless otherwise stated. 
2.2.4 Autoradioraphy 
Nucleic acids and proteins labelled with [321 were detected by exposure of gels or filters 
to X-ray film (Du Pont Cronex or Ainersham Hyperfilm-MP) in light-proof, lead-shielded 
cassettes by one of the following methods, depending on the amount of radioactivity in the gel or 
on the fflter. (in order of increasing sensitivity) (i) at room temperature; (ii) at -70 0C with a 
calcium-tungstate intensifying screen; (iii) with pre-flashed film at -70 0C with an intensifying 
screen (Lasky, 1984). 
2.2.5 Densitometry 
Quantitative comparison of the detected amounts of radiolabelled nucleic acid was 
performed by densitometric scanning of autoradiographs with a Shimadzu Dual-Wavelength 
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Chromato Scanner, model CS-930 (Howe, London) according to the manufacturer's operating 
instructions. 
2.2.6 Dialysis Tubing 
Dialysis tubing (Medicell International Ltd.) was prepared by boiling in a large volume 
of 2% (w/v) sodium bicarbonate, 1 mM EDTA for 10 minutes, rinsing thoroughly in dH 20 and 
boiling for 10 minutes in dH20, and it was stored at 4 0C in 50% (v/v) ethanol. Before use, the 
tubing (which was always handled with gloved hands) was washed, inside and out, with dH 20. 
2.2.7 Determination of Protein Concentration by the ESAU Assay 
For estimating the concentration of protein, a series of dilutions of the sample and a 
standard series of dilutions of BSA, ranging from 1 to 0.1 mg/ml, were prepared; 2 l each dilution 
was spotted onto a piece of Whatman No. 1 filter paper which was then dried in a 650C incubator. 
The filter was covered with ESAU stain [25% (v/v) propan-2-ol, 10% (v/v) acetic acid, 0.1% (w/v) 
Coomassie Brilliant Blue R250J and incubated for 5 minutes at room temperature, then rinsed 
under running tap water until the background staining was low. The relative intensities of the 
sample spots were compared to the standard spots to estimate protein concentration. 
2.2.8 Buffers 
lOx TAE: 	 0.4 M Tns-acetate (pH 7.5), 20 mM EDTA unsterilized. 
lOx TBE: 0.9 M Tris-borate (pH 8.3), 20 mM EDTA unsterilized. 
lOx TBS: 	 0.5 M Tris-HCL (pH 7.5), 1.5 M NaCl; autoclaved. 
2.3 GENERAL NUCLEIC ACID METHODS 
2.3.1 Storage of Nucleic Acids 
Double-stranded plasmid DNA was stored at 4 0C, while linearized plasmid DNA, 
oligodeoxynucleotides and RNA were stored at -20 0C. 
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2.3.2 Quantitation of Nucleic Acids 
The optical density at 260 nm of the nucleic acid solution was determined in an Ultrospec 
II spectrophotometer (Pharmacia LKB Biochrom) and its concentration calculated by assuming 
that an optical density of 1.0 corresponds to 50 pg/ml of double-stranded DNA, 40 jig/ml single-
stranded DNA or RNA, and 20 g/ml oligodeoxynucleotide (Sambrook et aL, 1989). 
2.3.3 Deproteinization of Nucleic Acid Solutions 
Aqueous nucleic acid solutions were deproteinised by extraction with phenol and 
chloroform. An equal volume of phenol:chloroform [1 part dH 20-equilibrated phenol to 1 part 
chloroform (24:1 (v/v) chloroform to iso-amyl alcohol) stored at 4 0C. up to one month] was added 
to the nucleic acid solution and the phases mixed by vortexing. The phases were separated by 
centrifugation in a microcentrifuge for 3 minutes and the upper (aqueous) phase transferred to 
a fresh tube. In order to retrieve nucleic acid material from the interface, a single back-extraction 
was performed following phenol:chloroform extraction. To the lower (organic) phase was added 
dH20, and the aqueous phase was extracted as described above and added to the aqueous phase 
from the previous extraction. Extraction with phenol:chloroform was repeated as necessary until 
no material was observed at the phase interface following centrifugation. 
2.3.4 Preparation of Escherichia coli tRNA 
A stock solution of 20 mg/ml E. coli tRNA was prepared by dissolving the solid tRNA 
(Sigma, Type XX) in dH20, followed by extensive extraction with phenoi:chloroform (see above). 
The solution was extracted once with dH 20-equiiibrated phenol, then repeatedly with 
phenol:chloroform until the phase interface was clear of any material. A final chloroform 
extraction was performed to remove residual phenol. This E. coli tRNA preparation was used for 
all procedures requiring nucleic acid as carrier during precipitations or as competitor for non-
specific RNA—protein interactions. 
2.3.5 Precipitation of Nucleic Acids with Ethanol 
To precipitate nucleic acid from an aqueous solution, 0.13 volume of 7.5 M ammonium 
acetate, 4 jAg E.coli tRNA (if needed as carrier), and 3 volumes of ethanol were added, and the 
mixture was incubated at -700C for 15 minutes or at -20 0C overnight. The precipitated nucleic 
acid was recovered by centrifugation in a microcentrifuge or Sorvali HB-4 rotor at 10,000 rpm for 
30 minutes at 40C. The pellet was washed by resuspending it in 70% ethanol and recovering by 
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centrifugation as above. Following the wash step, the supernate was aspirated with a drawn out 
pasteur pipette, and the pellet dried in a 650C incubator. The nucleic acid was then dissolved in 
the desired volume of dH 20. 
2.3.6 Measurement of Radioactivity in Nucleic Acids by Precipitation 
The percentage incorporation of radiolabelled nucleotides into nucleic acids was estimated 
by comparing acid-precipitable Cërenkov counts to total Cerenkov counts in a given reaction. A 
small aliquot of the reaction was diluted in dH 20, and 1 gl of the dilution was spotted onto a 
Whatman GFIC glass fibre disc. To 49 gl of 2.5 mg/ml tRNA was added 1 1A of the same dilution, 
and then 12.5 Al 50% (w/v) TCA was added. The mixture was incubated on ice for 15 minutes. 
Precipitated nucleic acid was collected by vacuum filtration onto a Whatman GF/C glass fibre disc, 
and washed with 10 ml ice-cold 10% (w/v) TCA and 10 ml ice-cold ethanol. The radioactivity of 
the two glass fibre discs was measured in a scintillation counter, and the two values were 
compared to obtain the percentage incorporation. 
2.3.7 Digestion of DNA with Restriction Endonucleases 
DNA was incubated with a greater than two-fold excess of restriction endonuclease in the 
buffer recommended by the enzyme's manufacturer with the volume of the enzyme stock solution 
added not exceeding 10% of the total volume. Incubations were continued for at least one hour 
at 370C. Reactions were terminated by freezing or extraction with phenol:chloroform (2.3.3). 
Completion of digestion was assessed by agarose gel electrophoresis (2.4.5). 
2.3.8 DNA Size Markers for Polvacrvlamide Gel Electrophoresis 
DNA size markers were prepared by a 3' end-filling reaction (Sambrook et aL, 1989) 
which incorporated label into the DNA fragments produced from an MspI restriction digestion 
(2.3.7) of pBR322 (Sutcliffe, 1979) and from an AvaI+NheI digestion of the same plasmid. 
Digested DNA (0.1-0.2kg) was incubated for 30 minutes at 37 0C in a 10il final reaction volume 
containing 10 mM Tris-HC1 (pH 8.0), 10 mM MgC1 2, 0.2 mM each of dATP, dGTP and TFP, 10 
Ci [a-32P]dCrP (3000 Ci/mmol, Amersham), and 1 U Klenow fragment of DNA polymerase. 
The labelled DNA was phenol:chloroform extracted and precipitated with ethanol (2.3.3;2.3.5), 
and stored at -20°C. Table 2.1 lists the lengths of the labelled DNA fragments generated by the 
above procedure. 
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Table 2.1 DNA size markers 
Restriction Fragments 
pBR322 Digest 	(length in nucleotides) 
AvaI+NheI 	 3167, 1196 
MspI 	 622, 527, 404, 309, 242, 
238, 217, 201, 190, 180, 
160, 147, 122, 110, 90, 
76, 67, 34, 26, 15, 9 
2.4 GEL ELECTROPHORESIS 
2.4.1 Deionization, Filtration, and Storage of Stock Gel Solutions 
Stock gel solutions were deionized by adding approximately 0.1 volume mixed bed ion-
exchange resin beads [Bio-Rad, AG501-X8(D)], and the mixture was stirred at room temperature 
for 30 minutes. The stock solution was then filtered through two sheets of Whatman No.1 paper. 
Gel solutions were stored at 4 0C, and new stocks were prepared monthly. 
2.4.2 Degassing of Gel Solutions 
Gel solutions were degassed immediately prior to pouring the gel in order to remove 
dissolved oxygen which inhibits acrylamide polymerization (Ausubel et aL, 1989). The gel solution 
was brought to room temperature, then placed in a vacuum dessicator attached to a vacuum 
pump, and degassing proceeded for 15 minutes. 
2.4.3 Denaturing Polyacrylamide Gel Electrophoresis of RNA and DNA 
Denaturing (sequencing) polyacrylamide gels, as described by Maxam and Gilbert (1980), 
contained 6% (WA') acrylamide (a 1:20 mixture of bisacrylamide to acrylamide), 8M urea, and lx 
KM 
TBE. Denaturing polyacrylamide gels used for the electrophoresis of small (less than 100 
nucleotides) RNA and DNA molecules consisted of 20% (wlv) acrylamide (1:20 bisacryla-
mide:aciylamide), 7M urea, and lx TBE. Stock solutions for 6% gels were prepared by dissolving 
1.5 g bisacrylamide and 28.5 g acrylamide in 150 ml dH 20; 235 g urea were added, and the 
mixture was stirred and heated until the urea went into solution. Stock solutions for 20% gels 
contained 5 g bisacrylamide, 95 g acrylamide, and 210 g urea. The volume of the stock solution 
was adjusted to 450 ml with dH 20, and the solutions were deionized, filtered, and stored at 4 0C 
(2.4.1). Gels were prepared by mixing 45 ml gel stock with 5 ml lOx TBE, degassing the gel 
solution (see above), and then adding polymerization initiator and catalyst (for 6% gel: 0.25 ml 
10% APS (made fresh daily) and 50 1il TEMED; for 20% gel: 0.4 ml 10% APS and 40 111 
TEMED). The gel mixture was poured with the aid of a 25 ml pipette between two 42 x 23 cm 
glass plates, separated along their edges by two 1 x 42 cm strips of 0.38 mm Plastikard (Slaters' 
Plastikard No. 0115, Derbyshire, UK) and sealed with sellotape (DRG, Herts, UK). Before sealing, 
the plates had been rinsed with dH 20 and ethanol, and rubbed with acetone. A Plastikard slot-
forming comb (18 x 8 mm wells) was inserted, and the gel allowed to polymerize (for 6% gel: at 
least 1 hour; for 20% gel: 15 minutes). The comb and the tape sealing the bottom edge of the gel 
were removed, and the gel placed in a vertical electrophoresis tank filled with lx TBE. The gel 
was pre-electrophoresed for at least 20 minutes at 33 W (6% gel) or 37 W (20% gel). Samples 
were combined with an equal volume of 2x urea load buffer [10M urea, lx TBE, 0.2% (w/v) each 
bromphenol blue and xylene cyanole; filter sterilized, and stored at -20 0C], heated to 900C for 3 
minutes, and loaded in flushed out wells with a drawn out glass capillary tube. After the 
completion of electrophoresis, the gel plates were prized apart, the gel was either transferred to 
blotting paper (6% gel) or kept on one glass plate (20% gel) and analysed by autoradiography 
(2.2.4). 
2.4.4 SDS Polyacrylamide Gel Electrophoresis of Proteins 
Proteins were separated by SDS-discontinuous polyacrylamide gel electrophoresis (SDS-
PAGE) as described by Laemmli (1970). An 8.5% separating gel mix (Table 2.2) was prepared 
[degassing (2.4.2) was performed prior to the addition of SDS, polymerization initiator and 
catalyst] and poured between two 16 x 16 cm glass plates (rinsed with dH 20 and ethanol, 
separated at their edges by 1.5 mm spacers, sealed with rubber tubing and clamped into an ATTO 
gel-casting apparatus, model SJ-1060) to within 5 cm of the notched plate. The gel mix was 
layered with dH20 and the assembly left in an upright position at room temperature for 30 
minutes to allow polymerization. The dH 20 was poured off the surface, stacking gel mix (Table 
2.2) was prepared, then poured onto the separating gel up to the top of the notched plate, and 
a Teflon slot-forming comb (12 x 0.5 cm wells) was inserted. The gel was allowed to polymerize 
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for 15 minutes, and the comb and sealing rubber tubing were removed. The gel assembly was 
transferred to an ATTO electrophoresis tank (model SJ-1060) which was filled with SDS-PAGE 
buffer [25 mM Tris-base, 192 mM glycine, 0.1% (w/v) SDS; pH 8.8; prepared as a lOx stock 
solution]. Samples were prepared by mixing with an equal volume of 2x protein load buffer [125 
mM Tris-HC1 (pH 6.8), 200 mM DTI', 4% (wAr) SDS, 40% (vAr) glycerol, 0.02% (w/v) bromphenol 
blue; stored at 40C for no more than 2 weeks] and heating to 100 0C for 5 minutes before being 
loaded on the gel. Electrophoresis was performed at 60-175 V for 3-16 hours. 
2.4.4.1 Protein Molecular Weight Markers 
Prestained SDS molecular weight standards (26.6, 36.5, 48.5, 58, 84, 116, and 180 kD; 
Sigma) or high molecular weight markers (28, 45, 66, 97, 116, and 205 kD; Sigma) were stored at - 
200C in 2x protein load buffer and were prepared for gel electrophoresis in the same manner as 
were other protein samples. 
Table 2.2 Composition of gel solutions for SDS polyaclylamide gel electrophoresis of proteins 
Separating Gel Stacking Gel 
8.5 ml 1.67 ml 30% aclylamide 
4.0 ml 1.30 ml 1.25% bisacrylamide 
11.2 ml - 1 M Tris-HC1 (pH 8.8) 
- 1.25 ml 1 M Ths-HC1 (pH 6.8) 
6.2 ml 5.78 ml dH20 
150 .d 50 p.1 20% SDS 
150 p.1 100 Al 10% APS 
15 Al 10 Al TEMED 
2.4.5 Agarose Gel Electrophoresis of DNA and RNA 
Horizontal 0.8% (wAr) (for DNA) or 1.2% (w/v) (for RNA) agarose slab gels were 
prepared by dissolving the agarose (BRL UltraPure) in lx TAE buffer by heating in a microwave 
oven for approximately 5 minutes. Agarose gels for the analysis of RNA contained 0.1% (vAr) 
diethyl pyrocarbonate (Sigma), an RNase inhibitor, which was added prior to heating the gel 
38 
solution. The gel solution was cooled to approximately 500C and ethidium bromide was added to 
a final concentration of 1 Ag/ml. The gel solution was poured into a 9 x 13 x 0.4 cm dish fitted 
with a perspex comb to form 0.4 cm wells. The gel was allowed to solidify for 45 minutes, then 
placed in a horizontal tank containing lx TAE. Before loading, 0.2 volumes of gel load buffer 
[30% (v/v) glycerol, 0.25% (w/v) each bromphenol blue and xylene cyanole] was added to the 
sample, and the gel was electrophoresed, using filter paper wicks, at 100 V for the appropriate 
time. DNA and RNA were visualized on a short wavelength UV transilluminator and, if required, 
photographed through a red filter using Ilford HP5 5 x 4 inch negative or Polaroid 667 positive 
film. 
2.5 YEAST IN VITRO SPLICING 
2.5.1 Preparation of Yeast Splicing Extract 
2.5.1.1 Growth and Storage of Yeast 
Yeast cells were propagated as described by Sherman et al. (1983). Cultures were grown 
in YPDA (10 g Difco Bacto yeast extract, 20 g Difco Bacto peptone, 20 g glucose, 20 mg adenine 
sulphate) at 30°C with continuous shaking, and their growth monitored by determination of the 
optical density of the culture at 600 nm. Strains were maintained on YPDA-agar plates, and cells 
in colonies on the surface of inverted agar medium plates remained viable for at least 1 month 
at 40C, while long-term storage was achieved by making a saturated liquid culture 15% (v/v) in 
glycerol and freezing at -70 0C. 
2.5.1.2 Whole Cell Splicing Extract 
The method for the preparation of yeast splicing extracts was modified from Lin et at 
(1985). The yeast strain BJ2412 (a/a, gaI2, leu2, pep4-3, prbl -1122, prcl -407, trpl, ura3-52; 
acquired from EJones) was grown, with vigorous shaking, at 300  C, in 11 YPDA, to an optical 
density at 600 nm of 0.5-0.6. The cells were harvested by centrifugation at 5,000 rpm for 5 minutes 
(Sorvall GS-3 rotor), resuspended in 50 mM potassium phosphate buffer (1 M potassium 
phosphate buffer: 1 M K2PO4 titrated to pH 7.5 with 1 M KH2PO4), and transferred to a 50 ml 
Falcon tube. The cells were pelleted at 3,000 rpm for 3 minutes (IEC Centra-4X bench-top 
centrifuge, 215A rotor), and resuspended in 40 ml lyticase buffer (1.2 M sorbitol, 50 mM 
potassium phosphate buffer, 30 mM DTT) with 2,500 U lyticase (Sigma; dissolved in dH 20 at 
2,500 U/mI and stored at 40  C). The cells were incubated with gentle agitation for 30 minutes at 
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300C, and the completion of spheroplasting was checked by examining digestion of the cell wall, 
as follows: an aliquot (25Al) of the cells was removed, and the cells pelleted for 1 minute in a 
microcentrifuge; the cells were resuspended in either dH 20 or 1.2 M sorbitol, and examined under 
the microscope; 90% lysis of the cells in dH 20 indicated sufficient removal of the cell wall. After 
the 30 minute incubation, the spheroplasts were gently washed twice (3 minutes at 2000 rpm, 
bench-top centrifuge) with 1.2 M sorbitol, then transferred to an Erlenmeyer flask with 250 ml 
YPDAS (YPDA with 1.2 M sorbitol), and incubated with gentle agitation for 1-1.5 hours at 30 0C 
to increase metabolic activity (Hutchinson and Hartwell, 1967). The spheroplasts were harvested 
(5 minutes at 5,000 rpm, Sorvall GSA rotor), resuspended in ice-cold SB-3 buffer [50 mM Tris-
HCL (pH 7.5), 1.2 M sorbitol, 10 MM  MgCl2, 3 mM DTI], then pelleted (3 minutes at 2,000 rpm, 
bench-top centrifuge) and weighed. The spheroplasts were resuspended (1 ml per gram wet 
weight) in ice-cold buffer A [10 mM HEPES-KOH (pH 7.5), 1.5 MM  MgCl2, 10 mM HC1, 0.5 mM 
DTT], and transferred to the receptacle of a 15 ml Dounce tissue homogenizer (Jencons Scientific 
Ltd., Leighton Buzzard, England) set in ice, and incubated 5 minutes. All subsequent 
manipulations were carried Out in a 4 0 C laboratory. The spheroplasts were lysed by 10 to 12 up-
and-down strokes with a tight-fitting Teflon pestle (Jencons PTFE pestle head, for 30 ml 
homogenizer; machined down to fit 15 ml homogenizer). The lysate was transferred with a glass 
pipette to a 10 ml beaker set in ice, and stirred while 2 M KC1 was added to a final concentration 
of 0.2 M. The lysate was stirred for 30 minutes, then transferred to a 30 ml polycarbonate tube 
(Sorvall Oak Ridge Bottle), and centrifuged at 17,000 rpm for 30 minutes at 4 0C (Sorvall SS-34 
rotor). The clear supernate was collected, avoiding the cloudy top layer of lipids and the pellet 
of cell debris, transferred to a 12 ml polycarbonate bottle (Beckman 5/8 x 3 Bottle AY), and 
centrifuged at 40C for 1 hour at 37,000 rpm (Beckman 50Ti rotor). The clear supernate was 
dialyzed for 3 hours against 11 buffer D [20 mM HEPES-KOH (pH 7.5), 0.2 mM EDTA, 0.5 mM 
DTT, 50 mM KC1, 20% (v/v) glycerol]. The extract was cleared of insoluble material by 
centrifugation (10 minutes at 40C, microcentrifuge), frozen in N 20) in small aliquots, and stored 
at -700C. Each aliquot of extract was thawed and refrozen no more than three times. The protein 
concentration of the extract was generally 20-25 mg/ml, as determined by the ESAU assay (2.2.7) 
2.5.1.3 40% Ammonium Sulphate Precipitate of Whole Cell Splicing Extract (40P 
The method for the preparation of 40P was modified from Vijayraghavan et aL (1986) and 
Cheng and Abelson (1986). A 2 1 culture of BJ2412 was grown, and similar procedures were 
followed as those for the preparation of whole cell extract (see above), with all operations 
correspondingly scaled up to accommodate the doubled mass of cells. In the preparation of 40P, 
the supernate from the 37,000 rpm centrifugation step was transferred to a 10 ml beaker on ice. 
As the supernate was stirred, solid ammonium sulphate (BDH grade for enzyme work; ground to 
a fine powder with mortar and pestle) was slowly added until the saturation of ammonium 
sulphate reached 40% (0.246 g ammonium sulphate/ml supernate; the percentage of ammonium 
sulphate represents percentage saturation at 25 0C). The 40% ammonium sulphate-saturated 
supernate was stirred for 30 minutes, then transferred to a 30 ml polycarbonate tube, and 
centrifuged at 4 0C for 20 minutes at 17,000 rpm (Sorvall SS-34 rotor). The pellet was dissolved 
in one-tenth the original volume of the supernate (from the 37,000 rpm centrifugation step) in 
buffer D (see above). The 40P fraction was dialyzed for 3 hours against two changes of 1 1 of 
buffer D followed by centrifugation (10 minutes at 4 0 C, microcentrifuge) to remove small 
amounts of insoluble material, and frozen and stored at 70 0  C in aliquots. As for the whole cell 
extract, aliquots were thawed and refrozen no more than three times. The protein concentration 
of 40P varied from 10-15 mg/ml, as estimated by the ESAU assay (2.2.7). 
2.5.2 In Vitro Transcription 
77 and SP6 polymerase-directed in vitro transcription reactions were performed essentially 
as described by Melton et aL (1984). The plasmids from which pre-mRNA was transcribed are 
described in Table 2.3. Linearized DNA (0.2 Ag, taken directly from the restriction endonuclease 
reaction, 2.3.7) was incubated at 37 0C for 30 minutes in a 10 Al reaction volume containing either 
Ix Ti buffer [40 mM Tris-HCI (pH8.0), 10 mM MgC1 2, 10 mM DTI', 10 mM NaC1] or lx SP6 
buffer [40 mM Tris-HC1 (pH 7.5), 6 mM MgC12, 10 mM DTI], 10 U RNasin (Promega), 0.5 mM 
each of ATP, GTP, Cl?, and UTP (Pharmacia, Ti grade), and either 10 U of T7 RNA 
polymerase (Boehnnger Mannheim) or 8 U of SP6 RNA polymerase (BRL). Reactions were 
stopped on ice. The transcription reactions were analysed for the presence of RNA by 
electrophoresis through a 1.2% agarose gel (2.4.5). 
Radiolabelled RNA transcripts were generated by supplementing the transcription 
reactions with 30 ILCi [a-32PIUTP  (800 Ci/mmol, Amersham), and reducing to 25 M the 
concentration of UTP (including radiolabelled UTP). For the production of high specific activity 
RNA transcripts, 60 pCi [a-32P]UTP (800 Ci/mmol, Amersham) were dried under vacuum 
(Genevac Centrifugal Evaporator CE100, Genevac Ltd., Ipswich, England) then resuspended in 
dH20 before being added to the transcription reaction. The percentage incorporation of radiola-
bel, as determined by precipitation with TCA (2.3.6), was generally 60%. Approximately 10 pmoles 
RNA were created in the transcription reactions conducted with limiting amounts of UTP. 
RNA transcripts were extracted with phenol:chloroform, back-extracted with dH 20, and 
precipitated with ethanol (2.3.3;2.3.5). The pellets were washed with 70% ethanol, dried in a 65 0C 
incubator, and resuspended in the appropriate volume of dH 20. RNA transcripts were stored at - 
200C; radiolabelled transcripts were kept for no more than 3 days. High specific activity transcripts 
were used only on the day they were prepared. 
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Table 2.3 Plasmids used for transcription of pre-mRNA 
Plasmid 	Gene 	Linearized 	Transcript 	 Origin 
pT7rp28s rp28 EcoRI 	wild-type 	 M.Lossky 
p1122 rp28 XbaI 	wild-type 	 A.Baker 
p(T7)GEM284 rp28 EcoRI 	Gi to A substitution 
at 5' splice site 	 A.Newman 
p(T7)GEM287 rp28 EcoRI 	A to C substitution 
at branchpoint 	 A.Newman 
pSPrp5lA rpSl BamHI 	wild-type, poly(A)-tailed Pikielny 
pSPrp5lA(5'-O) rpSl BamHI Y splice site deletion and 
pSPrp51A(z3B) rp5l BamHI 	UACUAAC box deletion Rctash (D85)  
2.5.3 In Vitro Splicing Assay 
The assay for the production of mRNA and splicing intermediates was performed 
essentially as described by Lin et aL (1985). Radiolabelled RNA (see above) was assembled with 
all components of the reaction at room temperature. The 10 Al reactions contained approximately 
5 nM RNA (0.075 MCi), 2.25 mM ATP, 2.5 mM Mg , 175 mM K, 2.6 mM citric acid (pH 3.0), 
11.3% (v/v) glycerol, 3% (w/v) polyethylene glycol 8000 (Sigma), 10 mM HEPES-K (pH 7.5), 
0.1 mM EDTA (pH 8.0), 0.25 mM DTT, and 10 to 12.5 mg/ml protein. Splicing extract 
(comprising 50% of the reaction volume) was the final component added, and the reactions were 
incubated at 250C for the appropriate time (30 seconds to 30 minutes). Reactions were terminated 
by a brief Incubation on ice, followed by the addition of 2 1d proteinase K solution [50 mM EDTA 
(pH &0), 1% (w/v) SDS, 1 mg/ml proteinase K (Boehringer Mannheim)] and a 20 minute 
incubation at 370C. Cocktail buffer [100 p.1; 50 mM sodium acetate (pH 5.3), 1 mM EDTA (pH 
8.0), 0.1% (wAr) SDS, 25 p.g/mi tRNA] and an equal volume of phenol:chloroform were added; 
the aqueous phase was extracted (2.3.3), and the RNA precipitated with ethanol (2.3.5). The RNA 
was resuspended in dH20 and urea load buffer, electrophoresed through a denaturing 6% 
ácrylamide gel for approximately 3.5 hours (2.4.3), and detected by autoradiography (2.2.4). Table 
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2.4 lists the expected nucleotide lengths of RNA precursor, splicing intermediates and products 
for the wild-type splicing substrates used in this work. 
Table 2.4 Expected pre-mRNA, intermediate and product sizes in nucleotides 
Plasmid:Linearized Transcript pre-mRNA exoni IVS-E2 IVS mRNA 
pT7rp28sEcoRI rp28 740 122 618 448 292 
pT722XbaI rp28K 670 142 529 448 223 
pSPrp5lA:BamHI rp5lA 897 77 820 400 497 
2.6 IMMUNOPRECIPLTATION 
2.6.1 Antisera and Antibodies 
Table 2.5 lists the antisera and antibodies used in this work. Antisera and antibodies were 
frozen in N20) in small aliquots and stored at -70 °C; individual aliquots were thawed and refrozen 
a maximum of 5 times. 
2.6.2 Adsorption of Antibodies to PAS Beads 
Protein A-Sepharose CL-4B (PAS; Sigma) beads were swollen in 1 ml NTN [150 mM 
NaCl, 50 mM Tris-HC1 (pH 7.5), 0.05% (v/v) Nonidet P40 (BRL)] with rotation (Voss of Maldon 
wheel) for 10 minutes at room temperature. The PAS beads were washed 3 times in NTN. A 
standard wash procedure was followed throughout the method of immunoprecipitation: 1 ml wash 
solution was added to the beads, and the slurry was vortexed briefly, the beads were pelleted for 
15 seconds in a microcentrifuge, and the supernate was carefully removed, leaving approximately 
100 IAI wash solution; in the final wash of each wash cycle, the last 100 l of wash solution was 
removed with a P-200 Gilson Pipetman, so as not to disturb the PAS bead bed surface. After the 
NTN washes, 3 bed volumes NTN (including the appropriate amount of antibodies or whole 
antiserum) were added to the PAS beads. The antibodies were allowed to adsorb to the PAS beads 
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Table 2.5 Antisera and antibodies 
Antiserum 
or Antibody Antigen Raised Against Origin 
anti-8.1 PRP8 fusion protein 8.1 this lab, 
Jackson et aL (1988) 
anti-8.2 PRP8 fusion protein 8.2 this lab, 
Jackson et aL (1988) 
anti-8.4 PRP8 fusion protein 8.4 this lab, 
Lossky et aL (1987) 
anti-pep PRP8 amino-terminal this lab, 
peptide (35 amino acids) Anderson (1989) 
anti-m3G 2,2,7-trimethylguanosine R.Luhrmann (Marburg), 
LUhrmann et aL (1982) 
KUng human auto-immune serum 
of anti-Sm specifity I.Mattaj (Heidelberg) 
JE human auto-immune serum D.Black (Whitehead Inst., 
of anti-Sm specificity Cambridge, USA) 
anti-PAB poly(A)-binding protein this lab, 
Whittaker et aL (1990) 
by rotating for 1 hour at room temperature. The antibody-bound PAS beads were then washed 
5 times with NTN, and either used immediately or stored at 4 0C in NTN with 0.05% (w/v) sodium 
azide. - 
2.6.3 Covalent Coupling of Antibodies to PAS Beads 
The direct coupling method was performed as described by Harlow and Lane (1988). After 
the antibodies were adsorbed to the PAS beads (see above), the beads were washed 3 times with 
0.2 M sodium borate (pH 9.0). The beads were resuspended in 0.2 M sodium borate (pH 9.0), and 
solid dimethylpimelimidate (Sigma) was added to a final concentration of 20 mM. The slurry was 
mixed by rotation for 30 minutes at room temperature. The coupling reaction was stopped with 
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1 wash 0.2 M ethanolamine (pH 8.0), and mixed with rotation for 2 hours at room temperature 
in 0.2 M ethanolamine (pH 8.0). The antibody-coupled beads were washed 3 times in NTN (see 
above), incubated with 0.1 M glycine (pH 3.0) for 5 minutes at room temperature with rotation 
(to remove noncovalently-bound antibodies), washed 3 times more with NTN, and stored at 4 0C 
in NTN with 0.05% (w/v) sodium azide. Stored in this manner, the antibody-coupled PAS beads 
are stable for up to 1 year. 
2.6.4 Immunoprecipitation from In Vitro Splicing Reactions 
The method for performing immunoprecipitations from splicing reactions was adapted 
from Cheng and Abelson (1986). Splicing reactions were quenched on ice, and an equal volume 
of 2x IPQ buffer [425 mM KC1, 2 mM magnesium acetate, 22 mM EDTA, 18 mM Tris-HC1 (pH 
8.0), 1.2 mg/ml E. co/i tRNA] was added to achieve final conditions of 300 mM K, 1 mM 
magnesium acetate, 11 mM EDTA, 9 mM Tris-HC1 (pH 8.0), and 0.6 mg/mI competitor RNA. 
These immunoprecipitation conditions were adapted from the sample buffer conditions used by 
Pikielny et at (1986) for the analysis of splicing complexes by non-denaturing gel electrophoresis. 
The samples were held on ice for 5-15 minutes, then added to the PAS-bound (2.6.2;2.6.3) 
antibodies. The samples were incubated at 4 0C for 2 hours with rotation (sample volume greater 
than 50 il) or with shaking (sample volume less than 50 1d) on a Titertek (Flow Laboratories). 
After immunoprecipitation, the PAS-bound antigen-antibody complexes were washed twice with 
NTN (2.6.2) and once with NT [150 mM NaCl, 50 mM Tris-HC1 (pH 7.5)]. If the immunopre-
cipitated proteins were to be analysed, 40 .il 1.33x protein load buffer (2.4.4) were added to the 
PAS-bound complexes, and the samples were prepared for SDS-PAGE as normal (2.4.4). For the 
analysis of immunoprecipitated RNA species, 50 pl IPK [300 mM NaCl, 50 mM Tris-HC1 (pH 
7.5), 5 mM EDTA, 1.5% (w/v) SDS, 2 mg/mI proteinase K (Boehnnger Mannheim)] were added 
to the washed PAS-bound complexes, and incubated with shaking for 30 minutes at 37 0C. After 
the incubation, 50 1A dHO was added to the sample and it was extracted with 100 Al 
phenol:chloroform, back-extracted with 50 /AJ dH20, and extracted again with 150 1A1 
phenol:chloroform (2.3.3). The RNA was recovered by precipitation with ethanol (2.3.5), and 
analysed by denaturing gel electrophoresis (2.4.3) and autoradiography (2.2.4). 
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CHAPTER THREE 
IMMUNOPRECIPITATION OF SPLICING COMPLEXES 
FROM IN VITRO SPLICING REACTIONS 
3.1 INTRODUCTION 
Antibodies are a potent experimental tool for investigating the roles of certain factors in 
the splicing process. Antibodies specific to the Sm epitope of snRNP proteins and antibodies 
raised against the trimethyl guanosine (m 3G) cap structure of snRNA molecules were utilized to 
demonstrate the active role of snRNPs in the splicing process (refer to sections 1.7.1 and 1.7.2 for 
further details and references). Anti-m 3G antibodies have also proven useful for the fractionation 
and purification of snRNPs from HeLa splicing extracts by immuno-affinity chromatography 
(Winkelmann et aL, 1989). 
Immunological procedures also have been utilized to characterize the molecular 
composition of spliceosomes. Bindereif and Green (1986) showed that mammalian splicing 
complexes are precipitable by anti-Sm antisera; this result identified snRNPs as components of 
spliceosomes. Active spliceosomes contain pre-mRNA, and the splicing reaction intermediates, 
exon 1 and lariat intron-exon 2. Immunoprecipitation of splicing complexes can be demonstrated 
by recovery of precursor RNA and splicing intermediates from an in vitro splicing reaction 
containing radiolabelled substrate RNA. Therefore, interactions of specific factors with splicing 
complexes can be detected by co-immunoprecipitation of splicing precursor, intermediates and 
products with the particular antigen. 
Even before yeast snRNPs were identified, Cheng and Abelson (1986) demonstrated that 
yeast snRNAs are associated with active spliceosomes, for anti-m 3G antibodies precipitate 
precursor RNA, splicing intermediates and lariat intron product from yeast in vitro splicing 
reactions. Yeast snRNAs possess an Sm binding site, a characteristic of metazoan snRNAs. The 
antigenic epitope(s) of Sin proteins also appear to be highly conserved, for human anti-Sm 
antisera can immunoprecipitate native Ui, U2, U5 and U4/1J6 snRNPs directly from yeast extracts 
(Tollervey and Mattaj, 1987; Siiciano a aL, 1987). Since Sm-type polypeptides are components 
of yeast snRNPs, it is likely that the Sm protein epitope is also associated with yeast splicing 
complexes. Results are presented which test this proposal by conducting immunoprecipitations 
from in vitro splicing reactions with anti-Sm antibodies. 
Antibodies raised against PRP gene products have helped to elucidate the role of some 
of the PRP proteins in the splicing process (see section 1.9.4). In this chapter, an immunological 
approach was adopted to investigate interactions of PRP8 protein with the yeast splicing 
apparatus. The diagram in Figure 3.1a displays the regions of the 280 kD PRP8 protein utilized 
to produce several PRP8 fusion proteins against which antibodies were raised (Lossky et aL, 1987; 
Jackson et aL, 1988). Anti-peptide ("anti-pep") antiserum was also produced against the amino-
terminal proline-rich region of PRP8 protein (Figure 3.1b). Immunodepletion of PRP8 protein 
with antibodies raised against fusion protein 8.1 (FP8.1) specifically abolished the activity of yeast 
in vitro splicing extracts, which confirmed that PRP8 plays a direct role in splicing (Jackson et aL, 
1988). 
It is possible that PRP8 protein has interactions with the spliceosome, for as a U5 snRNP 
protein, it is present in the U4/1J5/U6 snRNP particle (Lossky et aL, 1987), which is thought to 
assemble onto the active spliceosome (Bindereif and Green, 1987; Cheng and Abelson, 1987; 
Konarska and Sharp, 1987; Lamond et aL, 1988). Immunoprecipitations were performed from in 
vitro splicing reactions with anti-PRP8 antibodies to determine whether PRP8 protein is stably 
associated with splicing complexes, and the results from these experiments are presented below. 
3.2 MATERIALS AND METHODS 
3.2.1 In Vitro Splicing Reactions 
The radiolabelled RNA substrates used in the in vitro splicing reactions were produced 
by in vitro transcription of plasmids pT722, pT7rp28s and pSPrp5 1A with bacteriophage T7 or SP6 
RNA polymerase (2.5.2). Splicing reactions (2.5.3) of 0.01 ml contained 50% (v/v) splicing extract, 
either a mix of three parts whole cell extract (2.5.1.2) to two parts 40% saturated ammonium 
sulphate precipitate of whole cell extract (2.5.1.3) or whole cell extract alone. Splicing reactions 
were incubated at 250C for the appropriate time, then quenched on ice. 
3.2.2 Immunoprecipitations from In Vitro Splicing Reactions 
Immunoprecipitations were performed by the standard procedure (2.6.4). Antibodies used for 
immunoprecipitation are described in Table 2.5. JE antiserum (3 ILl), Küng antiserum (3 .&l), anti-
8.4 antiserum (3 p1), anti-8. 1 antiserum (3 p1), anti-pep antiserum (2.5 p1), or anti-m3G antibodies 
(20 pg) were adsorbed to 5 mg PAS (2.6.2). PAS-bound m 3G antibodies were incubated with 
samples for one hour, and the other immunoprecipitations were conducted for the standard two 
hours. 
For antigen competition experiments, the control or test peptide (0.5 /.Lg) was incubated 
with the PAS-bound antibodies and sample during the immunoprecipitation. 
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FIGURE 3.1 ANTI.PRP8 ANTIBODIES 
The regions of PRPS protein to which antibodies were raised. The restriction sites within the 
PRF8 gene that were utilized for construction of 0-galactosidase—PRP8 fusion proteins are 
indicated, as is the direction of the open reading frame (ORF). The size of each PRP8 protein 
region is given in amino acids (aa). 
PRPS peptide. The amino acid sequence of the amino-terminal peptide of PRP8 protein, 
against which anti-pep antibodies were raised. 
Barn HI 	Bgl II 	Bgl II 	Bgl II 	CIa I 
> OAF 
	
35 aa 	421 aa 441 aa 	802 aa 	488 aa 
peptide fusion 8.3 fusion 8.1 fusion 8.2 fusion 8.4 
anti-pep 	anti-8.3 anti-8.1 	anti-8.2 	anti-8.4 
antibodies 
anti-J3-galactosidase-PRP8 antibodies 
CSGLPPPPPGFEEDSDLALPPPPPPPPGYEIEELD (35 -mer) 
3.2.3 RNA Recovery and Fractionation 
Splicing reaction precursor, intermediates and products were recovered from splicing 
reactions or immunoprecipitates by treatment with proteinase K, extraction with 
phenol:chloroform, and precipitation with ethanol (2.5.3;2.6.4). RNA species were analysed by 
denaturing gel electrophoresis (2.4.3) followed by autoradiography (2.2.4), and, in some cases, 
densitometric scanning of the autoradiographs (2.2.5) was performed to quantitate the efficiency 
of immunoprecipitation of RNA species. 
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3.3.1 Anti-Sm Antibodies Immunoprecipitate Yeast Splicing Complexes from In Vitro Splicing 
Reactions 
In order to determine whether yeast splicing complexes possess protein epitopes similar 
to the human Sm-type protein epitope of snRNPs, immunoprecipitations were performed with 
JE and Kung antisera, anti-Sm antisera known to react against human snRNPs. Both JE and Kung 
antisera are derived from patients with the autoimmune disease systemic lupus elythematosis 
(SLE). 
Lane 1 of Figure 3.2 shows the radiolabelled RNA species fractionated from an in vitro 
splicing reaction. The expected nucleotide lengths of the RNA species produced during the spli-
cing reactions are listed in Table 2.4. The splicing intermediate lariat intron-exon 2 and the lariat 
intron product, although shorter in length than precursor RNA, demonstrate an anomalously slow 
mobility in the gel because of their branched structure. The other RNA species present in the 
sample are not products of the splicing reaction, but are prematurely terminated products of the 
transcription reaction that do not interfere with in vitro splicing. The splicing reaction was 
terminated at an intermediate stage in the reaction, in which lariat intermediate and lariat product 
were present in roughly equimolar amounts. The immunoprecipitations were conducted from 
splicing reactions stopped at this stage. 
Both JE and Kung anti-Sm antibodies precipitated precursor RNA, lariat intron-exon 2, 
exon 1, and excised intron from yeast in vitro splicing reactions (Figure 3.2, lanes 2 and 3, 
respectively). Therefore, both the active spliceosome (which contains pre-mRNA and splicing 
intermediates) and the post-splicing complex (which contains intron product) of yeast possess 
protein epitopes that are recognized by human anti-Sm antibodies. Anti-m 3G antibodies 
precipitated a similar profile of RNA species from an in vitro splicing reaction (lane 4), which 
demonstrates that snRNA molecules are present in the same complexes that contain yeast Sm- 
FIGURE 3.2 IMMUNOPRECIPITATION OF YEAST SPLICEOSOMES WITH ANTI-SM 
ANTIBODIES 
Radiolabelled rp28K pre-mRNA was incubated under splicing conditions. In vitro splicing 
reactions (lane 1) contained intermediates exon 1 (El) and lariat intron-exon 2 (IVS-E2), lariat 
product (IVS) and spliced exons (El-E2). Immunoprecipitations were conducted from splicing 
reactions with anti-Sm antibodies, JE (lane 2) and Kung (lane 3), and with anti-m 3G antibodies 
(lane 4). Lane 1 represents RNA species fractionated from 1 Al of splicing reaction mixture, and 
the immunoprecipitations in lanes 2-4 were conducted from splicing reactions of 10 IAI volume. 
FIGURE 3.3 IMMUNOPRECIPITATION OF SPLICING COMPLEXES WITH ANTI-PRP8 
ANTIBODIES 
In vitro splicing reactions containing rp28K pre-mRNA (lane 1) were subjected to 
immunoprecipitation with anti-m 30 antibodies (lane 2), antibodies to PRP8 fusion protein 8.4 
(lane 3) or PRP8 fusion protein 8.1 (lane 4). In lane 5, the supernate from an 
immunoprecipitation conducted with anti-8.1 antibodies was subjected to immunoprecipitation 
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epitopes. Both anti-Sm and anti-m 3G antibodies precipitated spliceosomal complexes at 10% (or 
greater) efficiency. Only a negligible amount of spliced exons was precipitated by JE, Ming and 
anti-m3G antibodies, which indicates that the spliced message is not associated with Sm-
polypeptides or snRNAs, and that it is released from the Sm- and snRNA-associated post-splicing 
complex which contains the intron product. 
These results demonstrate that the yeast splicing complexes associated with precursor 
RNA, splicing intermediates and intron product possess the yeast analogue of the human Sm 
epitope. Since free yeast snRNPs are themselves Sm-precipitable (Tollervey and Mattaj, 1987; 
Siliciano et at, 1987), it is likely that JE and Kung antisera recognize the Sm epitopes within yeast 
snRNP proteins associated with spliceosomal complexes. 
3.3.2 Immunoprecipitation from In Vitro Splicing Reactions with Antibodies to PRPS Fusion 
Proteins 
Results presented above suggest that yeast snRNP protein epitopes are associated with 
spliceosomes. Immunoprecipitation experiments were conducted with antibodies raised against the 
yeast U5 snRNP protein PRP8 to determine whether it associates with splicing complexes. In the 
experiment in Figure 3.3, antibodies raised against two different regions of PRP8 protein, 8.1 and 
8.4 (Figure 3.1a), were incubated with in vitro splicing reactions. Anti-8.4 antibodies precipitated 
pre-mRNA, splicing intermediates and lariat intron product from splicing reactions (Figure 3.3, 
lane 3), which demonstrates an association of PRP8 protein with both the active spliceosome and 
the post-splicing complex. 
Anti-8.1 antibodies, however, did not precipitate any RNA species (lane 4) above the 
background level recovered from a control precipitation in which no antibodies were bound to 
PAS (lane 6). Anti-m 3G antibodies precipitated intact splicing complexes from the supernate of 
an anti-8.1 immunoprecipitation (lane 5), with comparable efficiency to the anti-m 3G 
immunoprecipitation from unprecipitated splicing reactions (lane 2). Anti-8.1 antibodies are able 
to precipitate native PRP8 protein from yeast extracts (Jackson et at, 1988). Therefore, it is likely 
that the protein epitopes recognized by the anti-8.1 antibodies are not available to the antibodies 
when PRP8 is associated with splicing complexes, although the region of PRP8 protein recognized 
by anti-&4 antibodies is available for antigen-antibody interactions. 
Figure 3.4 shows immunoprecipitations with anti-8.4 antibodies conducted from a time 
course of in vitro splicing reactions. At the earliest time point, 30 seconds, a low level of splicing 
intermediates and lariat product were precipitated with anti-8.4 antibodies (Figure 3.4, lane 7). 
After the splicing reaction had progressed for 5 minutes, the precipitation of lariat intermediate, 
exon 1, and lariat product with anti-8.4 antibodies increased (lane 8), and at 15 and 20 minutes, 
the majority of immunoprecipitated RNA species was lariat product (lanes 9 and 10). This pattern 
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FIGURE 3.4 IMMUNOPRECIPITATION WITH ANTI-8.4 ANTIBODIES FROM IN VITRO 
SPLICING REACTIONS 
A time course of a splicing reaction containing rp5lA pre-mRNA is shown in lanes 1-5, with 
times (t) indicated in minutes (m). In lanes 6-10 are the corresponding immunoprecipitations with 
anti-8.4 antibodies conducted from each of the splicing reactions shown in lanes 1-5. 
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of precipitation with anti-8.4 antibodies correlates with the appearance of the RNA species in the 
splicing reactions (lanes 2-5), and they were precipitated approximately in proportion to their 
representation at each time point in the splicing reaction. This suggests that PRP8 protein is 
associated with spliceosomal complexes throughout the course of the splicing reaction. In control 
reactions without added Al?, in which neither step of the splicing reaction takes place (lane 1), 
anti-8.4 antibodies were unable to precipitate significant amounts of precursor RNA (lane 6), 
which indicates that PRP8 protein is not involved in stable associations with pre-mRNA in the 
absence of Al?. 
Immunoprecipitations from in vitro splicing reactions with anti-8.4 antibodies 
demonstrated that PRP8 protein participates in interactions with active spliceosomes and the post-
splicing intron complex. The association of PRP8 protein with spliceosomal complexes occurs 
early in splicing, and only in the presence of Al?. 
3.3.3 Efficient Precipitation of Splicing Complexes with Anti-pep Antibodies 
Antibodies have been raised (Anderson, 1989) against a 35 amino acid peptide, 
corresponding in sequence to the amino-terminal proline-rich region of PRP8 protein (Figure 
3. 1b). These PRP8-specific anti-pep antibodies immunoprecipitate US snRNPs and the U4/U5/U6 
snRNP particle from yeast splicing extracts (G.Anderson, pers. comm.). Since the amino-terminus 
of PRP8 protein is available for interaction with antibodies in the U4/U5/U6 particle, it is possible 
that this region of PRP8 protein is accessible in splicing complexes as well. Figure 3.5 compares 
immunoprecipitations from in vitro splicing reactions using anti-8.4 (lane 2), anti-pep (lane 3) or 
Kung anti-Sm antisera (lane 4). Anti-pep antibodies were able to detect the asssociation of PRP8 
protein with spliceosomes, and as expected, anti-pep antibodies precipitated the same RNA 
species as did anti-8.4 antibodies: precursor RNA lariat intron-exon 2; exon 1; and excised intron. 
The anti-pep immunoprecipitation of splicing complexes, however, was far more efficient than the 
anti-8.4 immunoprecipitation. Immunoprecipitations with anti-8.4 antiserum are generally 5-15% 
efficient. Immunoprecipitations from in vitro splicing reactions with anti-pep antibodies displayed 
comparable efficiency to those with anti-Sm antisera (Figure 3.5, compare lanes 3 and 4). 
The anti-pep antiserum was titrated for the immunoprecipitation of splicing complexes (Figure 
3.6), as judged by the ability to precipitate pre-mRNA, splicing intermediates and intron product 
from in vitro splicing reactions. Approximately 50% of splicing complexes were precipitated with 
2.5 jA l anti-pep antisera (lane 6); 50% represents the optimum immunoprecipitation efficiency of 
these antibodies under the conditions tested, for a four-fold excess of antibody did not yield 
greater precipitation of spliceosomal complexes (lane 8). 
The antigen competition experiment shown in Figure 3.7 demonstrates the specificity of 
anti-pep antibodies. The peptide against which the anti-pep antibodies were raised was present 
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with PAS-bound anti-pep antibodies and sample during immunoprecipitation. Under these 
conditions, the immunoprecipitation of precursor RNA, splicing intermediates and lariat product 
was eliminated (Figure 3.7, lane 5). Incubation with a control peptide had no effect on the 
precipitation of splicing complexes (lane 6), demonstrating that the inhibition of immunoprecipita-
tion of spliceosomal complexes had been due to the specific saturation of the anti-pep antigen 
binding sites with the PRP8 peptide. Figure 3.7 also shows that, as demonstrated with anti-8.4 
antibodies, pre.mRNA is not significantly precipitated with anti-pep antibodies from control 
splicing reactions conducted in the absence of ATP (lane 4). 
Immunoprecipitation of splicing complexes with antibodies raised against the amino-
terminal region of PRP8 protein provides further evidence that PRP8 protein participates in 
interactions with the spliceosome. 
3.3.4 The Effect of Salt and EDTA Concentration on Immunoprecipitation of Splicing Complexes 
In the development of optimum immunoprecipitation conditions, it became evident that the 
incubation buffer could influence some characteristics of the immunoprecipitation. The nature of 
the RNA species immunoprecipitated was not subject to change; rather, different buffer conditions 
affected the efficiency of precipitation of the RNA species, and altered the ratio of the 
precipitated RNA species. Anti-8.4 immunoprecipitations from in vitro splicing reactions, 
performed in splicing reaction buffer (175 mM K7Na; 2.5.3), were enriched for intron product 
with respect to other precipitated RNA species (Whittaker et at, 1990). An alternative 
immunoprecipitation buffer (adapted from the splicing reaction stop buffer utilized by Pikielny 
a at, 1986, for the analysis of splicing complexes by native gel electrophoresis) which contains 
among its components EDTA (11 mM), an increased salt concentration (300 mM), and tRNA (3 
mg/ml) as competitor, significantly reduced the background of nonspecifically precipitated RNA 
species (data not presented). In addition, these more stringent buffer conditions 
increased the recovery of both lariat species, in proportion to their representation in in vitro 
splicing reactions. The immunoprecipitation of exon 1, however, did not display an increase in 
efficiency under the more stringent conditions (data not presented). These immunoprecipitation 
conditions were adopted as standard (2.6.4) because of their efficient precipitation of the lariat 
species. 
The fact that more stringent buffer conditions exerted different effects on immunoprecipitation 
of the two splicing intermediates, the lariat intron-exon 2 and exon 1, suggested that the stringent 
immunoprecipitation conditions could be causing some destabilization of the active splicing 
complexes. This prompted a more thorough investigation of the effects of specific buffer 
components on the immunoprecipitation of splicing complexes. Shown in Figure 3.8 are 
immunoprecipitations of spliceosomal complexes with anti-8.4 antibodies, performed with the 
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FIGURE 3.5 IMMUNOPRECIPITATION OF SPLICING COMPLEXES: A COMPARISON 
OF ANTI-8.4, ANTI-PEP AND ANTI-SM ANTIBODIES 
In vitro splicing reactions containing rp28 pre-mRNA (lane 1) were subjected to 
immunoprecipitation with anti-8.4 antibodies (lane 2), anti-pep antibodies (lane 3) or Kung anti-
Sm antibodies (lane 4), and the precipitated RNA species were fractionated by denaturing gel 
electrophoresis. 
FIGURE 3.6 TITRATION OFANTI-PEP ANTISERUM FOR IMMUNOPRECIPITATION OF 
COMPLEXES FROM IN VITRO SPLICING REACTIONS 
Splicing reactions were assembled with rp51A pre-mRNA (lanes 1 and 2). Varying amounts of 
anti-pep antisera, from 0.25 A l to 10 1.d (lanes 3-8), were utilized for immunoprecipitation of 
splicing complexes from in vitro splicing reactions. 
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FIGURE 3.7 ANTIGEN SPECIFICITY OF ANTI-PEP ANTIBODIES 
In vitro splicing reactions were assembled with rp28 pre-mRNA in the presence or absence of ATP 
(lanes 1 and 2, respectively). Immunoprecipitations with anti-pep antibodies were conducted from 
a standard splicing reaction (lane 3), a splicing reaction mixture with no added ATP (lane 4), a 
standard splicing reaction in the presence of the amino-terminal PRP8 peptide against which the 
anti-pep antobodies were raised (lane 5) or in the presence of a control (C) peptide (lane 6). 
FIGURE 3.8 THE EFFECT OF EDTA ON IMMUNOPRECIPITATION OF SPLICING 
COMPLEXES WITH ANTI-8.4 ANTIBODIES 
Splicing reactions containing rp28 pre-mRNA (lane 1) were subjected to immunoprecipitation 
with anti-pep or anti-8.4 antibodies under standard buffer conditions (lanes 2 and 3, respectively). 
Immunoprecipitations with anti-8.4 antibodies were conducted in the absence of EDTA (lane 4) 
or in the presence of EDTA, varying in concentration from 10 mM to 100 mM (lanes 5-9). 
Figure 3.7 	 Figure 3.8 
UP- t 	 pep 
	
peptids 	 2a 	
8.4 
ATP - 	 * . 	 . 0 10 20 30 40 100 mM EDTA 






standard buffer but under increasing concentrations of EDTA. Although the anti-8.4 
immunoprecipitation under standard conditions (11 mM EDTA) was not very efficient in this 
experiment (Figure 3.8, lane 3), the experiment nonetheless demonstrated the effect of increasing 
concentrations of EDTA on the immunoprecipitation of splicing complexes. Densitometric 
scanning of the autoradiograph in Figure 3.8 showed that as the concentration of EDTA present 
during the immunoprecipitation was increased from 10 to 100 mM (lanes 5-9), the 
immunoprecipitation of pre-mRNA and both lariat species became more efficient, yet the 
precipitation of exon 1 did not increase in efficiency to the same degree. For example, in the 
absence of EDTA (Figure 3.8, lane 4), splicing intermediates lariat intron-exon 2 and exon 1 
displayed comparable immunoprecipitation efficiency from in vitro splicing reactions, at 4.7% and 
3.0% respectively; excised intron was immunoprecipitated under these conditions at 0.8% 
efficiency. In the presence of 100 mM EDTA (lane 9), the immunoprecipitation of pre-mRNA and 
intron product was 5-fold more efficient, and that of lariat intron-exon 2 was 1.5 times mote 
efficient compared to immunoprecipitations conducted without added EDTA (lane 4). The 
amount of exon 1 immunoprecipitated in the presence of 100 mM EDTA (lane 9), however, was 
only 60% of that immunoprecipitated in the absence of EDTA (lane 4). Even at 10 mM EDTA 
(lane 5) or 11 mM EDTA (lane 3; the concentration present under standard conditions), exon 1 
was much less efficiently immunoprecipitated than in the absence of EDTA (lane 4). EDTA may 
exert its effect on the structure of spliceosomal complexes, causing the dissociation of exon 1 from 
the complexes with which PRP8 protein associates. 
The lability of exon 1 in splicing complexes was more apparent upon investigation of the 
effects of monovalent cation (Na+  and  K+)  concentration on immunoprecipitations from in vitro 
splicing reactions. Immunoprecipitations were conducted with anti-m 3G or anti-8.4 antibodies in 
the presence of Na+/K  concentrations varying from 300 mM to 1 M (Figure 3.9a, lanes 2-9). 
Anti-m3G antibodies precipitated precursor RNA, lariat intermediate and lariat product at all 
monovalent cation concentrations tested (Figure 3.9a, lanes 2, 4, 6 and 8; the lower recovery of 
RNA species in lane 4 represents sample loading variability), yet the precipitation of exon 1 with 
anti-m3G antibodies was reduced above 300 mM Na+IK+,  and was negligible in the presence of 
1 M Na+/K+. Kung (anti-Sm) antibodies were also unable to precipitate exon 1 in the presence 
of 1 M Na'7K' (Figure 3.9b, lane 3) as efficiently as this species was precipitated under standard 
conditions (300 mM Na17K; Figure 3.9b, lane 2). As was the case with anti-m 3G antibodies, the 
precipitation of lariats and precursor RNA by Kung antibodies was relatively unaffected by high 
monovalent cation concentrations (1 M Na+/K+).  In the presence of 1 M Na+IK+,  the 
precipitation of lariat species and exon 1 by anti-8.4 antibodies was entirely disrupted (Figure 3.9a, 
lane 9). This reproducible result may reflect a sensitivity of the particular antigen-antibody 
interaction to high Na+/K+  concentrations, for Lossky (1989) reported that the precipitation of 
U4 and US snRNAs with anti-8.4 antibodies is sensitive to monovalent cation concentrations 
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FIGURE 3.9 THE EFFECT OF MONOVALENT CATION CONCENTRATION ON THE 
IMMUNOPRECIPITATION OF COMPLEXES FROM IN VITRO SPLICING 
REACTIONS 
Splicing reactions were assembled with rp28K pre-mRNA (lane 1). Immunoprecipitations were 
performed with anti-m 3G antibodies (lanes 2, 4, 6 and 8) or with anti-8.4 antibodies (lanes 3, 5, 
7 and 9) under standard buffer conditions (0.3 M NatfK+;  lanes 2 and 3) or in the presence of 
monovalent cation concentrations of 0.45 M (lanes 4 and 5), 0.575 M (lanes 6 and 7) or 1 M 
Na/K (lanes 8 and 9). 
Splicing reactions containing rp2SX pre-mRNA (lane 1) were subjected to 
immunoprecipitation with Kung anti-Sm antibodies in the presence of 0.3 M (lane 2) or 1 M (lane 
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above 300 mM. At Na/K concentrations of 300 mM (Figure 3.9a, lane 3), 450 mM (lane 5), 
and 575 mM (lane 7), anti-8.4 antibodies precipitated lariats and precursor RNA with similar 
efficiencies; at 450 mM and 575 mM Na+/K+,  however, the precipitation of exon 1 was markedly 
reduced. 
At monovalent cation concentrations above 300 mM, exon 1 appears to dissociate from 
Sm-precipitable and snRNA-containing complexes, and from those complexes which interact with 
PRP8 protein. If the disrupted anti-8.4 immunoprecipitation (Figure 3.9a, lane 9) reflects 
spliceosome destabilization at 1 M Na/K, then Sm-precipitable and snRNA-containing 
complexes remain associated with the lariat species and precursor RNA, for these species are 
precipitated by anti-m 3G antibodies (Figure 3.9a, lane 8) and Kung antibodies (Figure 3.9b, lane 
3). 
These results demonstrate that the immunoprecipitation of exon 1 is particularly sensitive 
to high monovalent cation or high EDTA concentrations, and this may reflect spliceosome 
destabilization under these conditions. 
3.4 DISCUSSION 
In this chapter, antibodies were used to investigate the stability and composition of 
splicing complexes and to characterize the association of PRP8 protein with spliceosomes. 
Immunoprecipitation of spliceosomal complexes demonstrated sensitivity to both high 
concentrations of monovalent cation and the presence of EDTA. Complexes appeared to become 
destabilized under these conditions, as evidenced by the increased lability of exon 1. 
Immunoprecipitation in the presence of EDTA (10-100 mM) resulted in increased efficiency of 
precipitation of both lariat RNA species (intron-exon 2 and intron product), although in these 
conditions exon 1, the other intermediate RNA species, was underrepresented. These data indicate 
that EDTA causes conformational changes in spliceosomal complexes, resulting in some 
dissociation of the two intermediate RNA species. In the presence of EDTA, the lariat 
intermediate is immunoprecipitated by anti-PRP8 antibodies with greater efficiency, which suggests 
that destabilization of the splicing complexes may result in the increased availability of certain 
PRP8 protein epitopes to the antibodies. EDTA-induced conformational change is not 
unprecedented, for Zillman et aL (1988) reported that 10 mM EDTA causes alterations in the 
conformation, composition, or both of spliceosomal complexes formed in mammalian cell extracts 
in vitro. 
Human anti-Sm antibodies were shown to precipitate yeast spliceosomal complexes from 
in vitro splicing reactions. It has already been demonstrated that yeast spliceosomes contain 
snRNA molecules homologous to those found in mammalian spliceosomes (Guthrie and 
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Patterson, 1988) and that yeast snRNAs are associated with the Sm epitopes of yeast snRNP 
proteins (Tollervey and Mattaj, 1987; Siliciano et aL, 1987). The data presented in this chapter 
indicate that yeast spliceosomes possess the yeast analogue of the human Sm epitope present in 
snRNPs. This provides more evidence that human and yeast spliceosomes are structurally similar. 
In this chapter, PRP8 protein, the first yeast snRNP protein to be identified (Lossky et 
aL, 1987), was demonstrated to be associated with spliceosomal complexes. Antibodies raised 
against FP8.4 and against a peptide corresponding to the amino-terminus of PRP8 protein 
precipitated pre-mRNA, splicing intermediates and intron product from in vitro splicing reactions. 
Antigen competition experiments demonstrated the specificity of both antisera (Whittaker et aL, 
1990 this chapter, section 3.3.3). The fact that antisera raised against two different regions of 
PRP8 protein both immunoprecipitate spliceosomal complexes provides evidence that .PRP8 
protein is involved in interactions with the spliceosome. The profile of immunoprecipitated RNA 
species indicates that PRP8 is associated with spliceosomal complexes during both steps of the 
RNA splicing reaction and with a post-splicing complex containing the excised intron. In addition, 
results from immunoprecipitation experiments demonstrated that PRP8 protein only associates' 
with RNA present in spliceosomal complexes, for precursor RNA was not precipitated from 
control splicing reaction mixtures with no added ATP or using a mutant substrate RNA that has 
the Y splice site deleted (Whittaker et aL, 1990). 
The demonstration of a splicing-specific association of PRP8 protein with pre-mRNA, and 
the protein's association with splicing complexes participating in all stages of the splicing reaction 
suggests that PRP8 protein may indeed be a component of the spliceosome. PRP8 may assemble 
with the U5 snRNP onto the pre-splicing complex, and after the RNA splicing process is com-
pleted, PRP8 protein remains associated with the excised intron in the post-splicing complex. 
Although all five antisera raised against different regions of PRP8 protein detect the 
protein efficiently by immunoblotting, only anti-8.1, anti-8.4, and anti-pep antibodies 
immunoprecipitate US snRNPs (Lossky et aL, 1987; G.Anderson, pers. comm.), and only anti-8.4 
and anti-pep antibodies precipitate spliceosomal complexes. This suggests that a large part of the 
protein is concealed in the free US snRNP and during interaction with the spliceosome. Anti-8.4 
and anti-pep antibodies also detect PRP8 protein in the U4/U5IU6 snRNP particle, although anti-
8.1 antibodies cannot. The protein epitopes recognized by anti-8.1 antibodies, although exposed 
in the free U5 snRNP, may be involved in interactions with the U4/U6 snRNP in the multi-
snRNP particle, and also may be involved in interactions with other factors within the 
spliceosome. ' 
It is interesting that the amino-terminus of PRP8 protein is accessible to antibodies in 
the free US snRNP, the U4/U5/U6 snRNP complex and in the spliceosome, for this region of 
PRP8 has unusual characteristics. It contains several blocks of multiple proline residues, 
interspersed with numerous acidic residues (see section 1.9.5), so this amino-terminal region may 
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protrude from the other globular domains of PRP8 protein. The PRP8 peptide itself does not 
inhibit in vitro splicing (data not presented), but anti-pep antibodies abolish splicing in vitro 
(J.Brown, pers. comm.). 
It is unclear what function the amino-terminal region of PRP8 may have, for it contains 
no known homology to other proteins. The amino-terminus of PRP8 protein may act as a signal 
peptide to target the US snRNP, multi-snRNP particle or the spliceosome to a specific location 
in the nucleus. Alternatively, this region could be involved in interactions with other components 
of the splicing machinery-, the acidic residues may specify a protein—protein interaction domain. 
No matter what role is played by the proline-rich, acidic amino-terminus of PRP8, its accessibility 
to antibodies is a powerful experimental tool. The efficient precipitation of PRP8-associated 
spliceosomal complexes with anti-pep antibodies will allow a more thorough characterization of 
the interactions of PRP8 protein with spliceosomes. 
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*These  plasmids contain poly(A) derivatives of wild-type and mutant rp5 1 genes (Pikielny and 
Rosbash, 1986). RNA transcripts from plasmids pSPrp5lA, pSPrp51A(i3B) and pSPrp51A(5 '-0) 
possess poly(A) tails of approximately 100 nucleotides. 
CHAPTER FOUR 
AFFINITY PURIFICATION OF SPLICEOSOMES REVEALS THAT 
PRP8 PROTEIN IS A COMPONENT OF YEAST SPLICEOSOMES 
4.1 INTRODUCTION 
As described in the previous chapter, immunoprecipitations from in vitro splicing 
reactions, using antibodies raised against PRP8, suggest an association of PRP8 with the 
spliceosome throughout the course of the splicing reaction. In order to confirm the physical 
presence of PRP8 within the active spliceosome, a method for the affinity purification of 
spliceosomes was developed (Figure 4.1). This method exploits the properties of the yeast poly(A)-
binding protein (PAB), which is endogenous to yeast splicing extracts, and which has high binding 
specificity for poly(A) RNA (Sachs et aL, 1986). In vitro splicing was performed using an RNA 
transcript with a 3' poly(A) tail; therefore, assembly of splicing complexes on the transcript is 
concomitant with PAB binding to the 3' end of the transcript. Immunoprecipitation from these 
in vitro splicing reactions, performed with antibodies raised against purified PAB, recovers the 
splicing complexes associated with the RNA substrate to which PAB is bound. Spliceosomes 
affinity selected in this manner were analysed for their snRNA content and for the presence of 
PRPS protein. 
4.2 METHODS AND MATERIALS 
4.2.1 In vitro Splicing Reactions 
The RNA substrates used in the in vitro splicing reactions were produced by in vitro 
transcription of plasmids pSPrp51A, pSPrp5 1A(3B) and pSPrp5lA(5 '-0) with bacteriophage SP6 
RNA polymerase (2.5.2)*  reactions performed to analyse the snRNA content of the 
affinity selected spliceosomes were carried out using non-radiolabelled RNA transcripts. In all 
other experiments, [a- 32P]UTP was incorporated into the RNA. Each splicing reaction contained 
20 nM RNA transcript, and the splicing extract used was a mix of three parts whole cell extract 
(2.5.1.2) to two parts 40% saturated ammonium sulphate precipitate of whole cell extract (2.5.1.3). 
The non-hydrolyzable ATP analogue, fi,y-methyleneadenosine 5' -triphosphate (AMP-PC?, 
FIGURE 4.1 STRATEGY FOR THE AFFINITY PURIFICATION OF YEAST 
SPLICEOSOMES 
Rp51A pre-mRNA was incubated under splicing conditions. During the splicing reaction, yeast 
poly(A)-binding protein (PAB) associates with the poly(A) tail of the RNA transcript. 
Spliceosomes were immunoprecipitated with anti-PAB (aPAB) antibodies adsorbed to PAS beads. 
PAB affinity-selected spliceosomes were analysed fro the presence of precursor RNA, splicing 
intermediates and products, snRNAs, and PRP8 protein. 
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Sigma), when used, was at a concentration of 2.2 mM. Splicing reactions (2.5.3) of 0.01 ml (for 
the analysis of reaction products and for the analysis of snRNAs by 3 end-labelling), of 0.04 ml 
(for Northern blotting) or 0.2 ml reactions (for immunoblotting) were incubated at 25 0C for 10 
minutes, then quenched on ice. 
4.2.2 Anti-PAB Antibody Purification 
Purified PAB, produced in E. co14 was obtained from Alan Sachs, and rabbit antiserum 
to PAB was raised (King, 1990) as described in Sachs et at (1986). Antibodies to PAB were 
affinity purified by methods described in Harlow and Lane (1988). PAB (3.5 mg) was coupled to 
cyanogen bromide-activated Sepharose 4B (1.0 g; Pharmacia) according to the manufacturer's 
instructions. Coupling efficiency was greater than 90% as determined by ESAU staining (2.2.7). 
The PAB-coupled bed support was transfered to a column (Bio-Rad Econo-Column 737-1505), 
and pre-washed with 10 bead bed volumes (30 ml) of each elution buffer before passing the anti-
PAB whole antiserum through the column. The PAB-specific antibodies were eluted from the 
column with 30 ml 100 mM glycine (pH 2.5) followed by 30 ml 100 mM Triethylamine (pH 11.5). 
Ten 3 ml fractions were collected during elution with each buffer, and the fractions were 
neutralized with 0.3 ml 1M Tris-HC1 (pH 8.0). The fractions containing antibody, identified by 
ESAU staining (2.2.7), were combined and concentrated by passage over a column (Bio-Rad 
Econo-Column 737-0704) of Protein A-Sepharose CL-4B (Sigma). The antibodies were eluted 
from the column with 100 mM glycine (pH 3.0). The final protein concentration of the combined 
fractions containing the PAB-specific antibodies was approximately 0.125 mg/ml (estimated by 
ESAU staining; 2.2.7), which represents a yield of approximately 0. 1875 mg anti-PAB antibodies 
from 5.0 ml anti-PAB whole antiserum. 
4.2.3 
Imniunoprecipitations were performed by the standard procedure (2.6.4) except that the 
splicing reactions were adjusted to 200 mM K+  rather than 300 mM K+,  and the samples were 
incubated with the PAS-bound antibodies for only 1 hour at 4 0C with mixing. Purified anti-PAB 
antibodies (approximately 0.375 i.tg) were adsorbed to 5 mg PAS for immunoprecipitations to 
analyse splicing reaction products or snRNAs by 3' end-labelling. For immunoprecipitation 
experiments to analyse snRNAs by Northern blotting, 1.5 pg PAB antibodies were adsorbed to 
7.5 mg PAS (2.6.2). For preparative affinity selection of spliceosomes followed by immunoblotting, 
7.5 ig PAB antibodies were covalently coupled to 7.5 mg PAS (2.6.3). 
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4.2.4 RNA Analyses 
4.2.4.1 RNA Recovery and Fractionation 
Splicing reaction products and snRNA species immunoprecipitated from splicing reactions 
were recovered by treatment with proteinase K, extraction with phenol:chloroform, and precipita-
tion with ethanol (2.5.3;2.6.4), and were analysed by denaturing gel electrophoresis (2.4.3) followed 
by autoradiography (2.2.4). 
4.2.4.2 Detection of snRNAs by Northern Blot Analysis 
Northern blot analysis of snRNAs was performed using a method modified from Church 
and Gilbert (1984). The immunoprecipitated RNA was fractionated through a 6% 
polyacrylamideIlM urea gel (2.4.3), electroblotted to Hybond N membrane (Amersham) in 0.5x 
TBE at 60 V for 1 hour, then UV-irradiated on a short-wave transilluminator for 5 minutes to 
covalently link the RNA to the membrane. The membrane was pre-hybridized in 0.5 M NaHPO4 
(pH 7.0), 7% (w/v) SDS, 1 mM EDTA for 1 hour, hybridized with 32P-labelled 5nRNA-specific 
oligodeoxynucleotides in the same buffer for 24 hours, and washed in 0.5 M NaPO4 (pH 7.0), 5% 
(w/v) SDS, 1 mM EDTA for 10 minutes. The pre-hybridization, hybridization and wash were 
performed at 280C. The oligodeoxynucleotides used as probes for the snRNAs are described in 
Table 4.1. The probes were prepared by 5' end-labelling 10 pmole oligodeoxynucleotide in lx 
kinase buffer[70 mM Tris-HC1 (pH 7.5), 10 mM MgCl2, 0.1 mM KC1, 5 mM Dli'] with T4 
polynucleotide kinase and 10 pCi [7- 32P]ATP (3000 Ci/mmol, Amersham). The unincorporated 
label was eliminated by passing the Y end-labelling reaction over a NAP 10 column (Pharmacia) 
according to the manufacturer's instructions, and the probe was eluted from the column in 1.5 ml 
10 mM NaPO4 (pH 7.0). 
4.2.4.3 Detection of snRNAs by 3 End-Labelling 
3' End-labelling was carried out by a modification of the method of England et aL (1980). 
The linmunoprecipitated RNAs were recovered by treatment with proteinase K, extraction with 
phenol:chloroform, and by precipitation with ethanol (2.6.4) using glycogen (8.0 jig) as carrier 
(the standard carrier, tRNA, is not used because it acts as a substrate for the 3' end-labelling 
reaction). The RNA pellet was resuspended in dH 20, and to this were added 1 iil (10 pCi) 
cytidine 3', 5'.[5'-32P]bis(phosphate) (pCp, 3000 Ci/mmole, NEN) and reaction mix to give a 
final reaction volume of 5 p1, containing 50 mM HEPES-Na (pH 7.5), 10 mM MgCl2, 3.3 mM 
Dli', 25 1iM ATP (Pharmacia Ti Grade), 10% (v/v) deionized dimethyl sulfoxide (Fluka), 10 
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g/ml BSA (Boehringer Mannheim Molecular Biology Grade), 5 U RNasin (Promega), and 1.25 
g T4 RNA ligase (provided by M.Gait, M.R.C. Laboratory for Molecular Biology, Cambridge, 
UK). The reactions were incubated overnight at 4 0C; RNA was recovered by treatment with 
proteinase K, extraction with phenol :chloroform, and precipitation with ethanol (2.6.4). The RNA 
was analysed by denaturing gel electrophoresis (2.4.3) and autoradiography (2.2.4). 
Table 4.1 Oligodeoxynucleotide probes for northern blot analysis of yeast snRNA species 
Region of 
snRNA Probe Sequence (5 	to 3') Complementarity Td(°C) 
Ui CITAAGGTAAGTAT 5' end 36 
U2 CTACACTFGATCFAAGCCAAAAGGC internal 72 
U4 CCGTGCATAAGGAT 5' end 42 
U5 AATATGGCAAGCCC internal 42 
U6 TCATCf'CrGTATFG internal 38 
*Td  is the temperature at which an RNA—oligodeoxynucleotide complex will be half-dissociated. 
The following formula (Suggs et aL, 1981) provides an approximate value for Td: 
Td = 4 degrees (C) per GC base pair + 2 degrees (C) per AT or AU base pair 
4.2.4.4 Quantitative Analysis of snRNAs 
Quantitative determination of the efficiency of immunoprecipitation and of the 
enrichment of each RNA species was performed by densitometric analysis of the autoradiographs 
(2.2.5).. 
4.2.5 Immunoblotting of Spliceosomal Proteins 
The PAS-coupled antibody-bound complexes recovered from immunoprecipitations were 
denatured by the addition of 40 p1 1.33x protein load buffer (2.4.4), and boiled for 5 minutes. The 
PAS beads were removed by pelleting for 45 seconds in a microcentrifuge, and the supernate 
fractionated by SDS-PAGE (2.4.4). The gel was electroblotted to nitrocellulose membrane 
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(Schleicher & Schuell) in 25 mM Tris-HCI, 192 mM glycine at 55 V for 3 hours (Towbin et al., 
1979). Proteins on the membrane were visualized by staining with Ponceau S (Sigma), and then 
the membrane was incubated in 5% (w/v) BSA, lx TBS, 0.05% (w/v) sodium azide at 37 0C for 1 
hour. The membrane was rinsed in lx TBS, then incubated overnight at 4 0C (with rotation) with 
anti-8.2 (2.6.1) or anti-PAB antiserum diluted 1:1500 in 1% (w/v) BSA, lx TBS, 0.05% (WA') 
sodium azide. All subsequent manipulations were carried out at room temperature. The membrane 
was washed 5 times in lx TBS, 0.1% (v/v) Tween 20 (BDH), then incubated for at least 1 hour 
with anti-rabbit IgG—alkaline phosphatase conjugate (Promega) diluted 1:7500 in 1% (wA') BSA., 
lx TBS. After 3 washes in lx TBS, 0.1% (VA') Tween 20, the blot was developed in detection 
buffer PB: 100mM Tris-HC1 (pH 9.5), 100 mM NaCl, 5 mM MgC121 containing substrates nitro 
blue tetrazolium (50 mg/ml stock solution; use 6.6 pl stock/ml DB) and 5-bromo-4-chloro-3-
indolyl phosphate (50 mg/ml stock solution; use 3.3 lil stock/ml DB) (Promega ProtoBlot System). 
4.3 RESULTS 
4.3.1 Development of High Efficiency Splicing Extracts 
In the development of the PAB spliceosome affinity-selection method, it was found that 
the splicing activity of a standard splicing extract (2.5.1.2) could be augmented by supplementation 
with a 40% saturated ammonium sulphate precipitate of whole cell extract (40P; 2.5.1.3). 40P 
alone has splicing activity greater than whole cell splicing extract, yet most efficient splicing is 
achieved with a mixture of two parts 40P to three parts whole cell extract. Figure 4.2a, lane 1, 
shows the reaction products from an in vitro splicing reaction performed with whole cell extract, 
and lane 2 demonstrates the increased production of splicing intermediates and products when 
the extract is supplemented with 40P. These splicing reaction samples were taken after the same 
length of incubation. 
Northern blot analysis of the snRNA content of the two extract preparations 
demonstrated at least a 2-fold enrichment of US and U6 snRNAs in the 40P-supplemented extract 
compared to whole cell extract (Figure 4.2b, compare lanes 1 and 2). In another experiment, the 
extract proteins were fractionated by gel electrophoresis, and the protein content of the two 
extract preparations was compared on immunoblots (Figure 4.2c). PRP8 protein is significantly 
enriched in 40P-supplemented extract (lane 4) compared to whole cell extract (lane 3). In contrast, 
PAB is present at similar concentrations in whole cell extract (lane 1) and in 40P-supplemented 
extract (lane 2). The protein concentration of 40P is half that of whole cell splicing extract 
(2.5.1.3); therefore, only certain proteins are precipitated from whole cell splicing extract with 40% 
saturated ammonium sulphate. 
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FIGURE 4.2 COMPARISON OF WHOLE CELL SPLICING EXTRACT WITH HIGH 
EFFICIENCY SPLICING EXTRACT 
Analysis of splicing extract activity. Rp51A pre-mRNA was incubated under splicing 
conditions with whole cell splicing extract (lane 1) or with a 40% saturated ammonium sulphate 
precipitate of whole cell extract (40P; lane 2), and the reaction products were fractionated by 
denaturing gel electrophoresis. 
Comparison of snRNA content. Preparations of whole cell extract (lane 1) or 40P-
supplemented whole cell extract (lane 2) were subjected to Northern blot analysis to detect U6 
snRNA and both the long (U51) and short (USs)  species of US snRNA. In lane 1, only one half 
of the lane width was recovered from the gel for Northern blot analysis. 
(C) Analysis of protein content. Poly(A)-binding protein (PAB) was detected with anti-PAB 
antibodies (lanes 1 and 2) and PRP8 protein was detected with anti-8.2 antibodies (lanes 3 and 
4) on western blots of whole cell extract (lanes 1 and 3) or 40P-supplemented whole cell extract 
(lanes 2 and 4). Sizes of protein molecular mass standards are given in kD. 
The bands at approximately 115 and 70 kD present in lanes 3 and 4 are most likely proteins which 
cross-react with anti-8.2 antibodies, since affinity purified anti-8.2 antibodies do not detect these 
proteins (G.Anderson, unpublished results). 
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The demonstration of enrichment for some snRNA species and a snRNP protein suggests 
that 40P is enriched for snRNPs. The high splicing activity observed in slOP-supplemented extract 
could be due to the apparent abundance of snRNPs in 'lOP. The 40P-supplemented extracts were 
subsequently used for all splicing reactions in the PAB spliceosome affinity-selection method, and 
these high activity extracts also became the standard extracts used in in vitro splicing reactions for 
all other experiments. 
4.3.2 Anti-PAB Antibodies Immunoprecipitate Splicing Intermediates and Products and Precursor 
RNA from In Vitro Splicing Reactions 
Figure 4.3a provides a comparison of the splicing reaction products that are 
immunoprecipitated with various antibodies. As described in Chapter 3, section 3.3.2, anti-m 3G 
and anti-8.4 antibodies immunoprecipitate RNA precursor, splicing intermediates and lariat 
product from in vitro splicing reactions with approximately 10% efficiency (Figure 4.3a, lanes 8 
and 9, respectively). Anti-PAB antibodies immunoprecipitate the precursor RNA, lariat-exon 2 
intermediate, and the spliced message with approximately 50% efficiency and exon 1 with 
approximately 25% efficiency from the splicing reaction (Figure 4.3b, lanes 1 and 2). The lower 
efficiency for immunoprecipitation of exon 1 may be explained by slight destabilization of the 
interaction between the two splicing intermediates due to the presence of 11 mM EDTA during 
immunoprecipitation. (The effect of EDTA on the immunoprecipitation of spliceosomes is 
described in more detail in Chapter 3, section 3.3.4.) The lariat product is inefficiently 
immunoprecipitated by anti-PAB antibodies, presumably due to the lack of a poly(A) tail and its 
rapid release from complexes containing the spliced message. 
A time course of the length of incubation with anti-PAB antibodies demonstrates that the 
efficiency of immunoprecipitation of the RNA species increases with time from 5 minutes (Figure 
4.3a, lane 2) to the optimum time of 1 hour (lane 6). Performing the inununoprecipitation for 2 
hours did not augment the recovery of RNA species (lane 7). In another experiment (not 
presented), the addition of purified PAB (0.1-10.0 pg/splicing reaction) did not increase the 
efficiency of immunoprecipitation with anti-PAB antibodies. In addition, the affinity-purified anti-
TAB antibodies were titrated for the ability to immunoprecipitate splicing reaction products. For 
immunoprecipitat ion from a standard 10 pi splicing reaction (4.2.2), purified antibodies 
(approximately 0.1875 pg) produced comparable results to those obtained with whole antiserum 
(3 1.il), and increasing the amount of purified antibodies three-fold did not increase the efficiency 
of the immunoprecipitation (data not shown). These results demonstrate that the concentration 
of anti-PAB antibodies, the length of immunoprecipitation and the abundance of PAB in splicing 
extracts are not limiting factors. Therefore, the observed efficiencies for precipitation of precursor 
RNA, lariat intermediate and spliced message (50%) and of exon 1 (25%) from in vitro splicing 
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FIGURE 4.3 IMMUNOPRECIPITATION OF COMPLEXES FROM IN VITRO SPLICING 
REACTIONS WITH ANTI-PAR ANTIBODIES 
Splicing reactions containing rp51A pre-mRNA (lane 1) were subjected to 
immunoprecipitation with anti-PAB antibodies (aPAB; lanes 2-7), anti-m 3G antibodies (am3G; 
lane 8), anti-8.4 antibodies (a8.4; lane 9) or with PAS only (lane 10). Splicing reactions were 
incubated with PAS-bound antibodies for various times (t), measured in minutes (m). 
Splicing reaction mixtures (lane 1) were subjected to immunoprecipitation with PAS-bound 
antibodies to PAB (lane 2) or with PAS only (lane 3). 
PAB 
C 5 15 30 45 60 120 120 120 120 	t(m) 
	 b 
IVS-E2 
- 	 I VS 
004< 
Ln Cs 








1 2 3 4 5 8 7 8 9 10 
El 
reactions with anti-PAB antibodies represent maximal efficiencies of immunoprecipitation under 
the conditions used. 
The ability of anti-PAB antibodies to precipitate splicing intermediates and precursor 
RNA efficiently from in vitro splicing reactions indicates that these antibodies can be employed 
to affinity select active spliceosomes. 
4.3.3 Characterization of the snRNA Content of Anti-PAB Affinity Selected Spliceosomes 
In the development of this method, it was found that lowering the final K+  concentration 
of the immunoprecipitation buffer from the standard 300 mM to 200 mM resulted in an increase 
in the efficiency of immunoprecipitation of snRNAs. The lower salt concentration did not cause 
an increase in the background of non-specifically precipitated snRNAs in control samples with 
no antibody bound to PAS (data not shown, but see Figure 4.4a, lanes 2 and 7, for a comparison 
of standard and control immunoprecipitations). 
Northern blot analysis of the snRNA species associated with the PAB-selected 
spliceosomes revealed the presence of all five of the snRNAs implicated in splicing (Ui, U2, U4, 
both species of U5, and U6; Guthrie and Patterson, 1988). Figure 4.4a, lane 1, shows the snRNAs 
present in 25% of the total, non-immunoprecipitated, liz vitro splicing reaction. This includes 
snRNAs present in free snRNPs as well as in spliceosomes. Lane 2 shows the five snRNA species 
which are present in the purified spliceosome fraction; these snRNAs are enriched 2- to 4-fold 
compared to a control reaction mixture to which was added the ATP analogue AMP-PCP (lane 
3), which blocks hydrolysis of the j6-y bond of ATP, resulting in the inhibition of splicing. In 
addition, the purified spliceosomal snRNAs (lane 2) are enriched 5- to 10-fold with respect to 
control reactions with no added substrate RNA (lane 6) or using mutant substrate RNAs 
containing a 5' splice site deletion (lane 4) or a UACUAAC box deletion (lane 5), mutations 
which result in the inhibition of spliceosome assembly (Pikielny and Rosbash, 1986). The Ui 
snRNA is present in similar concentrations in the purified spliceosome fraction (lane 2) and in 
the control reaction mixture containing AMP-PCP (lane 3), in contrast to the other snRNA 
species which are enriched in affinity selected spliceosomes (lane 2). This is explained by the fact 
that theU1 snRNP is known to bind pre-mRNA in the absence of ATP, during the early steps 
of spliceosome assembly (Ruby and Abelson, 1988; Seraphin and Rosbash, 1989). Therefore, Ui 
snRNP will be present on affinity purified precursor RNA in the presence (lane 2) or absence 
(lane 3) of Al?. 
The levels of snRNAs affinity-selected on the wild-type poly(A)-tailed pre-mRNA 
incubated with AMP-PCP (e.g., lane 3), or without added Al? or analogue, were reproducibly 
higher than the levels selected with mutant RNAs or with no pre-mRNA added (e.g., lanes 4-6). 
This is due to low levels of endogenous Al? in splicing extracts, sufficient to permit some 
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FIGURE 4.4 SnRNA CONTENT OF PAR AFFINITY-SELECTED SPLICEOSOMES 
Visualization of snRNAs by Northern blot analysis. Lane 1 shows 25% of the snRNAs present 
in an unfractionated splicing reaction mixture (this includes snRNAs from snRNPs not present 
in spliceosomes). Lanes 2-6 show snRNAs present in anti-PAR (aPAB) precipitates. 
Immunoprecipitations were conducted from a standard splicing reaction (lane 2), and from 
splicing reaction mixtures assembled with polyadenylated mutant precursor RNA with the 5' 
splice site deleted (5' -0; lane 4) or the UACUAAC box deleted (iS.3B; lane 5), and from reaction 
mixtures containing the ATP analogue AMP-PCP with or without the addition of wild-type rp51A 
pre-mRNA (lanes 3 and 6, respectively). Lane 7 is a control with no antibodies bound to the PAS, 
and lane 8 contains end-labelled MspI and AvaI+NheI digests of pBR322 DNA. 
Detection of snRNAs by 3 end-labelling. In vitro splicing reactions assembled with rp5 1A pre-
mRNA (lanes 1 and 2) or without rp5lA pre-mRNA (lanes 3 and 4) were subjected to 
immunoprecipitation with anti-PAR (aPAB) antibodies (lanes 1 and 3) or with anti-m 3G (am3G) 
antibodies (lanes 2 and 4) or PAS only (lane 5), and the precipitates were analysed for RNA 
content by 3' end-labelling. The nucleotide gize markers in lane 6 are end-labelled MspI and 
AvaI+NheI digests of pBR322 DNA. 
FIGURE 4.5 DETECTION OF PRP8 PROTEIN IN PAR AFFINITY-SELECTED 
SPLICEOSOMES 
Western blot analysis was used to detect PRP8 protein in unfractionated whole cell splicing extract 
(lane 4), in the protein fraction precipitated with anti-PAR antibodies from a standard splicing 
reaction mixture (lane 1), or from reaction mixtures with no added ATP (lane 2) or assembled 
with mutant substrate RNA lacking the 5' splice site (5'-&, lane 3). Sizes of protein molecular 
mass standards are given in kD. Antibodies present in the protein gel (and transferred to the 
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spliceosome assembly (assayed by nondenaturing gel electrophoresis; see Chapter 5, Figure 5.7a, 
lane 2) but no splicing activity. The low levels of the spliceosomal snRNAs selected by PAB 
antibodies from extracts to which mutant RNAs or no pre-mRNA had been added presumably 
represent the affinity selection of spliceosomes formed on a low level of unspliced pre-mRNA 
endogenous to the yeast splicing extract. 
3' End-labelling of the RNAs recovered in the PAB immunoprecipitate indicated that no 
other major snRNA species are fractionated with the affinity selected spliceosomes. Figure 4.4b, 
lane 1, demonstrates the presence of Ui, U2, U4, U5s  and  USL  snRNAs in the purified 
spliceosome fraction. These snRNAs are enriched in comparison to those present in a control 
reaction with no added substrate RNA (lane 3). The RNA species migrating between Ui and U2 
snRNAs at approximately 900 nucleotides is 3' end-labelled precursor RNA, and the shorter RNA 
species are most likely end-labelled premature termination products from the in vitro transcription 
reaction. The other RNA species migrating above U2 snRNA at approximately 1600 and 3300 
nucleotides are likely to be small ribosomal RNAs. Anti-m 3G antibodies immunoprecipitated 
additional snRNA species, both in the presence and in the absence of added pre-mRNA (lanes 
2 and 4, respectively). These other snRNA species are not associated with splicesomes, but possess 
a tnmethyl guanosine cap structure. The U6 snRNA is not observed in this experiment because 
it is a poor substrate for T4 RNA ligase, due to the presence of undine residues and a double-
stranded region at the 3 terminus (England et aL, 1980). 
The techniques of Northern blot analysis and 3' end-labelling were utilized to identify 
the snRNA species that co-fractionate with anti-PAB affinity-selected splicing complexes. It was 
demonstrated that the affinity purified splicing complexes are enriched for Ui, U2, U4, U5 and 
U6 snRNAs, species known to be associated with functional spliceosomes. 
4.3.4 Detection of PRP8 Protein in PAB Affinity-Purified Spliceosomes 
Affinity-selected spliceosomes were analysed for the presence of PRP8 by immunoblotting 
the purified spliceosomal proteins isolated from preparative in vitro splicing reactions, and probing 
with antibodies to the PRP8 fusion protein 8.2. 
Initially, the proteins derived from the antigen-antibody complexes were fractionated by 
gel electrophoresis after removing the PAS beads by boiling and centrifugation. It was found, 
however, that due to the preparative nature of immunoprecipitation for each sample, the high 
concentration of antibodies adsorbed to the PAS from the whole anti-PAB antiserum overloaded 
the sample wells with protein. For this reason, the PAB-specific antibodies were affinity-purified 
from the whole antiserum in order to limit the amount of IgG which bound to the PAS and, 
therefore, which was loaded on the gel. In addition, the purified antibodies were covalently 
coupled to the PAS so that the majority of the IgG molecules remained associated with the PAS 
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beads after heat denaturation. Nonetheless, as can be seen in the immunoblot (Figure 4.5, lanes 
1-3), some antibodies are still present in the gel. The antibody contamination consists of heavy 
chain molecules (55 kD), and the species higher up the gel may also be antibodies, presumably 
due to polymers formed by intermolecular covalent crosslinking during the antibody-PAS coupling 
procedure. Lane 4 in Figure 4.5 demonstrates the detection of PRP8 in unfractionated splicing 
extract, which includes PRP8 in uncomplexed U5 snRNPs as well as in spliceosomes. The species 
at approximately 116 kD may correspond to a cross-reacting protein or to a specific breakdown 
product of PRP8 that is sometimes observed (Jackson et aL, 1988). 
In lane 1 of Figure 4.5, the anti-8.2 antibodies detect PRP8 in spliceosomes affinity-
selected from a standard splicing reaction mixture. The PRP8 present in purified spliceosomes is 
enriched as compared to proteins immunoprecipitated from control splicing reactions incubated 
in the absence of Al? (lane 2) or with a mutant substrate RNA containing a 5' splice site 
deletion (lane 3); the level of enrichment in each case reflects that of the spliceosomal snRNAs 
under similar conditions (see 4.3.3). Anti-PAB affinity selection of splicing complexes has 
identified PRP8 as a spliceosomal protein. 
4.4 DISCUSSION 
A successful approach has been developed for the affinity purification of spliceosomal 
complexes, and it has provided conclusive evidence that PRP8 is a component of spliceosomes. 
A method was described for the preparation of high efficiency splicing extracts. A 40% 
saturated ammonium sulphate precipitate (40P) of whole cell splicing extract displays greater spli- 
cing activity than whole cell splicing extract alone, and optimum splicing activity is achieved with 
a mixture of 40P and whole cell extract. It appears that certain splicing factors are preferentially 
precipitated from whole cell extract in 40P, for 40P is enriched in two spliceosomal snRNAs, U5 
and U6 (enrichment for other snRNA species was not investigated), and in the US snRNP 
protein, PRP& Cheng and Abelson (1986) reported that Fraction I (a 70% saturated ammonium 
sulphate precipitate of whole cell splicing extract, followed by three successive 40% saturated 
ammonium sulphate precipitations) is enriched in several snRNA species. Fraction I, however, 
does not possess splicing activity unless complemented with fractions II and III or unfractionated 
whole cell splicing extract (Cheng and Abelson, 1986). It is possible that ammonium sulphate 
fractionation of whole cell extract produces precipitates enriched in some snRNPs. A higher 
concentration of snRNPs or other splicing factor(s) in 40P would explain its high splicing activity. 
It appears that other essential splicing factors are limiting in 40P, however, for optimum splicing 
efficiency is achieved only upon complementation with unfractionated whole cell splicing extract. 
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Anti-PAB antibodies precipitate splicing complexes with greater efficiency than anti-8.4 
or anti-m3G antibodies. PRP8-specific anti-pep antibodies precipitate splicing complexes at 
approximately 50% efficiency (see Chapter 3, section 3.3.3), which is comparable to the efficiency 
of precipitation with anti-PAB antibodies. Anti-pep antibodies, however, also precipitate free U5 
snRNPs (which contain PRP8 protein) with great efficiency; spliceosomal proteins 
immunoselected with anti-pep antibodies therefore would be contaminated with free snRNP 
proteins as well. Anti-PAB antibodies were utilized for the immunoaffinity purification of 
spliceosomes because of their efficient and specific precipitation of spliceosomal complexes. 
Complexes affinity selected with anti-PAB antibodies were analysed for their snRNA 
content to determine whether they possess snRNA species characteristically associated with 
splicing complexes. A combination of Northern blot analysis and 3' end-labelling of 
immunoprecipitated snRNAs indicated that all five spliceosomal snRNAs (Ui, U2, U4, US, U6) 
are precipitated with anti-PAB selected complexes. A low level of spliceosomal snRNAs are 
precipitated with anti-PAR antibodies from control splicing reaction mixtures, however. Some 
snRNAs are precipitated from control reactions without added ATP, for splicing extracts contain 
low levels of ATP which allow some complex assembly on pre-mRNA, although there is not 
sufficient ATP present for the splicing reaction to take place. A low background of spliceosomal 
snRNAs are also immunoprecipitated from control reactions with no added substrate RNA or 
using mutant substrate RNAs. This may represent affinity selection of splicing complexes formed 
on unspliced poly(A)-tailed pre-mRNA endogenous to yeast splicing extracts. 
The ability of anti-PAR antibodies to immunoprecipitate RNA precursor, splicing 
intermediates and the full complement of spliceosomal snRNAs from in vitro splicing reactions 
indicated that active spliceosomes are recovered by PAR affinity selection. The affinity purified 
spliceosomes were analysed for their protein content by immunoblotting, and the yeast US snRNP 
protein PRP8 was identified as a component of functional spliceosomes. 
Antibodies to PRP8 protein precipitate precursor RNA and splicing intermediates from 
in vitro splicing reactions (Chapter 3, sections 3.3.2 and 3.3.3), which indicates that PRP8 is pre-
sent in spliceosomal complexes upon initiation of the splicing reaction and during step 1 and 2 
of the splicing reaction. Anti-PRP8 antibodies also precipitate intron product from in vitro splicing 
reactions; although the PAB affinity purification method does not select post-splicing complexes, 
it is likely that the spliceosomal protein PRP8 remains associated with the excised intron in a 
multi-snRNP complex. 
PRP8 protein probably assembles onto the spliceosome with the U4/U5/U6 snRNP 
complex, designating an early role for PRP8 protein in spliceosome formation. PRP8 protein 
therefore may interact with other factors involved in spliceosome assembly or in the splicing 
reaction itself. The availability of various antibodies to PRP8 protein provides the experimental 
tools with which to probe PRP8's interactions and possible functions within the spliceosome. 
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The PAB affinity-purification procedure could be of general use for the analysis of the 
snRNA and protein components of spliceosomes. It could also be used for the isolation and 
characterization of other protein—RNA complexes by incorporation of a poly(A) sequence into 
an RNA component. The high background on the lower portion of the blot in Figure 4.5 is due 
to contaminating antibodies; it could be eliminated by alternative methods for the elution of 
isolated complexes, thereby making this affinity purification procedure suitable for the analysis of 
low molecular weight proteins. Elution could be performed with excess oligo(A) or with Cibacron 
Blue 3GA (Sigma), both of which compete strongly with poly(A)+ RNA for binding to PAB 
(A.Sachs, pers. comm.). 
Other methods have been described for the isolation of yeast spliceosomes. Pikielny and 
Rosbash (1986) used oligo(dl')-cellulose chromatography of spliceosomes formed with a 
polyadenylated RNA substrate in their studies to identify snRNAs associated with spliceosomes. 
Their purification procedure displayed snRNA background levels similar to those of the PAB 
affinity selection method. A disadvantage of oligo(dT)-cellulose chromatography, however, is that 
spliceosomes are isolated via RNA—DNA hybrids, which are susceptible to cleavage by RNase H, 
endogenous to yeast splicing extracts. Ruby and Abelson (1988) described a spliceosome affinity 
purification method in which the splicing substrate RNA was immobilized on a succinylated avidin 
biotin-agarose support via a biotinylated Ranchoru  RNA. They showed, however, that a distinct 
disadvantage of solid-phase splicing is that the use of immobilized pre-rnRNA decreases the 
efficiency of the splicing reaction. In comparison to the other available methods for the 
purification of yeast spliceosomes, the PAB procedure is both technically undemanding and 
efficient; approximately 50% of the spliceosomes can be purified from a splicing reaction. 
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CHAPTER FIVE 
PRP8 PROTEIN CONTACTS PRE-mRNA IMMEDIATELY PRIOR TO OR 
CONCOMITFANT WITH STEP I OF SPLICING 
5.1 INTRODUCTION 
In the previous chapter, affinity purification of yeast spliceosomes demonstrated that the 
U5 snRNP protein PRP8 is present in spliceosomal complexes. Immunoprecipitation studies 
indicated that PRP8 protein is associated with spliceosomal complexes during both steps of the 
splicing reaction, and it remains associated with the intron product upon completion of the 
splicing reaction (Whittaker et at, 1990; Chapter 3, section 3.3.2). It is possible that the 280 kD 
PRP8 protein may play a fundamental structural or catalytic role within the spliceosome. 
The technique of photochemical crosslinking was employed to investigate interactions 
between PRP8 protein and pre-mRNA. Photochemical crosslinking is a process in which short-
wave UV light is used to covalently crosslink RNA or DNA to proteins in close contact with the 
nucleic acid. In this way, specific interactions between protein and nucleic acid can be stabilized 
for further characterization and analysis. 
The chemistry of UV-crosslinking is only partly understood. Irradiation with UV light at 
254 nm forms a covalent linkage between nucleic acid bases and amino acid side-chains. 
Pyrimidine bases are more photoreactive than purines, and only eleven amino acids appear to be 
involved in the crosslinking reaction (Smith, 1976). The most reactive amino acids are cysteine, 
tyrosine, phenylalanine, histidine, arginine, and lysine (Smith, 1976). The chemical reaction 
induced by short-wave (254 nm) UV irradiation is specific, for no RNA—RNA crosslinks occur 
(Greenberg, 1979), nor do proteins become crosslinked to one another (Woppmann et at, 1988) 
under standard UV-crosslinking conditions. 
UV light has a short effective crosslinking range; this ensures that protein—nucleic acid 
adducts are formed only when the interacting molecules are close and the reactive groups are 
within one bond length apart (Smith, 1976). Therefore, those protein and nucleic acid molecules 
which become crosslinked are assumed to have been in direct contact, in a stable non-covalent 
complex. 
Greenberg (1979) initiated the use of UV-crosslinking to probe the architecture of 
complex RNA—protein particles. Greenberg (1980) irradiated isolated E. coli poly-ribosomes with 
254 nm UV light, and was able to identify particular ribosomal proteins that interact with mRNA. 
UV-crosslinking was also utilized to detect proteins in polyadenylation complexes that specifically 
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bind to polyadenylation precursor RNA (Wilusz and Shenk, 1988; Moore et aL, 1988). The UV-
crosslinking procedure has obvious application to the study of RNA—protein interactions in the 
spliceosome. Zamore and Green (1989) showed that the 65 kD polypeptide of splicing factor 
U2AF (see section 1.7.4) crosslinks specifically to the polypyrimidine tract and 3' splice site 
region of pre.mRNA. Garcia-Blanco et aL (1989) detected a 62 kD protein by UV-crosslinking 
which binds specifically to the polypyrimidine tract of introns; it is probably the same protein as 
that identified by Zamore and Green (1989). 
In this chapter, results are presented in which the techniques of UV-crosslinking and 
immunoprecipitation were combined in order to investigate interactions between PRP8 protein 
and pre-mRNA in spliceosomal complexes. 
5.2 METHODS AND MATERIALS 
5.2.1 In Vitro Transcription 
The radiolabelled substrate RNAs used for the in vitro splicing reactions were transcribed 
in vitro from plasmids pT7rp28s, p(T7)GEM284, p(T7)GEM287, pSPrpSlA, pSPrp5lA(5 '.0) and 
pSPrp51A(i3B) with bacteriophage 11 or SP6 RNA polymerase (2.5.2). High specific activity 
transcripts were utilized in samples to be UV irradiated; radiolabelled RNA transcripts of 
standard specific activity were produced for all other splicing reactions. 
Incorporation of the photoactivatable U1'P analogue 5-bromouridine 5' -triphosphate 
(BrUTP; Sigma) into high specific activity RNA transcripts was performed by substituting the 
limiting (0.25 11.M) UTP with 0.25 IAM BrUTP in the in vitro transcription reaction (2.5.2). The 
resulting RNA transcripts contained both [a-32PJUTP and BrUTP. BrUTP was stored in a 100 
mM stock solution in a light-proof container at -20 9C, and all manipulations were conducted in 
the dark, with the sample in an aluminium foil-wrapped microfuge tube, until the sample was UV 
irradiated. 
5.2.2 Oligodeoxynucleotide-directed Ribonuclease H Cleavage of Substrate RNAs 
Ribonuclease H digestion of RNA transcripts was conducted in splicing reaction buffers 
and extracts (2.5.3) prior to the addition of ATP and subsequent initiation of the in vitro splicing 
reaction. This method takes advantage of the endogenous Ribonuclease H activity present in yeast 
splicing extracts (Ryniond et aL, 1987). The oligodeoxynucleotides utilized for cleavage of substrate 
RNAs are listed in Table 5.1. The oligodeoxynucleotide was present in an approximately 150-fold 
excess over the target RNA transcript. The oligodeoxynucleotide (approximately 30 pmoles) was 
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allowed to anneal to its complementary region on the RNA transcript (0.2 pmoles) for 15 minutes 
at 250C in 6.25 mM MgCl2, 6.6 mM citric acid, 300 mM KPO4, 7.5% (w/v) polyethylene glycol 
8000 (Sigma), 3.33% (v/v) glycerol. Splicing extracts were added (comprising 55.5% of the final 
cleavage reaction volume), and the mixture was incubated at 25 0C for 10 minutes. Cleavage of the 
RNA—DNA hybrid was generally greater than 90% efficient. After the cleavage reaction, the same 
mixture was used for the subsequent in vitro splicing assay. Splicing was initiated upon the 
addition of ATP (in one tenth the final splicing reaction volume); splicing reaction conditions 
were as standard (2.5.3). 
Table 5.1 Oligodeoxynucleotides used for Ribonuclease H cleavage of substrate RNAs 
Oligodeoxynucleotide Target 
Sequence (5' to 3) Pre-mRNA 
Oligo 1 ATCAGTACGACCTAAA rp28 
Oligo 2 GAATGGAGCATCAGTA rp28 
Oligo A TAAAAAGTFTGTAAATGCAA rp51A 
Oligo C AAATGACGAAAAGCAATACA rp51A 
5.2.3 In Vitro Splicing Reactions 
Splicing reactions (2.5.3) of 0.01 ml (standard volume), 0.005 ml (for native gel 
electrophoresis of samples) or 0.05 ml (for immunoprecipitations from UV-irradiated samples) 
contained 50% (v/v) splicing extract, which consisted of either a mix of three parts whole cell 
extract (2.5.1.2) to two parts 40% saturated ammonium sulphate precipitate of whole cell extract 
(2.5.13) or whole cell extract only. Splicing reactions were incubated at 25 0C for the appropriate 
time, then quenched on ice. 
5.2.4 Native Gel Electrophoresis of Splicing Reactions 
Native gel electrophoresis was performed by a modification of the method of Pikielny et 
aL (1986). A vertical 15 cm x 15 cm x 1.5 mm composite gel was cast from 3% (wlv) acrylamide 
(60:1 aciylamide:bisacrylamide), 0.5% (w/v) agarose (BRL UltraPure), lx TBE-10 [90 mM Tris-
borate (pH 8.3), 10 mM EDTAI, with 0.5 ml 10% APS and 0.05 ml TEMED added to initiate and 
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catalyse polymerization. A Teflon slot-forming comb (10 x 9 mm wells) was inserted, and the gel 
allowed to set for 30 minutes. The gel was pre-electrophoresed at 4 0C for 1 hour at 80 V in lx 
TBE- 10. 
In vitro splicing reactions (0.005 ml) were assembled as normal, except that 5-fold more 
substrate RNA (approximately 20 nM) was used. Splicing reactions were terminated by incubation 
on ice, followed by the addition of an equal volume of 0 mix [450 mM KC1, 2.3 mM magnesium 
acetate, 23 mM EDTA, 18 mM Tris-HC1 (pH 7.5), 1.2 mg/nil total yeast RNA]. Samples were kept 
on ice for 10 more minutes, and 2.5 Al 5x load buffer [5x TBE-10, 50% (v/v) glycerol, 0.25% (sv/v) 
each bromphenol blue and xylene cyanolej were added. The gel wells were rinsed with running 
buffer, then the samples were loaded, and the gel was electrophoresed at 4 0C for 1 hour at 80 V, 
then for 3.5 hours at 150 V. After completion of electrophoresis, the gel was transferred to 
blotting paper, and analysed by autoradiography. 
5.2.5 Photochemical Crosslinking of Yeast Proteins to Pre-mRNA 
The method for UV-induced crosslinking of RNA to protein was modified from Moore 
et at (1988) and Garcia-Blanco et at (1990). Splicing reaction mixtures containing approximately 
20 nM high specific activity radiolabelled substrate RNA were quenched on ice. E. coli tRNA 
(2.3.4) was added at a concentration of 0.2 mg/nil to dissociate weakly bound proteins. Samples 
of 0.05 ml (for immunoprecipitations) or 0.01 ml (for analysis of total UV-crosslinked protein) 
were transferred to a 96 U-well microtiter plate (Cel-Cult, Sterilin Ltd., UK) kept on ice. The 
microtiter plate was placed directly under the bulb of a short-wave Bactericidal Ultra-Violet Unit 
(Hanovia Lamps, Slough, England); the energy density at the bottom of each well (a distance of 
1 cm from the bulb) was 3.7 mW/cm 2, as measured by a Blak-Ray Ultra-Violet Meter, Model J -
225 (Ultra-Violet Products, Inc., USA). The samples were UV-irradiated for 15 minutes (while 
kept on ice), then transferred to microfuge tubes. Samples were digested with either Ribonuclease 
Ti (2.5 U/gui; Boehringer Mannheim UK) or Ribonuclease A (1 g/&l; Sigma) for 30 minutes at 
370C. Samples then were prepared for SDS-PAGE as normal (2.4.4) or samples were either 
subjected to immunoprecipitation or stored at —70 0C before protein gel electrophoresis. 
5.2.6 Immunoprecipitation from In Vitro Splicing Reactions 
Anti-8.4 and anti-pep anusera are described in Table 2.5, and in more detail in Chapter 
3, sections 3.3.2 and 3.3.3. For immunoprecipitations from splicing reactions, anti-8.4 antibodies 
(3 1) or anti-pep antibodies (2.5 .&l) were adsorbed to 5 mg PAS beads (2.6.2). For 
immunoprecipitations from UV-irradiated in vitro splicing reactions, anti-8.4 antibodies (25 il) 
or anti-pep antibodies (12.5 Al) were covalently coupled to 7.5 mg PAS beads (2.6.3). 
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Immunoprecipitations were conducted by the standard procedure (2.6.4), except that E. coli tRNA 
was not added to UV-irradiated samples which already contained competitor RNA. 
For antigen competition experiments with anti-8.4 antiserum, purified fusion protein or 
fl-galactosidase was added (at a final concentration of 2 Ag protein/Al antiserum) during 
adsorption of antibodies to PAS beads. For antigen competition experiments with anti-pep 
antiserum, the control or test peptide (0.2 Ag peptide/pi antiserum) was present with PAS-bound 
anti-pep antibodies and sample during immunoprecipitation. 
In some instances, UV-irradiated samples were subjected to denaturing conditions prior 
to immunoprecipitation. After ribonuclease digestion, different denaturation buffers were added 
to the samples, giving the final conditions (100 &l total volume): 1%, 0.5%, 0.1% or 0.05% (w/v) 
SDS; 1%, 0.5%, 0.1% or 0.05% (v/v) Triton X-100 (BDH); 100 mM, 50 mM, 10 mM or 5 mM 
DTT. The samples were heated to 1000C for one minute, then placed on-ice.-Nine volumes (0.9 
ml) of 1.lx ff0 buffer [333 mM KC1, 1.11 mM magnesium acetate, 12.22 mvj EDTA, 10 mM 
Tris-HC1 (pH 8.0)] were added to each sample, thereby diluting the denaturing components by 
10-fold; and also maintaining standard immunoprecipitation buffer conditions. The samples were 
kept on ice for 5 minutes, centrifuged for 1 minute to remove precipitates, and the supernate (1 
ml) was subjected to immunoprecipitation as normal (2.6.4). 
5.2.7 Fractionation and Analysis of UV-Irradiated Proteins 
Proteins from UV-irradiated samples were fractionated by SDS polyacrylamide gel 
electrophoresis using the standard procedure (2.4.4). Immunoprecipitated proteins were prepared 
for gel electrophoresis as described previously (2.6.4). 
Following electrophoresis, the gel was incubated (with agitation) in protein staining 
solution [25% (vtv) propan-2-ol, 10% (v/v) acetic acid, 0.05% (w/v) Coomassie Brilliant Blue R 
(Sigma)] for 30 minutes at 37°C. The staining solution was decanted, and the gel was soaked in 
destain [25% (v/v) methanol, 10% (vlv) acetic acid] for 5-18 hours at room temperature. The gel 
was rinsed for 5 minutes in 10% glycerol, then dried for 1.5 hours at 80°C under vacuum (Bio-
Rad Model 583 Gel Dryer). The proteins (radiolabelled by the covalent addition of RNA 
oligonucleotides) were detected by autoradiography (2.2.4). 
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5.3 RESULTS 	 - 
5.3.1 UV-Crosslinking of RNA to Yeast Proteins 
During the RNA splicing process, many proteins must interact directly with pre-mRNA 
to effect both spliceosome assembly and excision of the intron. The technique of UV-crosslinking 
was employed to detect proteins which have specific interactions with substrate RNA. In Figure 
5. 1a is an autoradiograph of proteins fractionated from in vitro splicing reactions that were 
exposed to short-wave UV light (lane 2) and from in vitro splicing reactions that were not UV-
irradiated (lane 1). Lane 2 shows that UV-irradiation induces the covalent addition of substrate 
RNA molecules to a subset of yeast proteins; radioactive label from the in vitro transcribed pre-
mRNA was transferred to the proteins as a result of UV-crosslinking. Prior to electrophoresis, 
the UV-irradiated samples were digested with Ribonuclease A, so that only small RNA fragments 
remained attached to the proteins. None of the proteins present in in vitro splicing reactions 
became radiolabelled in the absence of UV-irradiation (Figure 5.1a, lane 1). Each of the 
radiolabelled proteins in lane 2 will have been in direct contact with the RNA at the time of UV-
irradiation. A variety of proteins became crosslinked to substrate RNA under splicing conditions. 
The most prominent of the radiolabelled proteins have approximate molecular weights of 65, 100 
and >200 kD (Figure 5.1a, lane 2). 
A time course for the length of UV exposure was performed to determine the optimum 
dosage of UV-irradiation for the detection of proteins crosslinked to substrate RNA in in vitro 
splicing reactions. Figure 5.1b shows proteins fractionated from samples which were UV -
irradiated for various lengths of time. The proteins were most intensely labelled after 15 minutes 
of exposure to short-wave UV light (Figure 5. 1b, lane 3). The proteins in Figure 5. 1b were more 
highly labelled than the proteins in Figure 5.1a because different ribonucleases were used in the 
two experiments. In Figure 5.1a, the samples were digested with Ribonuclease A, which cleaves 
RNA molecules adjacent to pyrimidines. Ribonuclease Ti, used in Figure 5.1b, has greater 
specificity, cleavage occurs 3' to 0 residues only. Therefore, digestion with Ribonuclease Ti 
produces longer RNA fragments than does digestion with Ribonuclease A. Consequently, more 
rádiolabel remained attached to the crosslinked proteins. RibonUclease Ti was used in all subse-
quent experiments. 
In order to increase the efficiency of crosslinking RNA to protein, the photoactivatable 
UT? analogue 5-bromouridine 5 '-triphosphate (BrUTP) was incorporated into RNA transcripts. 
Garcia-Blanco et aL (1990) reported an enhancement of short-wave UV-crosslinking efficiency 
with BrUTP-substituted RNA transcripts in mammalian in vitro splicing systems. In Figure 5.1c, 
lanes 1 and 2 show the radiolabelled proteins fractionated from a yeast in vitro splicing reaction 
containing BrUTP-substituted rp51A pre-mRNA. These samples were from the same experiment 
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FIGURE 5.1 UV-CROSSLINKING OF YEAST PROTEINS TO PRE-mRNA 
Short-wave UV light Induces the formation of RNA—protein adducts. Labelled rp28 pre-
mRNA was incubated with yeast whole cell extract under splicing conditions, then either exposed 
to UV light (lane 2) or held on ice (lane 1). Samples were digested with Rthonuclease A, and the 
proteins were fractionated by SDS-PAGE. Sizes of protein molecular weight markers are given 
in kD. 
A time course of UV exposure. In vitro splicing reactions assembled with rp51A pre-mRNA 
(51A) were UV-irradiated for various lengths of time (t), indicated in minutes (m). The 
Ribonuclease Ti-trimmed products were resolved by SDS-PAGE. 
(C) Comparison of substrate RNAs: UV-crosslinklng. Splicing reactions containing BrUTP-
substituted rp5 1A pre-mRNA (BrU; lanes 1 and 2) or rp28 pre-mRNA (28; lanes 3 and 4) were 
exposed to short-wave UV light for 10 minutes (lanes 1 and 3) or 20 minutes (lanes 2 and 4) 
before Ribonuclease Ti digestion and fractionation by SDS-PAGE. Sizes of protein molecular 
mass standards for Figures 5.1b and 5.1c are given in kD. 
(d) Comparison of substrate RNAs: in vitro splicing. Splicing reactions were assembled with rp51A 
pre-mRNA (51A, lane 1), rp28 pre-mRNA (28; lane 2) or BrUTP-substituted rp51A pre-mRNA 
(BrU; lane 3). The splicing reaction mixtures were incubated for 10 minutes, and the reaction 
products were fractionated by denaturing gel electrophoresis. 
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and the same autoradiograph exposure as those in Figure 5.1b. The presence of BrUTP in the 
substrate RNA did not increase the crosslinking efficiency after 10 minutes' exposure to short-
wave UV light; the proteins were radiolabelled to the same degree with or without BrUTP 
(compare Figure 5.1c, lane 1, with Figure 5.1b, lane 2). After 20 minutes of UV-irradiation, 
however, BrUTP-substituted pre-mRNA appeared to be more efficiently croslinked to proteins 
than did the standard transcript (compare Figure 5. 1c, lane 2, with Figure 5. 1b, lane 4). 
Surprisingly, BrUTP-substituted rp5iA pre-mRNA was not spliced in vitro (Figure 5.ld, 
lane 3), although the standard rp51A transcript is spliced very efficiently in vitro (Figure 5. id, lane 
1). R.R.Shukla, H.Sierakowska, Z.Dominski, J.Stutzinan and R.Kole reported the inhibition of 
mammalian in vitro splicing with BrUTP-substituted human fi-globin transcripts (pers. comm., 
CSH89). They suggested that a bulky substituent at position 5 of uridine could interfere with 
interactions between the pre-mRNA and splicing factors as a result of steric hindrance or altered 
secondary structure of the transcript. Garcia-Blanco et aL (1990) did not observe an inhibition of 
splicing with BrUTP-substituted AdlO RNA AdlO pre-mRNA may be less sensitive to BrUTP 
substitution than fl-globin pre-mRNA or the yeast rp51A pre-mRNA. A lower percentage of 
incorporation of BrUTP in the yeast transcript might not interfere with splicing. This alternative 
was not investigated, however, and BrUTP-substituted transcripts were not utilized for UV-
crosslinking studies. 
Transcript-specific radiolabelling of proteins was evident when comparing radiolabelled 
proteins fractionated from UV-irradiated in vitro splicing reactions containing rp5lA or rp28 pre-
mRNA, both of which are spliced efficiently in vitro (Figure 5.1d, lanes 1 and 2). For example, a 
protein of 45 kD was radiolabelled in splicing reactions containing rp5lA pre-mRNA (Figure 5.1b; 
Figure 5.1c, lanes 1 and 2) but not rp28 pre-mRNA (Figure 5.1a, lane 2; Figure 5.1c, lanes 3 and 
4). The 45 kD protein may bind to a specific sequence element on rp51A pre-mRNA which is not 
present in rp28 pre-mRNA alternatively, the protein may indeed be crosslinked to rp28 pre-
mRNA, but the different Ribonuclease Ti digestion pattern for the transcript may produce an 
unlabelled RNA fragment. 
Yeast splicing extracts contain many RNA-binding proteins which can be detected by UV-
crosslinking. Among these are proteins with molecular weights of approximately 45, 65, 100 and 
>200 kD. A subset of these proteins may interact with pre-mRNA in a splicing-specific manner. 
5.3.2 PRP8 Protein is Crosslinked to Pre-mRNA 
In the previous section, one of the proteins which became crosslinked to pre-mRNA has 
a molecular weight greater than 200 kD (Figure 5. lb). Immunoprecipitation experiments identified 
this protein as the 280 kD PRP8 protein. Figure 5.2, lane 1, shows the radiolabelled proteins 
fractionated from an in vitro splicing reaction irradiated with short-wave UV light. 
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FIGURE 5.2 PRJ'S PROTEIN IS CROSSLINKED TO PRE-mRNA 
In vitro splicing reactions of 10 1 volume, containing wild-type (WT) rp5 1A pre-mRNA in the 
presence of ATP (lane 1) or in the absence of added Al? (lane 2), or reaction mixtures 
containing mutant rp51A pre-mRNA with a deletion of the 5' splice site (5'-0; lane 3) or a 
deletion of the UACUAAC box (A3B; lane 4) were UV-irradiated, and the Ribonuclease Ti. 
trimmed proteins were fractionated by SDS-PAGE. Splicing reaction mixtures of 50 gl volume 
containing wild-type pre-mRNA (lanes 5, 6, 9 and 10) or mutant pre-mRNA (lanes 7 and 8) were 
UV-irradiated, treated with Ribonuclease Ti, and subjected to immunoprecipitation with anti-8.4 
antibodies (lanes 5-8), anti-8.4 antibodies pre-saturated with PRP8 fusion protein 8.4 (FP; lane 
9) or anti-8.4 antibodies pre-saturated with fl-galactosidase (fl-gal; lane 10). The 
immunoprecipitated proteins were resolved by SDS-PAGE. The positions of marker proteins are 
indicated (sizes in kD). 
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Immunoprecipitation from the UV-irradiated splicing reaction with anti-8.4 antibodies resulted 
in the recovery of a radiolabelled protein of apparent molecular weight greater than 200 kD 
(Figure 5.2, lane 5). This result indicated that PRP8 is in direct contact with pre-mRNA during 
the splicing reaction. An antigen competition experiment demonstrated the specificity of 
immunoprecipitation of PRP8 protein. Pre-incubation of anti-8.4 antibodies with purified FF8.4 
(the fusion protein to which the anti-8.4 antibodies were raised) inhibited precipitation of 
radiolabelled PRP8 (Figure 5.2, lane 9), due to successful competition by the fusion protein for 
the antigen binding sites. Pre-incubation of anti-8.4 antibodies with purified fi.galactosidase (the 
carrier polypeptide) did not interfere with immunoprecipitation of PRP8 protein (lane 10). 
The interaction between PRP8 protein and pre-mRNA was examined under various 
conditions. Radiolabelled PRP8 protein was not immunoprecipitated from UV-irradiated in vitro 
splicing reaction mixtures with no added ATP (Figure 5.2, lane 6). Nor was PRP8 protein evident 
among the total crosslinked proteins fractionated from the same splicing reaction mixture with 
no added ATP (lane 2). Radiolabelled PRP8 protein also was not apparent in splicing reaction 
mixtures assembled with mutant substrate RNAs rp5 1A(5 '-0) and rp5 1A(zS.3B) that have deletions 
at the 5 splice site and UACUAAC box (lanes 3 and 4, respectively). These mutant substrate 
RNAs neither form splicing complexes nor are they spliced in vitro (Pikielny and Rosbash, 1986). 
Anti-8.4 antibodies were unable to precipitate radiolabelled PRP8 protein from UV-irradiated in 
vitro splicing reaction mixtures containing rp51A(5 '-0) (lane 7) or rp51A(A3B) (lane 8) substrate 
RNAs. These investigations demonstrated that PRP8 protein only becomes crosslinked to pre-
mRNA molecules that undergo splicing, and only in the presence of ATP. 
Anti-pep antibodies also precipitated radiolabelled PRP8 protein from UV-irradiated in 
vitro splicing reactions (Figure 5.3a, lane 3), and the interaction between PRP8 protein and pre-
mRNA again was shown to be splicing-specific, for radiolabelled PRP8 protein was not 
immunoprecipitated from splicing reaction mixtures that did not contain added ATP (lane 4). As 
demonstrated with anti-8.4 antibodies, the immunoprecipitation of radiolabelled PRP8 protein 
with anti-pep antibodies is antigen specific. Immunoprecipitation of PRP8 protein was inhibited 
when amino-terminal PRP8 peptide (to which anti-pep antibodies were raised; see Chapter 3, 
section 3.3.3) was present during the immunoprecipitation (Figure 5.3a, lane 5). 
Immunoprecipitation was not affected by the presence of a control peptide (lane 6). The diffuse 
bands at approximately 66 kD were not competed from the immunoprecipitate by PRP8 peptide 
(lane 5); therefore, these proteins were non-specifically immunoprecipitated. 
In addition to PRP8, a number of other proteins were specifically precipitated with anti-
pep antibodies (Figure 5.3a, lanes 3 and 6). These most likely represent other spliceosomal 
proteins in contact with pre-mRNA, for anti-pep antibodies precipitate spliceosomes very 
efficiently (Chapter 3, section 3.3.3). Even after nuclease treatment, certain protein—protein 
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FIGURE 5.3 IMMUNOPRECIPITATION OF CROSSLINKED PRPS PROTEIN WITH ANTI-
PEP ANTIBODIES 
Antigen competition. In vitro splicing reactions were assembled with rpZS pre-mRNA in the 
presence of AT? (lane 1) or in the absence of added Al? (lane 2), exposed to short-wave UV 
light, treated with Ribonuclease Ti, and the RNA—protein adducts resolved by SDS-PAGE. UV-
irradiated, Ribonuclease Ti-treated splicing reaction mixtures with (lanes 3, 5 and 6) or without 
added AT? (lane 4) were subjected to immunoprecipitation with anti-pep antibodies (lanes 3 and 
4), with anti-pep antibodies in the presence of the amino-terminal PRP8 peptide against which 
the anti-pep antibodies were raised (lane 5) or with anti-pep antibodies in the presence of control 
(C) peptide (lane 6). Radiolabelled proteins which do not correspond to PRP8 protein, that are 
present in the anti-pep precipitates (lanes 3 and 6), are indicated with an asterisk (*). Sizes of 
protein molecular weight standards are given in kD. 
Radlolabelled proteins co-precipitated with PRPS are removed by denaturation. In vitro 
splicing reactions containing rp28 pre-mRNA were UV-irradiated, digested with Ribonuclease Ti, 
and subjected to immunoprecipitation with anti-pep antibodies; (lane 1), or prior to 
immunoprecipitation, were exposed to denaturing conditions of 0.05 - 1.0% (w/v) SDS, 0.05- 1.0% 
(v/v) Triton X-100 and 5 - 100 mM DTF (lanes 2-5). Radiolabelled proteins which do not 
correspond to PRP8 protein, yet are present in the anti-pep precipitate (lane 1), are indicated with 
an asterisk (*). The positions of marker proteins are indicated (sizes in kD). 
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interactions may be maintained, allowing co-precipitation of other spliceosomal proteins with 
PRP8. 
In Figure 5.3b, lanes 2 through 5, a variety of denaturation conditions were tested for 
their effects on mimunoprecipitation of radiolabelled proteins. In the absence of denaturation, 
many spliceosomal RNA-binding proteins were immunoprecipitated with anti-pep antibodies from 
UV-irradiated in vitro splicing reactions (lane 1). When the samples were boiled in SDS, Triton 
X-100 (a nonionic detergent) and DTT prior to immunoprecipitation, however, PRP8 was the 
predominant protein in the immunoprecipitate (lanes 2 and 3). Denaturation of samples in lower 
concentrations of SDS, Triton, and DTI' substantially decreased the recovery of PRP8 protein 
(lanes 4 and 5). Perhaps under these conditions, proteins aggregated and inadvertently were 
cleared from the sample during the centrifugation step prior to immunoprecipitation. 
Denaturation of the samples prior to immunoprecipitation resulted in the loss of the background 
of other spliceosomal proteins usually present in anti-pep immunoprecipitates. Presumably, the 
protein—protein interactions, which may have allowed for co-immunoprecipitation of these 
proteins with PRP8, were disrupted by the denaturing conditions. 
Immunóprecipitation of radiolabelled protein from UV-irradiated in vitro splicing 
reactions with both anti-8.4 and anti-pep antibodies demonstrated that PRP8 protein is in direct 
contact with pre-mRNA during the splicing reaction. The interaction of PRP8 protein with pre-
mRNA is splicing-dependent, for the contact event occurs only in the presence of ATP 
'
'and PRP8 
protein only interacts with pre-mRNA molecules that participate in the splicing reaction. 
5.3.3 PRP8 Protein Contacts Pre-mRNA Early in the Splicing Process 
In order to determine at what stage during the splicing reaction PRP8 protein contacts 
pre-mRNA, a time course experiment was performed. Samples were removed at various times 
from an in vitro splicing reaction, exposed to short-wave UV light, then subjected to 
immunoprecipitation with anti-8.4 antibodies. Figure 5.4a shows the RNA species present at each 
time point in the splicing reaction. No splicing occured in the absence of ATP (lane 1), and 
splicing intermediates (lariat intro n-exon 2 and exon 1) from the first step of the splicing reaction 
were not detected until the splicing reaction had been incubated longer than two minutes (lane 
2). At 7 minutes, the time at which the splicing intermediates were first observed in this 
experiment, some intron product from the second step of splicing also was present (lane 3). After 
30 minutes of splicing, the intron product was the major lariat species in the sample (lane 5); at 
this time, either step 1 of the splicing reaction was complete or step 2 was no longer the rate- ? 
determining step of the reaction. 
In the experiment shown in Figure 5.4b, PRP8 protein was immunoprecipitated from UV-
irradiated splicing reactions taken at the same time points (and from the same reaction mixtures) 
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FIGURE 5.4 INTERACTION OF PRP8 PROTEIN WITH PRE-mRNA: AN IN VITRO 
SPLICING REACTION TIME COURSE 
Analysis of splicing reaction products. Rp5 1A pre-mRNA was incubated under splicing 
conditions for 2, 7, 15 or 30 minutes (lanes 2, 3, 4 and 5, respectively) or with no added ATP for 
30 minutes (lane 1), and the RNA species were resolved by denaturing gel electrophoresis. 
UV-crosslinklng of PRP8 protein to pre-mRNA. In vitro splicing reactions containing rp5lA 
pre-mRNA wre incubated for 2, 7, 15 or 30 minutes (lanes 2, 3, 4 and 5, respectively), and 
reaction mixtures with no added ATP were incubated for 30 minutes (lane 1). Samples were UV-
irradiated, treated with Ribonuclease Ti, subjected to immunoprecipitation with anti-8.4 
antibodies, and the immunoprecipitated proteins were fractionated by SDS-PAGE. 
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as those in Figure 5.4a. Two minutes into the splicing reaction, PRP8 protein demonstrated an 
interaction with pre-mRNA (Figure 5.4b, lane 2). Contact of PRP8 protein with pre-mRNA was 
also evident 7 and 15 minutes into the splicing reaction (lanes 3 and 4). PRP8 protein maintained 
its interaction with pre-mRNA late in the splicing reaction, at 30 minutes, although less 
radiolabelled PRP8 protein was immunoprecipitated (lane 5). PRP8 protein had no interaction 
with pre-mRNA in the absence of ATP (lane 1). 
PRP8 protein interacts with pre-mRNA early in the splicing process, and its interaction 
with the substrate RNA is observed throughout the splicing reaction. Although UV-crosslinking 
of PRP8 protein to pre-mRNA was apparent at two minutes into the splicing reaction, prior to 
the appearance of splicing intermediates (Figure 5.4a, lane 2), it cannot be assumed that PRP8 
protein interacts with pre-mRNA prior to step 1 of the splicing reaciton. The first step of splicing 
may have been occurring at two minutes, but the observation of reaction products at early time 
points may be below the limits of detection of the species. From these experiments, it is concluded 
that PRP8 protein interacts with pre-mRNA, early in the splicing reaction. 
5.3.4 A System to Determine the Substrate Requirements for Interaction between PRP8 Protein 
and Pre-mRNA 
In order to delineate the sequence requirements for 5' cleavage and lariat formation in 
the yeast in vitro splicing system, Rymond et aL (1987) created a series of substrate RNAS, 
truncated at varying distances downstream from the UACUAAC box. The truncated pre-mRNAs 
were generated by oligodeoxynucleotide-directed Ribonuclease H cleavage of rp51A run-off 
transcripts. Using the cleaved substrate RNAs, Rymond et aL (1987) defined a sequence-
independent length requirement of at least 29 nucleotides downstream from the rp5lA 
UACUAAC element for the first step of splicing to proceed. 
A similar approach was employed to characterize the splicing substrate requirements for 
the interaction between PRP8 protein and pre-mRNA. Rp28 pre-mRNA was cleaved with 
Ribonuclease H and oligodeoxynucleotides complementary to regions 3' to the rp28 UACUAAC 
box. Figure 5.5a illustrates the two truncated rp28 transcripts, 28/1 and 2812, which were generated 
by the RNA cleavage procedure. 28/1 pre-mRNA was cleaved approximately 20 nucleotides 
downstream of the UACUAAC element. Cleavage of rp28 transcripts with oligo 2 produced a 
truncated 2812 pre-mRNA that retained the entire intron sequence plus approximately 10 nucleo-
tides of exon 2 (as estimated by the electrophoretic mobility of the spliced exons; data not 
presented). 
The oligo-cleaved rp28 pre-mRNAs were compared with full-length rp28 pre-mRNA as 
substrates for in vitro splicing reactions. Figure 5.6, lane 1, shows the RNA species fractionated 
from an in vitro splicing reaction containing full-length rp28 pre-mRNA, in which both steps of 
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FIGURE 5.5 PRE-mRNA SPLICING SUBSTRATES 
Rp28 pre-mRNA. The boxes represent exon 1 (122 nucleotides) on the left, exon 2 (170 
nucleotides) on the right, and the narrow line the intron (448 nucleotides). The filled circle 
indicates the position of branchpoint formation (the UACUAAC box). The expanded portion of 
the diagram represents the RNA sequence from the UACUAAC box of the intron to the 5' 
region of exon 2. Under the sequence, in heavy lines, are indicated the positions of hybridization 
of oligodeoxynucleotides 1 and 2. 28/1 and 28,2 represent the expected cleavage products from 
incubation of rp28 pre-mRNA with Ribonuclease H and oligo 1 or oligo 2, respectively. 
Rp5IA pre-mRNA. The 77 nucleotide exon 1 and 420 nucleotide exon 2 are represented by 
boxes on the left and right, respectively, of the 400 nucleotide intron, drawn as a narrow line. The 
filled circle designates the branchsite (UACUAAC box). The expanded portion of the diagram 
represents the entire RNA sequence between the UACUAAC box and the 3' splice site. The 
regions of hybridization of oligodeoxynucleotides A and C are indicated by heavy lines below the 
sequence. 51A/A and 51A/C show the expected cleavage products resulting from incubation of 
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splicing occurred. The splicing reaction shown in lane 2 did not proceed, for no ATP was added 
to the splicing reaction mixture. Lanes 3 and 4 of Figure 5.6 show the RNA species recovered 
from splicing reaction mixtures assembled with 28/1 or 2812 truncated pre-mRNA5, respectively. 
28/1 pre-mRNA was not spliced in vitro (lane 3); 28,2 pre-mRNA underwent both step 1 and step 
2 of splicing (lane 4). The splicing intermediate, lariat intron-exon 2, produced from the first 
splicing reaction with 2812 pre-mRNA, migrated only slightly slower than the lariat intron product 
because of the short exon 2 sequence (lane 4). In addition, the 10-12 nucleotide exon 2 produced 
a much shorter mRNA (lane 4) than the ligated exons produced from a splicing reaction 
containing full-length rp28 pre-mRNA (lane 1). 
In vitro splicing reactions assembled with full-length or truncated rp28 pre-mRNA were 
analysed by native gel electrophoresis for splicing complex formation. Figure 5.7a, lane 1, shows 
the complexes formed during an in vitro splicing reaction containing full-length rp28 pre-mRNA. 
A total of three splicing complexes were observed as the standard splicing reaction progressed. 
The nomenclature of Pikielny et at (1986) was adopted, and the three forms of the spliceosome 
were designated I, II, and III (refer to Chapter 1, section 1.8); the mature spliceosome is most 
likely represented by the terminal complex, II. The formation of complex III and a complex 
migrating between splicing complexes I and II was observed in the sample to which no ATP was 
added (Figure 5.7a, lane 2). This reproducible result indicates that there is sufficient Al? 
endogenous to yeast splicing extracts to promote some complex assembly, yet the concentration 
of Al? is not sufficient for the splicing reaction to take place (Figure 5.6, lane 2). Oligo 2-cleaved 
rp28 pre-mRNA, which underwent both steps of the splicing reaction (Figure 5.6, lane 4), 
presented a spliceosome assembly profile similar to that of full-length rp28 pre-mRNA three 
spliceosomal complexes were formed during the splicing reaction (Figure 5.7a, lane 4). Truncated 
28/1 pre-mRNA, although not spliced in vitro (Figure 5.6, lane 3), nonetheless exhibited efficient 
yet incomplete splicing complex assembly (Figure 5.7a, lane 3). Rymond et at (1987) reported 
similar results for oligo A-cleaved rp5lA pre-mRNA (51A/A; Figure 5.5b). 51A/A pre-mRNA, 
truncated approximately 12 nucleotides downstream of the UACUAAC box, was not spliced in 
vitro, and it also displayed incomplete complex assembly, a time course of complex formation 
suggested that the pre-splicing complex I, not complex II, was the terminal assembly product for 
51A/A pre-mRNA (Rymond etaL, 1987). Truncated 28/1 and 51AJA pre.mRNA molecules appear 
to become stalled in a complex before the completion of spliceosome assembly and prior to 
initiation of step 1 of the splicing reaction. 
Immunoprecipitations with anti-PRP8 antibodies were performed to investigate the 
association of PRP8 protein with splicing complexes containing full-length or oligo-cleaved pre-
mRNA substrates. As demonstrated in Chapter 3, section 3.3.3, anti-pep antibodies precipitated 
precursor RNA, splicing intermediates, lariat product, and a low level of spliced exons from a 
standard splicing reaction (Figure 5.6, lane 7); this profile of immunoprecipitated RNA species 
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FIGURE 5.6 IMMUNOPRECIPITATION OF RP28 RNA SUBSTRATES WITH ANTI-PEP 
ANTIBODIES 
Splicing reaction mixtures were assembled with full-length wild-type rp28 pre-mRNA (28; lane 1), 
oligo 1-cleaved rp28 RNA (/1; lane 3), oligo 2-cleaved rp28 RNA (12 lane 4), mutant rp28 pre-
mRNA containing a single nucleotide substitution at the 5 splice site (284; lane 5), mutant rp28 
pre-mRNA with a substitution at the branchpoint nucleotide (287; lane 6) or with no added All' 
(lane 2), and the reaction mixtures were subjected to immunoprecipitation with anti-pep 
antibodies (lanes 7-12). RNA species are indicated by diagrams in which exon 1 is represented by 
a filled box, exon 2 by an empty box, and the intron by a narrow line. 
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indicated an association of PRP8 protein with splicing complexes at all stages of the splicing 
reaction. From splicing reaction mixtures with no added ATP, in which no splicing occurred 
(Figure 5.6, lane 2), some pre-mRNA was precipitated with anti-pep antibodies (lane 8), as 
expected for the low level of complexes formed in the absence of exogenously added Al? (Figure 
5.7a, lane 2). In contrast, the precipitation of 28/1 pre-mRNA was very efficient (lane 9); this 
demonstrates a stable association of PRP8 protein with pre-splicing complexes that contain 28/1 
pre-mRNA. 
Other substrate RNAs that are not spliced in vitro were inefficiently precipitated with 
anti-pep antibodies, however. Splicing reaction mixtures were assembled with mutant rp28 pre-
mRNA substrates 284 and 287 (Figure 5.6, lanes 5 and 6, respectively; both constructs were a gift 
from A.Newman, MRC Laboratory of Molecular Biology, Cambridge, England). 284 RNA 
possesses an A residue rather than G at position 1 of the 5' splice site consensus sequence. 284 
RNA undergoes 5' cleavage and lariat formation in vivo, but is unable to proceed through the 
second cleavage-ligation reaction (A.Newman, pers. comm.). Under in vitro splicing conditions, 
however, 284 RNA was unable to participate in the splicing process, for splicing reaction 
intermediates were not observed (Figure 5.6, lane 5). 287 RNA has an A to C substitution at the 
branchpoint nucleotide in the UACUAAC box. 287 RNA is spliced neither in vivo (A.Newman, 
pers. comm.) nor in vitro (lane 6). Anti-pep antibodies precipitated only a negligible amount of 
mutant substrate RNA from splicing reaction mixtures assembled with 284 RNA (lane 11) or 287 
RNA (lane 12). Splicing reaction mixtures containing 284 or 287 substrate RNAs were not 
analysed by native gel electrophoresis for splicing complex formation, but it is possible that these 
mutant substrates may be similar to the 5 splice site and UACUAAC box deletion mutants of 
rp5 1A pre-mRNA, which neither are assembled into splicing complexes (Pikielny and Rosbash, 
1986) nor are precipitated with PRP8-specific antibodies (Whittaker et aL, 1990). 
Splicing precursor, intermediates and both products, lariat intron and ligated exons, were 
precipitated with anti-pep antibodies from in vitro splicing reactions containing 28,2 pre-mRNA 
(lane 10). It is interesting that the truncated mRNA product was so efficiently immunoprecipitated 
from the 2812 splicing reaction. Spliced exons generally are not recovered with much efficiency in 
anti-PRP8 precipitates (Figure 5.6, lane 7; see also Chapter 3, sections 3.3.2 and 3.3.3), presumably 
due to their release from the PRP(tein-associated intron-containing post-spiicng complex. 
Perhaps the truncated mRNA product is not released as efficiently from the post-splicing complex 
as are the full-length ligated exons. 
The interaction of PRP8 protein with oligo-cleaved pre-mRNA substrates was analysed 
by UV-crosslinking. in vitro splicing reactions were assembled with 28/1, 28/2 or full-length rp28 
pre-mRNA, irradiated with short-wave UV light, and denatured by boiling in 1% (w/v) SDS, 1% 
(vlv) Triton X-100 and 100 mM Dli'. The samples were diluted ten-fold, then subjected to 
immunoprecipitation with anti-pep antibodies (Figure 5.7b). Lane 1 of Figure 5.7b shows the 
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FIGURE 5.7a SPLICING COMPLEX FORMATION WITH FULL-LENGTH AND 
TRUNCATED RP28 RNA SUBSTRATES 
In vitro splicing reactions were assembled with full-length rp28 (28) pre-mRNA (lane 1), with 
oligo 1-cleaved rp28 RNA (28/1; lane 3), with oligo 2-cleaved rp28 RNA (2812; lane 4), or with 
no added ATP (lane 2), and the samples were analysed by native gel electrophoresis for splicing 
complex formation. Splicing complexes I, II and III are designated according to Pikielny et aL 
(1986). 
FIGURE 5.7b INTERACTION OF PRP8 PROTEIN WITH FULL-LENGTH AND 
TRUNCATED RP28 RNA SUBSTRATES 
A standard in vitro splicing reaction containing full-length rp28 pre-mRNA (28) was exposed to 
short-wave UV light, treated with Ribonuclease Ti, and the RNA—protein adducts were resolved 
by SDS-PAGE (lane 1). UV-irradiated, Ribonuclease Ti-treated splicing reaction mixtures 
containing full-length rp28 pre-mRNA (lane 2), oligo 1-cleaved rp28 RNA (/1; lane 3) or oligo 
2-cleaved rp28 RNA (12; lane 4) were subjected to denaturing conditions [1% (w/v) SDS, 1% (v/v) 
Triton X-100, 100 mM DIT] prior to immunoprecipitation with anti-pep antibodies. The 
precipitated proteins were fractionated by SDS-PAGE. Sizes of protein molecular weight standards 
are given in kD. 
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crosslinked proteins fractionated from a UV-irradiated splicing reaction containing full-length 
rp28 RNA; in lanes 2 through 4 are the radiolabelled proteins recovered from anti-pep 
immunoprecipitations of different splicing reaction mixtures. PRP8 protein was crosslinked to full-
length and 2812 pre-mRNA (lanes 2 and 4, respectively), but no crosslinking was observed between 
PRP8 protein and 28/1 pre-mRNA (lane 3). PRP8 protein is present in the pre-splicing complex 
formed with 28/1 pre-mRNA, as evidenced by the ability of anti-pep antibodies to precipitate 28/1 
RNA with high efficiency (Figure 5.6, lane 9), yet PRP8 protein does not contact 28/1 pre-mRNA. 
A direct interaction between PRP8 protein and pre-mRNA does not appear possible unless the 
pre-mRNA substrate is able to undergo splicing. 
5.3.5 PRP8 Protein Interacts with Pre-mRNA upon Initiation of Step 1 of the Splicing Reaction 
The crosslinking of PRP8 protein to truncated pre-mRNA substrates developed by 
Rymond et al (1987) was investigated in order to determine whether the completion of both steps 
of the splicing reaction or whether initiation of step 1 is sufficient to promote contact between 
PRP8 protein and pre-mRNA. 
Rymond etaL (1987) utilized rp5lA pre-mRNA for their studies of truncated pre-mRNA 
substrates. Figure 5.8a, lane 2, shows the products of a standard splicing reaction containing full-
length rp51A pre-mRNA, and in lane 3, no splicing was observed in a splicing reaction mixture 
without added ATP. The rp51A transcript, when cleaved with oligo A (51AIA Figure 5.5b), 
generates a pre-mRNA that, like 28/1 pre-mRNA, was not spliced in vitro (Figure 5.8a, lane 4) 
and displays incomplete spliceosome assembly (Rymond et aL, 1987). PRP8 protein is associated 
with pre-splicing complexes containing 5 lA/A RNA, as evidenced by the ability of anti-pep 
antibodies to precipitate 5 lA/A pre-mRNA efficiently from in vitro splicing reactions (Figure 5.8a, 
lane 8). Oligo C-cleaved rp51A transcripts (5 IA/C; Figure 5.5b) only undergo the first step of the 
splicing reaction (Figure 5.8a, lane 5). 5 lA/C pre-mRNA lacks exon 2, which results in the lariat 
and exon 1 being the reaction termination products as well as intermediates (Rymond et aL, 1987). 
51A/C exhibits complete spliceosome assembly (Rymond et aL, 1987), and splicing complexes 
containing 51A/C RNA were precipitated withanti-pep antibodies (Figure 5.8a, lane 9). 
Attempts were made to create a truncated rp28 transcript with similar properties to 
51A/C pre-mRNA however, the distance between the UACUAAC box and the 3' splice site of 
rp28 is 22 nucleotides. Rp28 pre-mRNAS truncated before the 3' splice site were unable to 
undergo step 1 of splicing, presumably because the transcripts did not fulfill the length 
requirements for lariat formation defined in the studies of Rymond et aL (1987) (see section 
5.3.4). Rp28 pre-mRNAs that were truncated at least 29 nucleotides downstream of the 
UACUAAC element were able to participate in the first step of splicing, but also contained 
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FIGURE 5.8 INTERACTION OF PRP8 PROTEIN WITH FULL-LENGTH AND 
TRUNCATED RPSIA RNA SUBSTRATES 
Immunoprecipitation of full-length and truncated RNA species with anti-PRP8 antibodies. In 
vitro splicing reaction mixtures were assembled with full-length rpSiA pre-mRNA (51; lane 2), 
oligo A-cleaved rp51A RNA (1A lane 4), oligo C-cleaved rpSlA RNA (IC; lane 5), or with no 
added ATP (lane 3), and samples were subjected to immunoprecipitation with anti-pep antibodies 
(lanes 6-9). The nucleotide size markers (M) in lane 1 are end-labelled MspI and AvaI+NheI 
digests of pBR322 DNA. RNA species are indicated by diagrams in which exon 1 is represented 
by a filled box, exon 2 by an empty box, and the intron by a narrow line. 
Crosslinking of PRPS protein to full-length and truncated RNA species. In lane 1, a 10 j.tl 
splicing reaction containing full-length rpSlA pre-mRNA (51) was exposed to short-wave UV 
light, and the Ribonuclease Ti-trimmed proteins were resolved by SDS-PAGE. In lanes 2-5, 
immunoprecipitations with anti-pep antibodies were conducted from UV-irradiated, Ribonuclease 
Ti-treated 50 l splicing reaction mixtures that contained full-length rp5lA pre-mRNA (lane 2), 
oligo A-cleaved rp51A RNA (/A lane 4), oligo C-cleaved rp51A RNA (/C; lane 5), or no added 
ATP (lane 2), and the immunoprecipitated proteins were fractionated by SDS-PAGE. PRP8 
protein is indicated with an arrowhead (lanes 1, 2 and 5), and the 40 kD protein of unknown 
identity (lane 4) is indicated by an asterisk (*). Sizes of protein molecular mass standards are 
given in kD. 
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enough exon 2 sequence to undergo step 2 as well (as is the case for the 2812 transcript). It does 
not appear possible to create a cleaved rp28 transcript similar to 5 lA/C pre-mRNA. 
Figure 5.8b compares the crosslinking of PRP8 protein to full-length rp51A, 5 lA/A, and 
5 lA/C pre-mRNA5. UV-irradiated in vitro splicing reactions were subjected to standard (non-
denatured) immunoprecipitation with anti-8.4 antibodies. As was the case with 28/1 pre-mRNA, 
PRP8 protein did not become crosslinked to 5 lA/A pre.mRNA (lane 4). The radiolabelled protein 
of approximately 40 kD that was recovered in the anti-8.4 precipitate and exhibited crosslinking 
to 5 lA/A RNA (lane 4) is of unknown identity. Denaturation of the sample prior to 
immunoprecipitation with anti-PRP8 antibodies prevented the recovery of the 40 kD protein (data 
not presented). It is unlikely that the 40 kD protein is a non-specific degradation product of PRP8 
protein, because it is reproducibly observed on crosslinking experiments utilizing either 28/1 or 
5 lA/A substrate RNAs. The 40 kD protein may interact with PRP8 protein in the pre-splicing 
complex that contains 5 lA/A pre-mRNA. PRP8 protein did, however, become crosslinked to 
5 lA/C pre-mRNA (lane 5). These results suggest that PRP8 protein will interact only with RNA 
substrates in pre-splicing complexes capable of participating in at least the first step of the splicing 
reaction. Abilityto complete the second step of splicing is not a requirement for binding of PRP8 
protein to pre-mRNA Alternatively, the substrate RNA simply may need to fulfill spatial 
requirements, if PRP8 protein interacts with pre-mRNA in the region downstream of the 
branchpoint which is not present in 28/1 and 5 lA/A pre-mRNAs. 
5.4 DISCUSSION 
Immunoprecipitation and UV-crosslinking have proven to be a powerful combination of 
biochemical techniques with which to probe the interactions of PRP8 protein within the yeast 
spliceosome. This experimental approach has identified PRP8 protein as a spliceosomal trans-
acting factor which has a direct interaction with pre-mRNA. 
UV-crosslinking of in vitro splicing reactions detected a number of proteins in yeast 
splicing extracts that have direct interactions with pre-mRNA. The majority of these proteins, 
however, are RNA-binding proteins whose interactions with pre-mRNA do not appear to be 
splicing-dependent. PRP8 protein was detected among the proteins that interact with pre-mRNA 
by immunoprecipitation from UV-irradiated in vitro splicing reactions with anti-PRP8 antibodies. 
Further analysis of the interaction between PRP8 protein and pre-mRNA defined it as a splicing-
specific event. Crosslinking of PRP8 protein to pre-mRNA was observed only in the presence of 
Al? and with substrate RNAs that participate in the splicing reaction. 
The pre-mRNA sequence requirements for interaction with PRP8 protein were delineated 
by using a set of substrate RNAs truncated at various distances downstream of the UACUAAC 
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element. Rymond et aL (1987) originally developed this system to determine the oligonucleotide 
length downstream of the UACUAAC box required for initiation of step 1 of the splicing reaction 
(described in more detail in Chapter 1, section 1.6.3). It appears that the minimum length 
downstream of the UACUAAC box required for step 1 of splicing to proceed, as defined by 
Rymond et aL (1987), is also the minimum sequence requirement for interaction between PRP8 
protein and pre-mRNA. In fact, even if the substrate RNA does not participate in the second 
cleavage-ligation reaction of splicing, PRP8 protein still becomes crosslinked to the substrate 
RNA. The ability of the pre-mRNA to participate in at least step 1 of the splicing reaction is 
sufficient to promote interaction between PRP8 protein and pre-mRNA. 
If the substrate and ATP requirements for the RNA—protein interaction are fulfilled, 
PRP8 protein contacts pre-mRNA early in the splicing reaction. Immunoprecipitation studies 
(Chapter 3, sections 3.3.2 and 3.3.3) demonstrated an early association of PRP8 protein with 
splicing complexes, which suggests that PRP8 protein interacts with pre-mRNA concomitant with 
its assembly onto the spliceosome. Immunoprecipitation and UV-crosslinking experiments 
conducted with 28/1 and 5 lA/A truncated pre-mRNA5, however, demonstrated that this is not the 
case. PRP8 protein is associated with pre-splicing complexes containing the cleaved RNA species 
28/1 and 51A/A these pre-mRNAs are unable to participate in the splicing reaction. The presence 
of PRP8 protein in the complex was not sufficient to initiate the contact event between PRP8 
protein and pre-mRNA, for no crosslinking was observed between PRP8 protein and the truncated 
pre-mRNAs. PRP8 protein does, however, become crosslinked to a truncated transcript (5 lA/C) 
that is able to participate in the first step of the splicing reaction. 
Therefore, it appears that the assembly of PRP8 protein onto the pre-splicing complex 
and the direct interaction between PRP8 protein and pre-mRNA are two separate events that are 
governed by different cis- or trans-acting factors within the splicing apparatus. 28/1 and 5 lA/A pre-
mRNAs, and/or the complexes that contain them, possess the requirements only for association 
with PRP8 protein. 5 lA/C pre-mRNA (and other pre-mRNAs able to undergo at least step 1 of 
splicing) and/or its associated complexes provide additional cis- or trans-acting factor(s) which 
make possible the contact event between PRP8 protein and pre-mRNA. Rymond et aL (1987) 
showed that there exists a sequence-independent length requirement downstream of the 
UACUAAC box in order for step 1 of splicing to proceed. The interaction of PRP8 protein with 
pre-mRNA may share this requirement. PRP8 protein may either bind to the region downstream 
of the branchpoint directly, or its interaction with pre-mRNA may rely on interaction with other 
trans-acting factor(s) which themselves recognize elements required for the initiation of the first 
step of the splicing reaction. 
In this chapter, it was demonstrated that the spilceosomal protein, PRP8, interacts with 
pre-mRNA in a splicing-specific manner. This interaction occurs immediately prior to or 
simultaneously with step 1 of splicing. This suggests that PRP8 protein may be a trans-acting 
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factor involved directly or indirectly in the 5 cleavage event. A clearer picture of the role of 
PRP8 protein in the splicing process could be obtained from identification of the protein's binding 
site(s) on substrate RNA, or from identification of the protein epitope(s) of PRP8 which contacts 
pre-mRNA. Anderson (1989) identified a good candidate for the PRP8 RNA-binding domain. 
TRP8.5 is a PRP8 fusion protein that contains a segment between amino acids 85 and 124, in 
which 19 out of the 39 amino acids are basic. TRP8.5 displays non-specific RNA-binding activity. 
This putative RNA-binding region could be rendered specific by its association with the other 
domains of PRP8 protein or by its interaction with other factors within the splicing apparatus. 
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CHAPTER SIX 
PRELIMINARY LOCALIZATION OF THE BINDING SITE(S) OF 
PRPS PROTEIN ON PRE-mRNA 
6.1 INTRODUCTION 
It was established in the preceeding chapter that PRP8 protein interacts directly with pre-
mRNA within functional spliceosomes. It is of great interest to localize the specific site(s) on pre-
mRNA which becomes crosslinked to PRP8 protein, for this information could aid in elucidating 
the role of PRP8 protein in the splicing process. 
An effective method for mapping interactions between RNA and RNA-binding 
components within ribonucleoprotein complexes is protection of the bound RNA from 
ribonuclease digestion (Black et aL, 1985; Chabot et aL, 1985; Ruskin and Green, 1985b; Bindereif 
and Green, 1986; Chabot and Steitz, 1987; K.rämer, 1988). Black et aL (1985) identified regions 
of pre-mRNA that interact with Ui and U2 snRNPs by treating mammalian in vitro splicing 
reactions with Ribonuclease Ti and immunoprecipitating the protected RNA fragments with 
human anti-(Ui)RNP and anti-(U2)RNP antibodies. 
In this chapter, a similar approach to that of Black et aL (1985) was adopted to investigate 
the region(s) of pre-mRNA and pre-mRNA-derived molecules that are protected by the yeast 
splicing complexes immunoprecipitated with anti-PRP8 antibodies. A Ribonuclease Ti protection 
assay was also utilized to map the specific region(s) of the substrate RNA which becomes 
crosslinked to PRP8 protein. Figure 6.1 illustrates these two experimental approaches. In vitro 
splicing reactions were UV-irradiated, partially digested with Ribonuclease Ti, then subjected to 
immunoprecipitation with anti-PRP8 antibodies. The immunoprecipitated RNA—protein 
complexes were analysed in either of two ways: (a) the RNA fragments protected by the 
iminunoprecipitated complexes were recovered from the immunoprecipitate, and fractionated on 
a gel; the RNA fragments were eluted from the gel and redigested with Ribonuclease Ti; the 
resulting oligoribonucleotides were compared to the Ribonuclease Ti digestion pattern of pre-
mRNA to identify the protected region(s) of substrate RNA or (b) the immunoprecipitate was 
fractionated by SDS-PAGE in order to separate radiolabelled PRP8 protein from other co-preci-
pitated radiolabelled proteins; the PRP8 protein—RNA adduct was excised from the protein gel, 
the protected RNA fragments were eluted from the gel slice, and the fragments digested to 
completion with Ribonuclease Ti; the resulting oligoribonucleotides were compared to the 
Ribonuclease Ti digestion pattern of pre-mRNA to identify the region(s) of substrate RNA which 
had been crosslinked to PRP8 protein. Preliminary results from these studies are presented. 
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FIGURE 6.1 EXPERIMENTAL PROCEDURES USED FOR RIBONUCLEASE 
PROTECTION MAPPING 
In vitro splicing reactions were UV-irradiated, treated with Ribonuclease Ti and subjected to 
immunoprecipitation with PRP8-specific antibodies. The immunopiecipitates were either (a) 
phenol extracted to recover protected RNA fragments, which were then fractionated on a 
denaturing 20% aciylamide gel, excised and eluted from the gel, and digested to completion with 
Ribonuclease Ti; the protected fragments' composite oligonbonucleotides were identified by 
comparison with the Ribonuclease Ti digestion pattern of full-length pre-mRNA or (b) 
fractionated by SDS-PAGE to visualize the radio labelled PRP8 protein—RNA adduct, which was 
then excised from the gel and digested with protease; the protected RNA fragment was recovered 
from the gel slice by electroelution, digested with Ribonuclease Ti, and the resulting 
oligoribonucleotides were fractionated by denaturing gel electrophoresis, and identified by 
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6.2 METHODS AND MATERIALS 
6.2.1 In vitro Transcription 
Radiolabelled substrate RNA was transcribed in vitro from plasmid pT7rp28s with 11 
RNA polymerase (2.5.2). High specific activity radiolabelled transcripts were utilized for the 
analysis of RNA fragments UV-crosslinked to PRP8 protein. 
In experiments to investigate the Ribonuclease Ti digestion pattern of the rp28 transcript, 
radiolabelled transcripts of standard specific activity were utilized. Rp28 transcripts truncated prior 
to the UACUAAC element were produced by transcription from plasmid pT7rp28s linearized with 
MspI (see Figure 6.2). In addition, radiolabelled CTP, rather than UT?, was incorporated into 
some transcripts. These rp28 transcripts were synthesized by the standard method (2.5.2) except 
that the transcription reaction was supplemented with 30 iCi [a- 32P]CTP (800 Cilmmol, 
Amersham); the final concentration of CTP was limiting (25 M) in the presence of optimal 
concentrations (0.5 mM) of ATP, GTP and UT?. 
6.2.2 In vitro Splicing Reactions 
In vitro splicing was performed by the standard procedure (2.5.3) in preparative volumes 
of 0.9 ml or 0.6 ml. Splicing reactions contained approximately 10 nM high specific activity 
radiolabelled RNA transcript and 50% (v/v) splicing extract, comprising a mix of 3 parts whole 
cell extract (2.5.1.2) and 2 parts 40% saturated ammonium sulphate precipitate of whole cell 
extract (2.5.1.3). Reactions were incubated at 25 0C for 7 minutes, then quenched on ice. 
6.2.3 Ribonuclease Digestion of RNA 
6.2.3.1 Digestion of RNA with Ribonuclease Ti 
Conditions for Ribonuclease Ti digestion of RNA were modified from Donis-Keller et 
aL (1977). RNA was digested for 30 minutes at 30 °C in a total reaction volume of 5 il, 
containing 20 mM sodium citrate (pH 5.0), 1 mM EDTA, 6 M urea, 5 pg E. co/i tRNA, and 12.5 
U Ribonuclease Ti (Boehringer Mannheim UK). An equal volume (5 l) of 2x urea load buffer 
was added, the samples were heated to 90 0C for 3 minutes, then loaded directly onto a denaturing 
20% acrylamide gel (2.4.3). The fractionated RNA fragments were visualized by autoradiography 
(2.2.4). 
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6.2.3.2 Digestion of RNA with Ribonuclease H 
RNA was incubated for 30 minutes at 37 0C in a reaction volume of 5 1il containing 50 
mM Tris-HCI (pH 7.5), 50 pmoles oligodeoxynucleotide (Table 6.1 lists the oligodeoxynucleotides 
used in these experiments), and 2.5 U Ribonuclease H (BRL). Digested samples were fractionated 
on a 20% acrylamide gel as described above. 
6.2.3.3 Simultaneous Digestion of RNA with Ribonuclease Ti and Ribonuclease H 
Specific oligoribonucleotides resulting from Ribonuclease Ti digestion of RNA were 
targeted for degradation by performing oligodeoxynucleotide-directed Ribonuclease H digestion 
simultaneously with Ribonuclease Ti digestion. The dual digestion was performed in a total 
reaction volume of 5 ILI, containing 50 mM Tris-HC1 (pH 7.5), 50 pmoles oligodeoxynucleotide 
(see Table 6.1), i2.5 U Ribonuclease Ti (Boehringer Mannheim UK), and 2 U Ribonuclease H 
(BRL). Samples were incubated at 37 0C for 30 minutes, then analysed as described in section 
6.2.3.1. 
Table 6.1 Oligodeoxynucleotides used for targeted Ribonuclease H digestion of rp28 transcripts 
Oligodeoxynucleotide 
Sequence (5' to 3') 
Oligo 18 	CVFGATA1TA rrir iG 
Oligo 21 CTAAGAAAGTGTAT 






6.2.4 Elution of RNA Fragments from 20% Acrvlamide Gels 
RNA fragments were localized in the gel by autoradiography, and the band(s) was excised 
from the gel. The gel slice was submerged in 0.3 ml elution buffer containing 0.75 M ammonium 
acetate, 0.1% (w/v) SDS, 0.1 mM EDTA, and 5 ig E. coli IRNA (Frendewey and Keller, 1985). 
The RNA was eluted at 37 0C for 5 hours. The eluate was extracted twice with phenol:chloroform, 
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back-extracted once with dH 20 (2.3.3), and precipitated with ethanol (2.3.5). The RNA pellet was 
resuspended in dH20 (1 &1) prior to further manipulation. 
6.2.5 Ribonuclease Ti Protection Assay 
Standard in vitro splicing reactions (2.5.3) of 0.05 ml volume were stopped on ice, and E. 
co/i tRNA was added to a final concentration of 0.2 mg/mi. Samples were exposed to short-wave 
UV light as described (Chapter 5, section 5.2.5), although UV-crosslinking was not required for 
ribonuclease protection. Ribonuclease Ti (Boehringer Mannheim UK) was added at 2.5 U/ui, and 
the samples incubated at 37 0C for 30 minutes. Standard immunoprecipitations (2.6.4) were 
performed using either anti-8.4 antibodies (25 p.1) or anti-pep antibodies (12.5 p.1) (antibodies are 
described in section 2.6.1) which were adsorbed to 7.5 mg PAS beads (2.6.2). The protected RNA 
fragments were recovered from the immunoprecipitate as described in section 2.6.4, fractionated 
by electrophoresis through a 20% acrylamide gel (2.4.3), and visualized by autoradiography (2.2.4). 
The RNA fragments were eluted from the gel as described above, and subjected to redigestion by 
ribonuclease (6.2.3). 
6.2.6 Analysis of RNA Fragments UV-Crosslinked to PRP8 Protein 
6.2.6.1 UV-Crosslinking of Protein to Pre-mRNA 
UV-crosslinking was performed exactly as described in Chapter 5, section 5.2.5. 
Preparative volumes of splicing reactions were distributed among the wells of a microtiter plate, 
with no more than 0.06 ml of sample per well, and the samples were UV-irradiated as normal. 
6.2.6.2 Immunoprecipitation of the PRP8 Protein—RNA Adduct from UV-Irradiated In Vitro 
Splicing Reactions 
Anti-pep antibodies (0.2 ml) were covalently coupled to 30 mg PAS beads (2.6.3). 
Preparative UV-irradiated splicing reactions of 0.9 ml were combined with an equal volume of the 
standard lmmunoprecipitation buffer (2.6.4), but E. co/i tRNA was not added because the UV-
irradiated samples already contained competitor RNA (5.2.5). The sample and PAS-bound 
antibodies were distributed equally among three microfuge tubes, and immunoprecipitation was 
performed by the standard procedure (2.6.4). After the final wash, the precipitated proteins were 
eluted from the antibodies by boiling each of the samples in 0.15 ml 2x protein load buffer (2.4.4). 
The sample supernates were loaded onto a preparative gel (with a sample well of 8.5 cm width) 
and the proteins were fractionated by SDS-PAGE (2.4.4). 
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6.2.6.3 Elution of Crosslinked RNA from Protein Gels 
The PRP8 protein—RNA adduct was excised from the gel with the aid of the 
autoradiograph, and incubated in 5 ml protein gel elution buffer, containing lx TEE, 0.1% (w/v) 
SDS, and 0.5 mg/ml proteinase K (Boehringer Mannheim UK), for 15 minutes at 37 0C (Kramer, 
1988). The gel slice was rinsed twice in lx TBE, then enclosed in dialysis tubing with 3 ml lx TBE 
and 10 pg E. coil tRNA.. The dialysis bag was submerged in lx TBE in the chamber of a 
horizontal gel tank (BRL Model H5), and electroelution was performed at 150 V for 2.5 hours 
at room temperature. The polarity of electrophoresis was reversed for one minute to recover any 
RNA fragments adhering to the inside of the dialysis bag. 
6.2.6.4 Recovery of Eluted RNA Fragments 
The eluate was removed from the dialysis bag, extracted with phenol:chloroform, and 
back-extracted with dH20 (2.3.3). The aqueous phases were combined and transferred to a 
siliconized 30 ml corex tube. The RNA was precipitated with ethanol (2.3.5), and pelleted by 
centrifugation at 10,000 rpm for 10 minutes at 4 0C in a Sorvall RC-5B Superspeed centrifuge 
fitted with an HB-4 rotor. The RNA pellet was washed with 95% (v/v) ethanol, then centrifuged 
as above for 10 more minutes. The pellet was dried in a 650C Incubator, resuspended in 0.15 ml 
dH20, then transferred to a siliconized microfuge tube. The RNA was reprecipitated with ethanol 
(2.3.5), washed with 95% (v/v) ethanol, and the RNA pellet was resuspended in 1 P1 dH 20. The 
appropriate buffers were added, and the recovered RNA was subjected to ribonuclease digestion 
and analysis as described above, in section 6.2.3. 
6.2.6.5 Isolation of RNA Fragments UV-Crosslinked to PRP8 Protein by Protease 
Digestion 
UV-crosslinking was performed as described above, in section 6.2.6.1. After partial 
digestion with Ribonuclease Ti, the preparative UV-irradiated splicing reaction (0.6 ml) was 
subjected- to denaturing conditions prior to immunoprecipitation, as described in Chapter 5, 
section 5.2.6. Briefly, the samples were boiled in 1% (w/v) SDS, 1% (v/v) Triton X-100 (BDH) 
and 100 mM DTF, then diluted 10-fold with 9 volumes of i.ix IPQ buffer. Immunoprecipitation 
was conducted as normal (2.6.4), with anti-pep antibodies (0.15 ml) adsorbed to 90 mg PAS beads 
(2.6.2). Following immunoprecipitation, 0.6 ml protease buffer [0.3 M NaCl, 50 mM Tris-HC1 (pH 
7.5), 10 mM EDTA, 1.5% (w/v) SDS, 1 mg/ml proteinase K (Boehringer Mannheim UK), 2 mg/ml 
pronase E (Sigma)] were added to the washed beads, and the samples were incubated at 37 0C for 
one hour. After protease digestion, the RNA fragments were recovered by extraction with 
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phenol:chloroform and precipitation with ethanol as described above, and the recovered RNA was 
analysed by further ribonuclease digestion as described in section 6.2.3. 
6.3 RESULTS 
6.3.1 Establishment of the Ribonuclease Ti Digestion Pattern for R1228 Pre-mRNA 
Rp28 was chosen as the ideal substrate RNA for Ribonuclease Ti mapping of the PRP8 
protein contact site on pre-mRNA. The predicted Ribonuclease Ti digestion pattern for rp22 pre-
mRNA produces unique oligoribonucleotides of diverse lengths within the intron and in the 5' 
and 3' splice site regions, thereby allowing for the unambiguous identification of Ribonuclease 
Ti fragments from these important locations on the pre-mRNA molecule. Figure 6.2 illustrates 
the RNA sequence and Ribonuclease Ti cleavage sites of rp28 pre-mRNA. Ribonuclease Ti 
cleaves RNA molecules 3' to G residues. The longest fragment generated by Ribonuclease Ti 
digestion of rp28 is a 31mer which encompasses the UACUAAC box and the entire intron 
region downstream of this sequence element to the 3' splice site AG dinucleotide. Throughout 
the rest of the intron are other unique Ribonuclease Ti fragments of 12, 13, 16, 17, 18 and 20 
nucleotides in length. In the flanking exon sequences of rp28 pre-mRNA are a 21-mer at the 3' 
end of exon 1 and a unique 14-mer at the 5' end of exon 2. 
Figure 6.3 shows the results of digesting rp28 pre-mRNA transcripts with Ribonuclease 
Ti. In lane 1 is the undigested, full-length transcript which did not migrate very far into the high 
percentage acrylamide gel. Lane 3 shows the oligoribonucleotides generated from Ribonuclease 
Ti digestion of the rp28 transcript. RNA fragments were observed with lengths ranging from 8 
to approximately 29 nucleotides, as estimated by comparison with the DNA size markers in lane 
2. (RNA demonstrates slower mobility in sequencing gels than do DNA molecules of the same 
length; RNA appears 5 to 10016 smaller than the corresponding DNA marker, Sambrook et aL, 
1989) In this experiment, fragments of fewer than 8 nucleotides in length were not detected. 
The Ribonuclease Ti digestion pattern of rp28 pre-mRNA did not include a unique 31 
nucleotide fragment (Figure 6.3, lane 3). Rather, a 25-29 nucleotide ladder of fragments was 
observed, even though no Ribonuclease Ti digestion products of these lengths were expected. In 
order to localize the region of rp28 pre-mRNA from which the ladder originated, Ribonuclease 
Ti digestion was performed on rp28 RNA transcribed from the rp28 plasmid DNA linearized with 
MspI. The RNA transcript produced from this DNA is truncated 20 nucleotides upstream of the 
UACUAAC sequence element (see Figure 6.2). As a consequence, Ribonuclease Ti digestion of 
the truncated transcript would lack the RNA oligonucleotides derived from the final 200 
nucleotides (approximately) of the full-length rp28 pre-mRNA. Shown in Figure 6.3, lane 5, is the 
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FIGURE 6.2 PREDICTED RIBONUCLFASE Ti DIGESTION PATTERN OF RP28 
PRE-mRNA 
The partial RNA sequence of the rp28 transcript is shown, with Ribonuclease Ti cleavage sites 
designated by breaks in the sequence. Unique oligoribonucleotides generated from the digestion 
are underscored, with lengths in nucleotides given below each fragment. 5' and 3' splice sites are 
indicated by vertical arrows, and the UACUAAC sequence element is boxed. The site where the 
rp28 RNA is truncated, when transcribed from plasmid pr7rp28s linearized with MspI, is indicated 
by a vertical arrow. 
.AACUG CUCCAAAG UCUG ACAAUG UCUACUUG AAAUUG UUAG jLC  
5' Splice Site 
AAAUUAUACACUUUCUUAG CUC1G UAUG UUCAAAAAUAAUAUCAAG G G UUUUAACCAACG 
21 	 V 	 18 	 12 
CCAAUUAUG G UUAG AAG G AUUCUG UUACAUUG AAUAUAAUAG AUUAUCCUG AACUUU 
G G UAAG UUCAUUG G UUUUCUAUAAAUAUUCG UUAUG G UUUG CUG AAAAAUAUUG G 
17 
UUAAUG UUUUUCG CG AUCAUCUAG CUUUG CIJUCUG AUG UG ACAAUUAUUG G UCAG U 
UUAUUG AACUG AAUCUG G CUAAAAUAG UCAUACCAG AAG AAG CUAG ACG UAUUAAA 
13 
AUUCUG CG AG UG CAAACG G G UAUAUUUG AG G AACG AUAUG UUUCUUUUACATCAC 
16 
G UUUUG UG CG G UAUUG CAAACCAG UG AG CAG AAUCUUUUUCUAAUUUAAUG AAAU 
20 
Msp I 
AUUUG UACG G AAAACUAUUG UUUUCj,CGG UCCUUCG AUCCAUUAG LlUACUAAc&UwUU 
3' Splice Site 
UCAUUUUUUUUUUUUAG1 GUCG UACUG AUG CUCCAUUCAACAAG G UUG UCUUG AAG G 
31 	 V 	 14 
CUUUG UUCUUG UCUAAG AUCAACAG ACCACCUG UUUCUG UCU CUAG AAUUG CUAG AG 
CUUUG AG CAAG AAG G UG CUG CUAACAAG ACUG UUG..................... 
FIGURE 6.3 RJBONIJCLEASE TI DIGESTION OF RP28 RNA TRANSCRIPTS 
Full-length rp28 RNA transcript (28; lane 1), truncated rp28 RNA transcribed from plasmid 
pT7rp28s linearized with MspI (28/M; lane 4), or full-length rp28 RNA transcribed using 
radiolabelled CTP rather than UTP (28/C P; lane 6) were incubated with Ribonuclease Ti, and 
the oligoribonucleotides resulting from each of the digestions (lanes 3,5 and 7, respectively) were 
fractionated by electrophoresis through a denaturing 20% aciylamide gel. The oligoribonucleotides 
derived from Ribonuclease Ti digestion of full-length rp28 RNA transcripts (lane 3) are 
numbered to the right of each band according to their nucleotide length. The nucleotide size 
markers (M) in lane 2 are an end-labelled MspI digest of pBR322 DNA bands of 15, 26 and 34 
nucleotides are indicated. 
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Ribonuclease Ti digestion pattern of rp28/MspI RNA. As expected, the unique 14 nucleotide 
fragment from the Y end of exon 2 was missing from the digestion. In addition, the entire 25-29 
nucleotide ladder was not observed; therefore, these RNA species are derived from the 3 end of 
the rp28 pre-mRNA. 
Inspection of the nucleotide sequence of the 31-mer (Figure 6.2) reveals a stretch of six 
uridine residues followed by another stretch of 12 undine residues. Since radiolabelled UTP was 
incorporated into these transcripts, the concentration of UTP was limiting in the in vitro 
transcription reaction. Perhaps, under these conditions, the Ti RNA polymerase was unable to 
synthesize the complete stretches of uridine residues, which resulted in a "nucleotide skipping" 
effect. The synthesis of transcripts with undine stretches of variable length could explain both the 
absence of a full-length fragment of 31 nucleotides and also the existence of the heterogeneous 
population of 25-29 nucleotide fragments. 
In order to test the possibility that the 25-29 nucleotide ladder was a result of RNA 
polymerase error, full-length rp28 pre-mRNA was transcribed in the presence of standard 
concentrations of UTP by incorporating radiolabelled CT? rather than UTP into the transcripts. 
Limiting concentrations of CFP were expected to be less deleterious, for the 31-mer contains only 
three cytdine residues (Figure 6.2). Figure 6.3, lane 7, shows the pattern of RNA fragments 
produced from Ribonuclease Ti digestion of rp28 transcripts labelled with CrP. Although a 
ladder of fragments was still produced, the component fragments demonstrated less variability 
of length and were of greater overall length than those resulting from Ribonuclease Ti digestion 
of UTP-labelled rp28 pre-mRNA. 
In summary, the Ribonuclease Ti digestion pattern for rp28 pre-mRNA was ascertained. 
The unique fragment of 31 nucleotides, spanning the region of the intron from the UACUAAC 
box to the 3' splice site, does not exist as a discreet band, but rather as a heterogeneous 
population of RNA fragments with lengths of 25 to 29 nucleotides. This may be caused by 
synthesis errors made by the RNA polymerase during initial transcription of the pre-mRNA these 
errors possibly were aggravated by limiting concentrations of UT?. 
6.3.2 Ribonuclease Protected Fragments Precipitated by Anti-PRP8 Antibodies Include the 5' 
Splice Site and the Intron Branch Region 
In vitro splicing reactions were treated with Ribonuclease Ti, then subjected to 
immunoprecipitation with anti-PRP8 antibodies. Analysis of the recovered RNA species 
demonstrated that three protected fragments were precipitated with anti-PRP8 antibodies (Figure 
6.4a, lane 3). Based upon their migration in the high percentage acrylamide gel, the bands were 
estimated to have lengths of approximately 50 nucleotides (band A), 70 nucleotides (band B), and 
200 nucleotides (band C). The lengths of the protected RNA species could have been more 
FIGURE 6.4 ANALYSIS OF PROTECTED RNA FRAGMENTS PRECIPITATED FROM IN 
VITRO SPLICING REACTIONS WITH ANTI-PRPS ANTIBODIES 
Rp28 pre-mRNA was incubated under splicing conditions, then digested with Ribonuclease 
Ti; subsequent unmunoprecipitation with anti-8.4 antibodies recovered three RNA species, 
designated A, B and C (lane 3). In lane 1 is an end-labelled MspI digest of pBR322 DNA, with 
fragment sizes in nucleotides indicated to the left of each band. The oligoribonucleotides 
generated from Ribonuclease Ti digestion of rp28 pre-mRNA (lane 2) have their respective 
nucleotide lengths indicated on the right. The 25-29 nucleotide ladder is labelled as p31" to 
indicate the full-length Ribonuclease Ti fragment from which it is derived. 
RNA fragments A, B and C were eluted from the gel shown in Figure 6.4a and redigested with 
Ribonuclease Ti. The oligoribonucleotides generated from digestion of the protected fragments 
A, B and C are shown in lanes 2, 3 and 4, respectively, with the nucleotide sizes of the 
oligoribonucleotides indicated on the right. The nucleotide size markers (M) in lane 1 are an end-







































accurately assessed by observing their migration on lower percentage gels, but this was not carried 
out. 
Each of the three protected fragments was eluted from the gel and redigested with 
Ribonuclease Ti. Band A was composed primarily of two Ribonuclease Ti fragments that 
appeared to migrate as an 18-mer and a 21-mer (Figure 6.4b, lane 2). Bands B and C, although 
they reproducibly demonstrated significantly different migration patterns in high percentage gels, 
appeared to be composed of similar Ribonuclease Ti fragments. Upon redigestion with 
Ribonuclease Ti, both bands B and C yielded fragments of apparent 18 and 9 nucleotide length, 
in addition to a set of fragments which could correspond to the RNA fragment ladder generated 
by the 31-mer (Figure 6.4b, lanes 3 and 4). In addition, band B contained other unidentifiable 
fragments migrating between the putative 31-mer ladder and the 21-mer (lane 3). It has not been 
investigated why band B demonstrates a faster mobility than band C, even though band B appears 
to contain more fragments than band C. 
To verify the composition of the protected bands, each RNA species was targeted for 
specific degradation by incubation with Ribonuclease H and an oligodeoxynucleotide 
complementary to the appropriate Ribonuclease Ti fragment of rp28 pre-mRNA. In Figure 6.5, 
the first three lanes show the Ribonuclease Ti digestion patterns of protected fragments C, B and 
A recovered from an anti-8.4 immunoprecipitate. In lanes 4 through 10, simultaneous 
Ribonuclease Ti and H digestions were performed on bands C, B and A recovered from an anti-
pep immunoprecipitate. The protected RNA fragments A, B and C recovered from Ribonuclease 
Ti-treated splicing reactions with anti-pep antibodies demonstrated identical migration on gels 
and identical Ribonuclease Ti digestion patterns to those of fragments A, B and C recovered with 
anti-8.4 antibodies (data not presented). Anti-pep antibodies were used to recover bands A, B and 
C for the dual digestion studies because immünoprecipitation with these antibodies is more 
efficient than with anti-8.4 antibodies (see Chapter 3, section 3.3.3). It was presumed that the 
bands recovered in the two immunoprecipitates were identical. 
Shown in Lane 9 of Figure 6.5 are the RNA fragments that resulted from simultaneous 
digestion of band A with Ribonucleases Ti and H in the presence of an oligodeoxynucleotide 
complementary to the 21-mer. The putative 21-mer of band A appeared to be specifically degraded 
under these conditions, for although present in lane 3, it was no longer apparent in lane 9, and 
additional uncharacteristic smaller bands appeared with approximate lengths of 13 and 15 
nucleotides, which presumably represent the degradation products of the 21-mer. Likewise, in lane 
10, incubation of band A with Ribonucleases Ti and H in the presence of an oligodeoxynucleotide 
complementary to the 18-mer resulted in its absence from the digestion pattern. It can be 
concluded that the RNA fragments which comprise protected fragment A correspond to the 21 
and 18 nucleotide fragments predicted for Ribonuclease Ti digestion of rp28 pre-mRNA. 
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FIGURE 6.5 IDENTIFICATION OF PROTECTED RNA FRAGMENTS' COMPOSITE 
OLIGORIBONUCLEOTIDES BY RIBONUCLEASE H DIGESTION 
In vitro splicing reactions were treated with Ribonuclease Ti and subjected to 
immunoprecipitation with PRP8-specific antibodies. Protected RNA fragments recovered from the 
immunoprecipitate were fractionated by denaturing gel electrophoresis, then excised and eluted 
from the gel. Fragments A, B and C, recovered from an anti-8.4 immunoprecipitate (see Figure 
6.4a, lane 3) were redigested with Ribonuclease Ti (lanes 3, 2 and 1, respectively); the nucleotide 
lengths of the resulting oligoribonucleotides are indicated on the left. Fragments A, B and C, 
recovered from an anti-pep immunoprecipitate were subjected to simultaneous Ribonuclease Ti 
and Ribonuclease H digestion (lanes 4-10) in the presence of an oligodeoxynucleotide (oligo) 
complementary to a particular oligoribonucleotide (the 18-mer, 21-mer or 31-mer) produced from 
Ribonuclease Ti digestion of rp28 pre-mRNA. Band A was digested with Ribonucleases Ti and 
H in the presence of an oligodeoxynucleotide complementary to the 18-mer (lane 10) or 21-mer 
(lane 9), band B was subjected to the dual digestion in the presence of an oligodeoxynucleotide 
complementary to the 18:mer (lane 8), 21-mer (lane 7) or 31-mer (lane 6), and band C underwent 
dual ribonuclease digestion in the presence of an oligodeoxynucleotide complementary to the 18-
mer (lane 5) or the 31-mer (lane 4). In lane 11 are the RNA fragments generated from 
Ribonuclease Ti digestion of rp28 pre-mRNA the nucleotide lengths of the oligoribonuleotides 
are indicated to the right. 
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The 21-mer and 18-mer map to the 5 splice site region of the pre-mRNA, where they 
flank two Ribonuclease Ti fragments of four nucleotides each at the 5' cleavage site (Figure 
6.6a). The 21-zuer, 18-mer and two 4-mers create a linear fragment of 47 nucleotides in length, 
which correlates well with the estimated length of 50 nucleotides for band A. Therefore, both the 
apparent length and the fragment profile of band A indicate protection of the 5' splice site of 
pre-mRNA (Figure 6.6b). 
Oligodeoxynucleotide-directed Ribonuclease H digestion was also utilized to verify the 
identities of the fragments produced by Ribonuclease Ti digestion of bands B and C. Lanes 1 and 
2 of Figure 6.5 show the fragments generated by Ribonuclease Ti digestion of bands C and B, 
respectively. Digestion of band C with Ribonucleases Ti and H in the presence of an 
oligodeoxynucleotide complementary to the 31-mer resulted in depletion of the fragment ladder 
from the digestion pattern of band C (lane 4). In addition, a set of novel bands appeared, 
migrating below the putative 18-mer, which most likely represent the degradation products of the 
31-mer ladder. Similarly, incubation of band C with Ribonucleases Ti and H and with an 
oligodeoxynucleotide complementary to the 18-mer caused a loss of the 18 nucleotide fragment 
from the sample (lane 5). 
The 18-mer is also a component RNA fragment of band B, as confirmed by targeted 
Ribonuclease H digestion of the 18-mer simultaneous with Ribonuclease Ti digestion of band B 
(Figure 6.5, lane 8). Dual digestion of band B with Ribonucleases Ti and H in the presence of 
oligodeoxynucleotide complementary to the 31-mer resulted in depletion of the 31-mer ladder 
(lane 6) and production of the putative degradation products of the 31-mer (as seen for band C 
in lane 4). In addition, the bands migrating below the 31-mer ladder, observed after Ribonuclease 
Ti digestion of band B (lane 2), were absent after targeted Rthonuclease H digestion of the 31-
mer ladder (lane 6), which indicates that these fragments were derived from the 31-mer. 
Identification of the other bands generated from Ribonuclease Ti digestion of band B proved 
to be less straightforward. In the experiment shown in Figure 6.5, there were a greater number 
of fragments observed after Ribonuclease Ti digestion of band B (lane 2) than in the previous 
experiment (Figure 6.4b, lane 3). In lane 6 of Figure 6.5, a band of apparent 21 nucleotide length 
remained after cleavage of the 31-mer ladder. The identity of this fragment is unclear, for targeted 
digestion of the 21-mci did not result in its depletion from the dual digestion pattern of band B 
(compare lanes 2 and 7). In addition, the putative degradation products of the 21-mer (as seen 
for band A in lane 9) were not observed in lane 7. The band of apparent 21 nucleotide length may 
be an incomplete Ribonuclease Ti digestion product of two or more smaller fragments. 
Other unidentified fragments resulting from Ribonuclease Ti digestion of band B 
migrated directly below the 18-mer in lane 2, but were not observed among the RNA products 
of the dual ribonuclease digestions of band B (lanes 6, 7 and 8). (The bands below the 18-mer in 
lane 6 are believed to correspond to the Ribonuclease H degradation products of the 31-mer 
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FIGURE 6.6 PROTECTED REGIONS OF RP28 PRE-mRNA AND PRE-mRNA-DERIVED 
MOLECULES 
A partial nucleotide sequence of rp28 pre-mRNA, displayed according to the fragments 
generated by digestion with Ribonuclease Ti. The numbers below the sequence refer to the 
nuleotide length of the individual digestion products. The regions of RNA protected by complexes 
immunoprecipitated with PRP8-specific antibodies are underscored with a broken line. Y and 3' 
splice sites are indicated by vertical arrows, and the UACUAAC sequence element is boxed. 
The location of the protected oligoribonucleotides in rp28 pre-mRNA, In splicing intermediates 
and in excised intron. The pre-mRNA is shown as a narrow line, with the site of branch formation 
indicated by an asterisk. 5' and 3' splice sites are represented by vertical arrows. The apparent 
length of the internal intron region of the pre-mRNA (dotted line) has been significantly 
shortened in this diagram. The locations of the protected oligoribonucleotides are designated by 
heavy lines, with their nucleotide lengths indicated below or adjacent to each fragment. The 
oligorthonucleotides are positioned according to their location in the pre-mRNA molecule, in 
exon 1, and in the branch structure of both lariat intermediate and lariat product. 
M- 
5' Splice Site 
AAAUUG UUAG UCAAAUUAUACACUUUCUUAG CUç]G UAUG UUCAAAAAUAAUAUCAAG 
6 	4 	 21 	 4\I 	4 	 18 
G G UUUUAACCAACG CCAAUUAUG .......... intrOn. ......... AAAACUAUUG UUUUCCG G UCCUUC 
11 	12 	 9 	 10 	7 	1 	7 
3' Splice Site 
G AUCCAUUAG U4ACUAAUUUUUUCAUUUUUUIJIJU AG! GUCG UACUG UAG CUCCA.... 
9 	 31 	 '14 	5 	3 	14 
19 
5' Splice Site 	 3' Splice Site 




Exon 1 	 Lariat 
ladder; see above.) It is a possibility that these fragments were an artifact resulting from the 
particular anti-8.4 immunoprecipitation in lane 2, for they were not observed among the fragments 
resulting from Ribonuclease Ti digestion of band B from the anti-8.4 immunoprecipitate in Figure 
6.4b, lane 3. Alternatively, the different digestion conditions used in lanes 6, 7 and 8 of Figure 6.5 
may have resulted in the absence of these species, if, for example, the bands represented fragments 
displaying anomalous migration due to secondary structure. 
Despite the unresolved ambiguities, the above experiments nonetheless confirmed that 
protected fragments B and C both included the 31-mer ladder and the 18-mer. A fragment of 9 
nucleotides in length was produced by Ribonuclease Ti digestion of both band B (Figure 6.4b, 
lane 3; Figure 6.5, lane 2) and band C (Figure 6.4b, lane 4; Figure 6.5, lane 1). Surprisingly, these 
three Ribonuclease Ti digestion products of rp28 are derived from non-adjacent regions of the 
pre-mRNA. Although dual ribonuclease digestion experiments were not performed to confirm the 
identity of the 9-mer, it was assumed to correspond to the 9-mer which is located directly 
upstream of the 31-mer; both of these fragments map to the 3' end of the intron (Figure 6.6a). 
The 18-mer, however, is located at the 5 end of the intron (Figure 6.6a). 
The 18-mer and the 31-mer cannot be derived from the same linear fragment because the 
protected fragment containing the two oligonbonucleotides would consist of the entire intron, and 
would be nearly 450 nucleotides in length. In addition, the Ribonuclease Ti digestion pattern of 
the postulated linear protected fragment would also include multiple oligonbonucleotides from 
internal regions of the intron. The first modification of the pre-mRNA molecule during the 
splicing reaction, however, is the covalent attachment of the 5' end of the intron to the 
branchpoint at the 3' end of the intron. The generation of this lariat species in rp28 RNA joins 
the 18-mer to the branchpoint within the 31-mer, via two shorter Ribonuclease Ti fragments of 
one and four nucleotides in length (Figure 6.6b). it is plausible that the protected substrate RNA 
in bands B and C includes the lariat branch structure. The observed mobility of band B (and, of 
course, band C) is slower than that expected for a linear fragment composed of 31, 18, 9, 4 and 
single nucleotide fragments; the migration of this species may be affected by its "Y' structure. 
The conclusion that bands B and C represent the protected lariat branch structure could 
only be confirmed by the existence of a single debranching enzyme cleavage site (Ruskin and 
Green, 1985c) within the protected fragments. Since the 31-mer spans the region from the 
branchpoint to the 3 AG, it is unclear as to whether the 3' splice site is protected as well. In the 
above studies, no protection of the unmodified UACUAAC box region of pre-mRNA was 7 
observed. Protection of this region prior to lariat formation would have resulted in the 
immunoprecipitation of a Ribonuclease Ti-resistant fragment composed solely of the 31-mer 
ladder, and possibly the 9-mer as well. 
The nature of the complexes which protect the Y splice site and branch region is unclear. 
In the above nbonuclease protection experiments, the anti-PRP8 immunoprecipitations were 
92 
performed under conditions in which complete spliceosomes are generally recovered (see Chapter 
3, sections 3.3.2 and 3.3.3). In addition, in Chapter 5, section 5.3.2, it was apparent that even after 
exposure of spliceosomes to ribonuclease, other pre-mRNA-binding proteins can be co-
precipitated with PRP8 protein dunng immunoprecipitation with anti-PRP8 antibodies. Therefore, 
protection of the 5' splice site and branch region may be mediated by whole or partially disrupted 
spliceosomes. No attempt was made to characterize the complexes immunoprecipitated from 
Ribonuclease Ti-treated splicing reactions with anti-PRP8 antibodies. 
6.3.3 Preliminary Analysis of the RNA Fragment(s) with which PRP8 Protein has Direct 
Interactions 
Results presented above demonstrate that anti-PRP8 antibodies precipitate Ribonuclease 
T1-resistent RNA species which include the 5' splice site of pre-mRNA and the branch region 
of the lariat intermediate and/or lariat product of the splicing reaction. Both the 5' splice site and 
UACUAAC box regions of pre-mRNA are known to be protected in the spliceosome, as 
evidenced by oligodeoxynucleotide-directed Ribonuclease H cleavage studies performed by 
Rymond and Rosbash (1986). UV-crosslinking experiments described in Chapter 5 demonstrated 
direct contact between PRP8 protein and the substrate RNA during the splicing reaction. In order 
to determine whether PRP8 protein itself interacts with either or both of the protected regions 
of substrate RNA, the procedures of Ribonuclease Ti mapping and UV-crosslinking were 
combined to localize the specific region(s) of the RNA which becomes crosslinked to PRP8 
protein. 
Preparative UV-irradiated in vitro splicing reactions were treated with Ribonuclease Ti 
and subjected to immunoprecipitation with anti-pep antibodies. The immunoprecipitated proteins 
were fractionated by SDS-PAGE, and the band containing the PRP8 protein—RNA adduct was 
excised from the gel. The gel slice was incubated with protease to liberate the RNA fragments 
crosslinked to PRP8 protein. The protected RNA fragments were isolated by electroelution from 
the gel slice, then digested to completion with Ribonuclease Ti. Shown in Figure 6.7, lane 3, are 
the RNA species recovered from complete Ribonuclease Ti digestion of the RNA that was 
crosslinked to PRP8 protein. Comparison of the recovered RNA species to a complete. 
Ribonuclease Ti digestion of rp28 pre-mRNA (lane 2) allowed the identification of discreet bands 
of 21, 18 and 9 nucleotides in length. These three bands are unlikely to be non-specific 
contaminants from lane 2, because similarly or more highly labelled fragments in the Ribonuclease 
Ti digest of rp28 pre-mRNA are not present in lane 3. The recovery of RNA in this and similar 
experiments was extremely inefficient; Figure 6.7 is a 6-week exposure of the gel. Consequently, 
not enough material was recovered for a more thorough analysis of the three fragments by dual 
ribonuclease digestion studies. Therefore, it is possible, but not certain, that the 21-mer, 18-mer 
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FIGURE 6.7 ISOLATION OF RNA FRAGMENTS CROSSLINKED TO PRPS PROTEIN 
In vitro splicing reactions wee UV-irradiated, treated with Ribonuclease Ti, and subjected to 
immunoprecipitation with anti-pep antibodies. Immunoprecipitated proteins were fractionated by 
SDS-PAGE, and the PRP8 protein—RNA adduct was excised from the gel. After protease 
treatment, the crosslinked RNA fragments were electroeluted from the gel slice, redigested with 
Ribonuclease Ti, and fractionated on a denaturing 20% aciylamide gel (lane 3). 
Oligonbonucleotides in lane 3 which demonstrate similar migrations in the gel to the 21-mer, 18-
mer and 9-mer that result from Ribonuclease Ti digestion of rp28 pre-mRNA (lane 2) are 
indicated with arrowheads. A diffuse band of radiolabelled material (lane 3) is marked with an 
asterisk. The nucleotide markers (M) in lane i are an end-labelled MspI digest of pBR322 DNA 







and 9-mer derived from analysis of the protected regions of RNA crosslinked to PRP8 protein 
may correspond to the RNA species recovered from protection of the 5 splice site and branch 
region. 
The majority of radiolabelled species recovered from the PRP8 protein—RNA adduct 
migrated as diffuse bands above 34 nucleotides (Figure 6.7, lane 3). The identity of these 
radiolabelled species is unclear. They demonstrated variable mobility from experiment to 
experiment (data not presented). One possibility is that the diffuse bands represent RNA 
fragments with covalently attached amino acids; amino acids or small peptides still may be 
retained on the RNA after protease digestion of PRP8 protein. Both the bulk and the charge of 
the amino acids could impede the migration of the RNA in the gel. In an attempt to remove the 
residual amino acids presumably attached to the RNA, the PRP8 protein—RNA adduct was 
incubated with pronase E (a mixture of extremely non-specific acid and serine proteases; 
Sambrook et aL, 1989) in addition to standard protease (proteinase K, an active serine protease; 
Sambrook et aL, 1989), but the diffuse bands were still observed (data not presented). 
Thorough characterization of the discreet and diffuse bands isolated from PRP8 
protein—RNA adducts will only be possible if the efficiency of recovery of these species can be 
significantly increased. At present, it is unclear why the procedure used above is so inefficient. It 
is possible that the RNA species were inadvertently eluted from the excised protein gel slice 
during protease digestion, prior to the electroelution step. Alternatively, if amino acids do remain 
on the RNA following protease digestion, their presence could cause the majority of RNA 
fragments to be retained at the interface or in the organic phase during phenol extraction of the 
RNA samples. 
A procedure was developed for the characterization of the putative RNA content of 
diffuse bands isolated from UV-induced RNA—protein adducts. If enough material were 
recovered, the diffuse band(s) could be isolated from the gel, then subjected to Ribonuclease H 
digestion in the presence of oligodeoxynucleotides complementary to a specific region of the pre-
mRNA. Specific degradation would indicate the presence of the RNA sequence to which the 
oligodeoxynucleotide was complementary. 
The diffuse band analysed in Figure 6.8, lanes 4-7, was isolated in an experiment to 
recover the RNA fragments UV-crosslinked to PRP8 protein by a procedure which avoided the 
elution of RNA fragments from the protein gel. Denaturation of UV-irradiated splicing reactions 
prior to immunoprecipitation with anti-pep antibodies resulted in the recovery of radiolabelled 
PRP8 as the major crosslinked protein without significant contamination of the 
immunoprecipitate with other RNA-binding proteins, as assayed by SDS-PAGE (see Chapter 5, 
section 5.3.2 and also Figure 5.3b). Preparative UV-irradiated and Ribonuclease Ti-treated 
splicing reactions were exposed to denaturing conditions, then subjected to immunoprecipitation 
with anti-pep antibodies. The crosslinked RNA fragments were released from the 
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FIGURE 6.8 ANALYSIS OF A "DIFFUSE BAND" ISOLATED FROM UV-INDUCED 
PROTEIN—RNA ADDUCTS 
UV-irradiated, Ribonuclease Ti-treated in vitro splicing reactions were subjected to denaturing 
conditions, then to immunoprecipitation with anti-pep antibodies. The immunoprecipitated 
protein—RNA adducts were digested with protease, and the released RNA fragments were 
redigested with Ribonuclease Ti, and fractionated by denaturing gel electrophoresis. A diffuse 
band (D) of radiolabelled material (see Figure 6.7, lane 3) was excised and eluted from the gel, 
and incubated with Ribonuclease H in the absence (-) of oligodeoxynucleotide (lane 4) or in the 
presence of an oligodeoxynucleotide (oligo) complementary to the 18-mer (lane 5), 21-mer (lane 
6) or 31-mer (lane 7). Rp28 pre-mRNA was subjected to simultaneous digestion with 
Ribonucleases Ti and H in the absence of oligodeoxynucleotide (lane 2) or in the presence of an 
oligodeoxynucleotide complementary to the 18-mer (lane 3). In lane 1 is an end-labelled MspI 
digest of pBR322 DNA. 
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immunoprecipitated protein by digestion with proteases. The fragments were recovered by phenol 
extraction, and then digested to completion with Ribonuclease Ti. Two diffuse bands were 
C 
recovered; the band of fastest mobility migrated between the 26 and 34 nucleotide DNA markers 
(data not presented). This particular band also contained the most radiolabelled material, so it 
was isolated for analysis. For unexplained reasons, the discreet bands that were recovered from 
the immunoprecipitate corresponded to regions along the entire length of the pre-mRNA (data 
not presented). The initial Ribonuclease Ti digestion of the splicing reaction may not have 
proceeded efficiently in this experiment, or the immunoprecipitate may have contained, in addition 
to PRP8, other RNA-binding protein(s) with molecular weights of less than 45 kD which would 
not have been visualised on the protein gel in Figure 5.3b. In light of these uncertainties, it 
cannot be assumed that the diffuse band analysed in the experiment shown in Figure 6.8 is 
comparable to the diffuse bands recovered from analysis of the RNA fragments specifically UV-
crosslinked to PRP8 protein (Figure 6.7, lane 3). 
Nonetheless, the procedure developed for analysis of diffuse bands was tested on the 
material isolated from the above experiment. The diffuse band was selectively degraded with an 
oligodeoxynucleotide complementary to the 31-mer of rp28 pre-mRNA (Figure 6.8, lane 7), but 
was not degraded by Ribonuclease H in the presence of oligodeoxynucleotides complementary to 
the 18-mer (lane 5) or 21-mer (lane 6). Although it is apparent that the diffuse band contained 
RNA sequence corresponding to the 31-mer, it cannot be concluded that it did not contain 
sequences related to the 21-mer and 18-mer. Uncharacterized properties of the diffuse band may 
have impeded hybridization of the particular oligodeoxynucleotide to the RNA and/or the 
enzymatic activity of Ribonuclease H. 
6.4 DISCUSSION 
Preliminary results are presented concerning the identification of the site(s) on substrate 
RNA with which PRP8 protein has direct interaction during the splicing process. 
Ribonuclease Ti mapping was conducted with rp28 pre-mRNA. Analysis of the 
Ribonuclease Ti digestion pattern for rp28 pre-mRNA suggested that the in vitro transcripts are 
heterogeneous in the region of a 31 nucleotide Ribonuclease Ti fragment, resulting in the 
recovery of a ladder of fragments, rather than a single discreet band, following Ribonuclease Ti 
digestion of the pre-mRNA. It is proposed that this was caused by transcription fidelity errors 
made by the RNA polymerase at either of the two consecutive stretches of multiple uridine 
residues located within the 31-mer fragment of rp28 pre-mRNA. 
The observed discrepancy in RNA fragment length is not unprecedented. Kramer (1988) 
used a Ribonuclease Ti protection assay to map the interactions between pre-mRNA and 
components fractionated from HeLa nuclear extract. A unique fragment of 18 nucleotides was 
expected from Ribonuclease Ti digestion of the substrate RNA 10, yet Kramer (1988) observed 
the production of additional fragments of 16 and 17 nucleotides as well. The 18-mer of RNA 10 
contains a stretch of 8 uridine residues. Kramer (1988) produced the radiolabelled RNA 10 
transcripts under conditions of limiting UT!'; therefore, RNA polymerase transcription errors, 
aggravated by limiting concentrations of UTP, may also explain the appearance of shorter 
fragments in the RNA 10 digestion pattern observed by Kramer (1988). Alternatively, the observed 
sequence heterogeneity may have occurred at the level of the DNA template. Errors may have 
been committed by DNA polymerase during propagation of the plasmid in E. coli. 
Results from Ribonuclease Ti protection studies demonstrate that the 5' splice site of 
pre-mRNA and the branch region of the lariat intermediate and/or lariat product are protected 
in splicing complexes precipitated with anti-PRP8 antibodies. It is unclear whether the observed 
protection is mediated by the entire spliceosome or by partially dissociated complexes containing 
spliceosomal factors resistant to Ribonuclease Ti digestion. It is interesting that in these studies, 
no protection of the branchpoint region of the pre-mRNA was detected prior to lariat formation. 
Black et aL (1985) demonstrated specific Ribonuclease Ti protection of the branchpoint region 
of mammalian pre-mRNA by U2 snRNP. This suggests that not all splicing complexes were 
precipitated with anti-PRP8 antibodies. 
Additional experiments must be performed to try to characterize the immunoprecipitated 
complexes. Identification of the snRNPs within the complexes cannot be performed by analysis 
of the immunoprecipitated snRNA species, because the splicing reactions were treated with 
Ribonuclease Ti. Perhaps specific site-directed ribonuclease digestion of the pre-mRNA only 
(Rymond and Rosbash, 1986) could avoid this problem. In order to determine whether the RNA 
fragments precipitated with anti-PRP8 antibodies represent all of the protected fragments or a 
subset of the total, a comparison could be made between the immunoprecipitated fragments and 
the protected fragments recovered from a Ribonuclease Ti-treated in vitro splicing reaction not 
subjected to immunoprecipitation. In addition, RNA fragments precipitated with anti-PRP8 
antibodies could be compared to the fragments precipitated with other antibodies, such as anti-Sm 
antibodies, which precipitate yeast spliceosomes (Chapter 3, section 3.3.i). It is unknown, however, 
which yeast snRNPs are immunoprecipitated with anti-Kung or anti-JE antibodies. As other 
antibodies become available, it may be possible to further characterize the complexes which 
protect the 5' splice site and lariat branch region. 
UV-crosslinking studies presented in Chapter 5 indicated that PRP8 protein has direct 
interactions with pre-mRNA during the splicing reaction. It is possible that PRP8 protein contacts 
RNA in the regions protected by splicing complexes precipitated with anti-PRP8 antibodies. 
Localization of the region(s) of pre-mRNA UV-crosslinked to PRP8 protein was performed by 
Ribonuclease Ti protection mapping of the crosslinked RNA fragments. 
In a preliminary experiment, RNA fragments of 21, 18 and 9 nucleotides and a diffuse 
band of radiolabelled material were recovered from the PRP8 protein—RNA adduct (Figure 6.7, 
lane 3). The 21-, 18- and 9-mers may correspond to the RNA fragments which comprise the 5 
splice site and lariat branch structure (Figure 6.6b). The diffuse band is composed of RNA, as 
demonstrated by its susceptibility to Ribonuclease H degradation (Figure 6.8, lane 7). Speculation 
that the diffuse band represents RNA covalently attached to amino acids suggests a possible 
interpretation of the results in Figure 6.7. It is likely that RNA fragments attached to amino acids 
are not analysable by conventional methods used for the analysis of unmodified RNA fragments. 
The discreet bands of 21, 18 and 9 nucleotides obtained from the PRP8 protein—RNA adduct may 
not have been covalently attached to PRP8 protein, but perhaps were protected by PRP8 protein 
during initial exposure of splicing complexes to Ribonuclease Ti. The second Ribonuclease Ti 
digestion, performed in the absence of PRP8 protein, would have freed the 21, 18 and 9 
nucleotide fragments from adjacent RNA fragments which had been covalently attached to PRP8 
protein. These Ribonuclease Ti fragments which had been crosslinked to PRP8 protein would not 
migrate as discreet bands in the gel, due to the retention of amino acids, but as diffuse bands. 
Perhaps the species observed in lane 3 of Figure 6.7 represent both the RNA fragments 
crosslinked to PRP8 protein and also their adjacent non-crosslinked RNA fragments. This suggests 
that PRP8 protein becomes crosslinked to some part of the 31-mer within the branch structure 
(Figure 6.6b), allowing the liberation of the 18-mer and 9-mer upon further Ribonuclease Ti 
digestion, with retention of the 31-mer in a diffuse band. Similarly, PRP8 protein may become 
crosslinked to either of the 4-mers which compose the 5 cleavage site (Figure 6.6b), and 
redigestion of the protected RNA fragment with Ribonuclease Ti would yield the observed 
discreet bands of 18 and 21 nucleotides. This interpretation of the limitted data cannot be tested, 
however, until sufficient material can be recovered for a thorough analysis of the RNA fragments 
crosslinked to PRP8 protein. Further efforts must be made to increase the efficiency of the 
procedure described in this chapter. If this proves intractable, an alternative approach could be 
adopted to analyse the RNA fragments contacted by PRP8 protein. For example, utilization of 
a reversible RNA—protein crosslinking agent could avoid the inherent difficulties of analysing 
chimeric RNA/protein molecules. 
The results presented in this chapter suggest that PRP8 protein may have direct 
interactions with both the 5' cleavage site of pre-mRNA and with the UACUAAC box/3' splice 
site region of the branch structure of the lariat intermediate and/or lariat product. If PRP8 protein 
does indeed make direct contact with these regions of RNA during the splicing reaction, it 
suggests a fundamental role for PRP8 protein in mediating the interaction between U5 snRNP 
(or the U4/U5/U6 multi-snRNP complex) and cis- or trans-acting factors within the splicing 
apparatus. PRP8 protein may play a regulatory role in selection of the 5' cleavage site or in lariat 
formation. 
97 
FINAL DISCUSSION AND SPECULATIONS 
Previous genetic and biochemical studies established that the 280 kD protein product of 
the PRP8 gene is essential for nuclear pre-mRNA splicing in vivo and in vitro (Jackson et aL, 
1988). Subsequent identification of PRP8 protein as a component of the U5 snRNP (Lossky et 
at, 1987) suggested an intimate association of PRP8 protein with the nuclear splicing machinery. 
Indeed, in this thesis I have shown that antibodies raised against two distinct regions of PRP8 
protein, the amino-terminal 35 amino acids of PRP8 and approximately 500 amino acids at the 
protein's carboxy terminus, precipitate spliceosomal complexes from in vitro splicing reactions 
(Chapter 3, sections 3.3.2 and 3.3.3). The immunoprecipitation of splicing precursor RNA, 
intermediates and lariat product indicated that PRP8 protein associates with spliceosomal 
complexes during both steps of the splicing reaction and with a post-splicing complex containing 
the excised intron. The stable interaction of PRP8 protein with spliceosomes was confirmed by 
its detection in affinity purified spliceosomes (Whittaker et at, 1990). Results from UV-
crosslinking experiments have further characterized PRP8 protein as a spliceosomal factor that 
interacts directly with pre-mRNA during the splicing reaction (Chapter 5, section 5.3.2). 
Homologues of PRP8 protein have been detected in a variety of higher organisms. 
Antibodies raised against PRP8 fusion proteins 8.1, 8.2 and 8.4 (see Figure 3.1a) react with a 
protein in HeLa cell nuclear extracts that is similar in size to the yeast protein (>200 kD) and 
is associated with purified HeLa US snRNPs (Anderson et at, 1989). Pinto and Steitz (1989) 
detected the same protein in HeLa U4/U5/U6 multi-snRNP particles and in affinity purified HeLa 
spliceosomes. In addition, the putative mammalian homologue of PRP8 protein is reported to 
bind pre-mRNA in the spliceosome (Garcia-Blanco et at, 1990). PRP8 protein is also conserved 
with respect to size and immunological epitopes as a snRNP protein in Drosophila (T.Paterson, 
D.Finnegan and J.Beggs, unpublished results) and in Nicotiana tabacum (H.Kulesza, G.Simpson, 
J.Brown and J.Beggs, unpublished results). The existence of homologues of PRP8 protein suggests 
that PRP8 plays a sufficiently important role in splicing for several features to be conserved across 
a wide phylogenetic spectrum. The conservation of its exceptionally large size, together with widely 
spaced epitopes, is significant in that PRP8 protein may act as a scaffold in the spliceosome, with 
multiple domains having different functions or interactions with other splicing factors. 
It is particularly significant that the splicing-specific pre-mRNA-binding capability of 
PRP8 protein is conserved from yeast to man. The implication is that this particular function of 
PRP8 protein is fundamental to the splicing process. Although it is not yet known at which site(s) 
the human homologue of PRP8 protein contacts pre-mRNA, preliminary results presented in this 
work (Chapter 6, section 6.3.3) suggest that the yeast protein may interact with both the Y splice 
site region of pre-mRNA and the branch structure of pre-mRNA-derived molecules. Experiments 
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with truncated RNA substrates established that the interaction of PRP8 protein with pre-mRNA 
is dependent on the ability of the pre-mRNA molecule to participate in at least step 1 of the 
splicing reaction (Chapter 5, section 5.3.5). This prerequisite implicates other cis- or trans-acting 
factor(s) in effecting the PRP8 protein—RNA contact event. That PRP8 protein acts in concert 
with other factors suggests that it may be involved in a cooperative event, such as the regulation 
and/or initiation of the first cleavage-ligation reaction of splicing. 
Genetic studies of the role of yeast US snRNP in splicing complement the above 
preliminary biochemical investigations of the U5 snRNP protein PRP8. Newman and Norman 
(pers. comm., CSH90) demonstrated that yeast US snRNA participates either directly or indirectly 
in the 5' cleavage event. A single nucleotide substitution in the highly conserved loop I of U5 
snRNA resulted in the use of a cryptic 5' splice site in a mutant pre-mRNA molecule (see 
Chapter 1, section 1.7.5). The participation of US snRNP in 5' splice site cleavage corroborates 
the biochemical evidence of Winkelmann et aL (1989) whose studies with purified HeLa snRNPs 
demonstrated that U5 snRNP is necessary for the efficient initiation of the first step of the 
splicing reaction. 
It is most likely that US snRNA interacts indirectly with the 5' splice site, via a protein 
factor(s), perhaps a protein component of U5 snRNP or U4/U5/U6 multi-snRNP complex. 
Zhuang and Weiner (1986), Seraphin et aL (1988) and Siliciano and Guthrie (1988) provided 
genetic evidence in both mammalian and yeast systems which suggested that U! snRNA-5' splice 
site base-pairing is essential, but not sufficient, for 5' splice site selection (see Chapter 1, section 
1.7.3). The notion arose that the base-pairing interaction creates a recognition "window" within 
which the cleavage site is selected by other factor(s). Protein component(s) of US snRNP may well 
represent the auxiliary factor(s) needed for 5' splice site selection; these auxiliary factors may act 
as intermediaries for the putative catalytic action of US snRNA. The fact that PRP8 protein 
probably binds the 5' splice site region of pre-mRNA makes this US snRNP protein a good 
candidate for an auxiliary factor which participates in 5' splice site selection. In addition, there 
exists genetic evidence for a direct or indirect interaction between PRP8 protein and loop I of U5 
snRNA a yeast strain containing both a temperature-sensitive allele of the pp8 gene and a 
growth-Impairing U5 snRNA loop mutation is inviable (Guthrie and Patterson, 1988). 
The idea that PRP8 protein acts in concert with US snRNA and/or other US snRNP 
proteins to influence 5' splice site selection, is made more attractive by the fact that PRP8 protein 
is known to have a direct interaction with the putative helicase protein SPP81. SPP81 was isolated 
as a suppressor of the prp8-1 mutation (Chapter 1, sections 1.9.2 and 1.9.5). Perhaps SPP81 
unpairs Ui snRNA from the 5' splice site region, thereby making the pre-mRNA available for 
interaction with PRP8 protein. PRP8 protein may serve to anchor the splicing machinery to the 
appropriate cleavage site. Upon selection of the 5' splice site, cleavage follows, perhaps catalyzed 
by another factor that has interactions with US snRNA. 
The postulated role of PRP8 protein in the splicing reaction cannot be tested until more 
information has accumulated about its molecular interactions within both the U5 snRNP and 
splicing complexes. The first priority of future work is the verification of the sites on pre-mRNA 
with which PRP8 protein interacts. Once that has been accomplished, a number of experimental 
routes can be investigated. 
The UV-crosslinking technique provides an assay for PRP8 protein function. Other factors 
required for the interaction between pre-mRNA and PRP8 protein could be identified by analysis 
of PRP8 protein function in temperature-sensitive splicing extracts, such as those produced from 
prpló, pip17 and pip18 yeast strains, each of which displays inhibition of step 2 of the splicing 
reaction (see Chapter 1, section 1.9.4). Results from these experiments could determine whether 
the PRP8 protein—RNA interactions at the 5' splice site and branch structure do indeed occur 
independently of the second cleavage-ligation reaction of splicing. Alternatively, mutant pre-
mRNA substrates which result in the use of cryptic 5' splice sites in vitro could be used to 
investigate whether the interaction of PRP8 protein with the 5' end of the intron is altered. A 
change in the binding site of PRP8 protein on the mutant pre-mRNA with respect to wild-type 
pre.mRNA could indicate a role for PRPS protein in 5' splice site selection. The UV-crosslinking 
procedure could also be modified to investigate possible direct interactions between PRP8 protein 
and U5 snRNA within the US snRNP. 
Examination of PRP8 protein's interactions within ribonucleoprotein complexes inevitably 
leads to the analysis of PRP8 protein itself. It would be of great interest to determine which 
protein domain(s) of PRP8 contacts pre-mRNA. The availability of antibodies raised against 
distinct regions of PRP8 protein makes such an investigation feasible. Perhaps this would lead to 
the identification of a novel protein motif for RNA interactions. In addition, cloning of the human 
homologue of PRP8 protein could provide information as to which aspects of the protein were 
conserved from yeast in order to preserve the protein's function. Further analysis of PRP8 protein 
and investigations of its role in yeast and mammalian splicing systems could serve to elucidate 
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Affinity purification of spliceosomes reveals that the precursor 
RNA processing protein PRP8, a protein in the U5 small nuclear 
ribonucleoprotein particle, is a component of yeast spliceosomes 
(yeast splicing/poly(A)-binding protein) 
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ABSTRACT 	Nuclear pre-mRNA splicing in Saccharomy- 
ces cerevisiae, as in higher eukaryotes, occurs in large RNA—
protein complexes called spliceosomes. The small nuclear RNA 
components, UI, U2, U4, Us, and U6, have been extensively 
studied; however, very little is known about the protein com-
ponents of yeast spliceosomes. Here we use antibodies against 
the precursor RNA processing protein PRP8, a protein com-
ponent of the U5 small nuclear ribonucleoprotein particle, to 
detect its association with spliceosomes throughout the splicing 
reaction and in a post-splicing complex containing the excised 
intron. In addition, an indirect immunological approach has 
been developed that confirms the presence of precursor RNA 
processing protein PRP8 in isolated spliceosomes. This method 
has possible general application for the analysis of ribonucle-
oprotein particle complexes. 
PRP8 (precursor RNA processing 8, the protein product of 
the PRP8 gene; formerly called RNA8; ref. 1) of Saccharo-
mvces cerevisiac is essential for nuclear pre-mRNA splicing 
in vivo and in vitro. The mutation prp8-1 (2) causes temper-
ature-sensitive growth with accumulation of unspliced pre-
mRNA at the nonpermissive temperature (1). In vitro the 
splicing activity of a cell extract prepared from the prp8-I 
strain displays increased temperature sensitivity (3), and an 
extract from wild-type cells loses RNA splicing activity after 
immunological depletion of PRP8 (1). PRP8 is exceptionally 
large, as estimated by denaturing gel electrophoresis (1), and 
is predicted from the sequence of the cloned PRP8 gene to be 
280 kDa (S. P. Jackson and J.D.B., unpublished results). By 
using an immunological approach, it was demonstrated that 
PRP8 is specifically associated with U5 small nuclear ribo-
nucleoprotein particles (snRNPs) and with U4/U5/U6 sn-
RNP complexes that form when yeast splicing extracts are 
incubated in the presence of ATP (4). It has been proposed 
(4, 5) that these snRNP complexes may facilitate efficient 
spliceosome assembly since the U4, US, and U6 small 
nuclear RNAs (snRNAs) appear to enter spliceosomal com-
plexes simultaneously; however, a precursor—product rela-
tionship has not been demonstrated. 
The RNA components of yeast spliceosomes have been 
extensively characterized (6), but very little is known about 
the protein content. Only PRP11. a 30-kDa nuclear protein, 
has been shown conclusively to be a yeast spliceosomal 
protein. When in vitro-synthesized and radiolabeled PRP11 
was used to complement the splicing defect of a prpll 
heat-inactivated extract, PRP11 was demonstrated to enter 
40S spliceosomal complexes (7). 
In our studies of the role of PRP8 and of its interaction with 
other splicing factors, an important question is whether this 
protein remains associated with US snRNPs as they assemble 
The publication Costs of this article were defrayed in part by page charge 
payment. This article must therefore be hereby marked "advertisement" 
in accordance with 18 U.S.C. §1734 solely to indicate this fact. 
into spliceosomes and, if so, whether PRP8 is present in 
spliceosomes at all stages of the RNA splicing reaction. The 
experiments described here demonstrate the presence of 
PRP8 in spliceosomes throughout the splicing reaction and in 
a post-splicing complex containing excised intron. We de-
scribe a method for purification of spliceosomes based on 
indirect immuno-affinity selection through antibodies against 
poly(A)-binding protein that associates with a poly(A) se-
quence attached to the 3' end of the substrate RNA. 
MATERIALS AND METHODS 
In Vitro Splicing Reactions. Precursor RNAs were tran-
scribed in vitro using bacteriophage SP6 or T7 RNA poly-
merase (8). Actin pre-mRNA was transcribed from pSPT19-
actin/alu DNA (1), and plasmids pSPrp51A, pSPrp5lA[5'-OJ, 
or pSPrp51A[3b] (9) were used as templates to produce the 
polyadenylylated precursor RNAs. Yeast whole cell extracts 
were prepared and in vitro splicing reactions were performed 
as described (1, 10). The splicing extract used for the affinity 
selection of spliceosomes was a mix of 3 parts whole cell 
extract (10) to 2 parts 35% saturated ammonium sulfate 
precipitate of whole cell extract (11). For the affinity selec-
tion of spliceosomes, 0.01 ml, 0.04 ml, and 0.2 ml of splicing 
reaction mixture (for the analysis of reaction products and 
snRNAs and for immunoblotting, respectively) were incu-
bated at 25°C for 10 min and then quenched on ice. 
Immunoprecipitations. Antisera to PRP8—f3-gal act osidase 
fusion proteins were raised as described (1, 4). Splicing 
reactions were quenched on ice, adjusted to 150 mM Na/ 
K, 10 mM HepesKOH (pH 7.0). 2.5 MM  MgCl2 , 0.1% 
Nonidet P-40, and then immunoprecipitated with antibodies 
to FP8.4 or with purified anti-trimethylguanosine antibodies 
as described (4). For antigen competition, 2 .cg of purified 
fusion protein was added during binding of antibodies to 
protein A-Sepharose (PAS). In the PAS control, no antibod-
ies were bound to the PAS. For the time-course experiment, 
at each incubation time. 9 gl of a 10-41 splicing reaction 
mixture was immunoprecipitated and RNA was extracted 
from the remaining 1 iil without further treatment. 
Affinity Selection of Spliceosomes. Rabbit antiserum to 
poly(A)-binding protein (PAB) was raised as described in ref. 
12. PAB-specific antibodies were affinity-purified against 
pure PAB and concentrated on a PAS column (13). Antibod-
ies were bound to PAS in NTN buffer (150 mM NaCl/SO mM 
TrisHCl, pH 7.5/0.05% Nonidet P-40) and washed three 
times with the same buffer. For analysis of the protein 
components of affinity-selected spliceosomes, PAB antibod- 
Abbreviations: PAS. protein A-Sepharose; PAB, poly(A)-binding 
protein; PRP. precursor RNA processing; PRP8, protein product of 
the PRP8 gene; snRNA, small nuclear RNA; snRNP, small nuclear 
ribonucleoprotein particle. 
*Current address: Department of Biochemistry, Brandeis Univer-
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FIG. 2. (A) Strategy for the affinity 
purification of spliceosomes by immu-
noprecipitation with antibodies to 
PAB. PAB affinity-selected spliceo-
somes were analyzed for the presence 
of precursor RNA, splicing intermedi-
ates, and products, snRNAs. and 
PRP8, as shown in B, C, and D. (B) 
Splicing reaction mixtures containing 
32P-labeled rp51A precursor RNA (lane 
1) were subjected to immunoprecipita-
tion with PAS-bound antibodies to PAB 
(lane 2) or with PAS only (lane 3). (C) 
Anti-PAB precipitates were analyzed 
by Northern blot to visualize the 
snRNAs associated with affinity-
purified spliceosomes from a standard 
splicing reaction mixture (lane 2) and 
from mock splicing reaction mixtures 
(lanes 3-6), in either the absence of 
ATP and with (lane 3) or without (lane 
6) the addition of wild-type i -p51A pre-
cursor RNA or the presence of ATP 
and with polyadenylylated mutant pre-
cursor RNA with the 5' splice site de-
leted [5'-0] (lane 4) or the "TAC-
TAAC" box deleted [3b] (lane 5). 
Lane 1 shows 25% of the snRNAs pres-
ent in an unfractionated splicing reac-
tion mixture (this includes snRNAs 
from snRNPs not present in spliceo-
somes), lane 7 is a control with no 
antibodies bound to the PAS, and lane 
8 contains end-labeled Msp I and Ava 
I-Nhe I digests of pBR322 DNA. (D) 
Western blot analysis was used to de-
tect PRP8 in an unfractionated whole 
cell splicing extract (lane 4), in the 
protein fraction precipitated with PAB 
antibodies from a standard splicing re-
action mixture (lane 1), or from mock 
splicing reaction mixtures without the 
addition of ATP (lane 2) or using a 
mutant substrate RNA with the 5' 
splice site deleted [5'-0] (lane 3). Sizes 
of protein molecular mass standards are 
given in kDa. The background in the 
lower portion of the blot is due to 
antibodies present in the gel. 
proximately 50% efficiency and exon 1 with 22% efficiency 	may have partially destabilized spliceosomes, giving reduced 
from an in vitro splicing reaction mixture. As with PRPS yields of exon 1. The excised intron was not precipitated due 
antibodies, the presence of EDTA during immunoprecipita- 	to the lack of a binding site for PAB and, presumably, 
tion resulted in optimal recovery of poly(A)-tailed RNAs but because the spliced exon product [which has a poly(A) tail] 
